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1.1 Use of monoclonal antibodies in targeting cancer 
Surgery and external radiation therapy are the major treatment modalities for 
primary tumours and large metastases (Fig. 1.1). Chemotherapy is used for 
disseminated tumour diseases and may be curative in cases of lymphomas, 
testicular tumours and tumours in the paediatric group. 
 
Fig. 1.1. Schematic illustration of strategies for tumour therapy. Surgery and external radiation 
therapy form the basis when locally growing tumour masses are treated. Chemotherapy in various 
forms is applied when there is tumour cell dissemination. New therapy approaches will be tried 
when chemotherapy is not effective in its present forms and these can be based on e.g. signal 
transduction interference with kinase inhibitors or modification of apoptotic processes. Some 
general and `biology-based´ concepts are immunotherapy, differentiation therapy, anti-
angiogenesis therapy and gene therapy. Radionuclide therapy is based on the same effect 
mechanism as external radiation therapy, namely induction of severe DNA-damage, and is 
therefore a form of radiotherapy. However, radionuclide therapy is placed among the new forms of 
`biology-based´ therapies because it is dependent to a large extent on antigen and receptor 
expression and the biological factors that regulate them. (Carlsson et al., 2003) 
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Table 1.1 FDA-approved agents and the spectrum of targeted cancers (Abou-Jawde et al., 2003; 
Imai and Takaoka, 2006) 
  Targeted cancer 
  Solid tumours Haematological tumours 
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mAbs               
Cetuximab (Erbitux) EGFR (ERBB1)   √‡    √§       
Trastuzumab 
(Herceptin)¶ HER2 (ERBB2)  √            
Bevacizumab 
(Avastin)# VEGF   √           
Rituximab (Rituxan)** CD20            √  
Ibritumomab tiuxetan 
(Zevalin)* 111In/90Y CD20            √  
Tositumomab 
(Bexxar)* 131I CD20            √  
Gemtuzumab ozo-
gamicin (Mylotarg)‡‡ CD33        √      
Alemtuzumab 
(Campath-1H) CD52          √    
 
Small-molecule inhibitors              
Imatinib mesylate 
(Gleevec) TKs (BCR-ABL, KIT, PDGFR)    √       √   
Gefitinib (Iressa) TK (EGFR) √             
Erlotinib (Tarceva) TK (EGFR) √     √§§        
Sunitinib (Sutent) TKs (VEGFR, PDGFR, KIT, FLT3, RET)    √ √         
Sorafenib (Nexavar) Kinases (B-Raf, VEGFR2, EGFR, PDGFR)     √         
Bortezomib (Velcade) 20S proteasome             √ 
All-trans-retinoic acid 
(ATRA) 
Induces promyelotic 
differentiation (PML-RARα)         √     
Arsenic trioxide 
Direct effect on the 
mitochondria, apotosis (PML-
RARα) 
        √     
Agents are shown as generic names with trade names in parentheses. The table lists cancers to which each targeted 
agent is approved. *Radiolabeled with Yttrium-90 or Iodine-131. ‡In combination with irinotecan or administered as a single 
agent. §In combination with radiation therapy or administered as a single agent. ¶In combination with paclitaxel or 
administered as a single agent. #In combination with 5-fluorouracil-based chemotherapy. **In combination with CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone) or other anthracycline-based chemotherapy regimens. 
‡‡This mAb is linked to N-acetyl- calicheamicin, a bacterial toxin. After internalization of the mAb, the released toxin binds 
to DNA and causes double-strand DNA breaks. §§In combination with gemcitabine. AML, acute myeloid leukaemia; APL, 
acute promyelotic leukaemia; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; CRC, colorectal 
cancer; EGFR, epidermal growth factor receptor; FLT3, fetal liver (or Fms-like) tyrosine kinase 3; GIST, gastrointestinal 
stromal tumour; KIT, stem cell factor receptor; NSCLC, non-small-cell lung cancer; HNSCC, head and neck squamous-cell 
carcinoma; PDGFR, platelet-derived growth factor receptor; RAR, retinoic acid receptor-alpha; RET, neurotrophic factor 
receptor; TK, tyrosine kinase; VEGFR, vascular endothelial growth factor receptor. 
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Currently, there is no curative treatment in the quantitatively large groups of 
patients with disseminated adenocarcinomas (e.g. breast, prostate, colorectal, 
lung and ovarian tumours) and squamous cell carcinomas (e.g. lung, 
oesophagus and head-neck tumours), where a palliative effect and/or prolonged 
survival can at best be achieved with chemotherapy. This is also true for 
malignant gliomas and various other types of disseminated tumours, e.g. 
malignant melanomas and neuroendocrine tumours (Carlsson et al., 2003). 
Successes of targeted strategies against the big killers (lung, breast and 
colorectal cancer) have been reported. These strategies have in common that 
they start from a target that has been identified as playing an important role in 
tumour biology and oncogenesis. The agents include monoclonal antibodies 
(mAbs), small molecules, peptide mimetics and antisense oligonucleotides. The 
different targeted strategies have been intensively reviewed over the past five 
years and include modification of apoptosis, differentiation, signal transduction 
interference, anti-angiogenesis, gene therapy, immunotherapy and radiotherapy 
(Carlsson et al., 2003; Kim, 2003; Abou-Jawde et al., 2003; Brannon-Peppas, 
2004; Mariani, 2005; Koppe et al., 2005; Newell, 2005; Lambert, 2005; Reubi 
et al., 2005; Wu et al, 2005; Sharkey and Goldenberg, 2005; Larson et al., 
2005; Imai and Takaoka, 2006) (Fig.1.1). 
Two classes of agents have been FDA-approved including monoclonal 
antibodies and small molecules. Table 1.1 shows the today’s FDA-approved 
agents and the spectrum of targeted cancers. Categorization of the different 
strategies is difficult, since there are many overlaps in use of agents as well as 
mechanism of action. In this overview, we will discuss the potential role of 
immunotherapy, and more specifically discuss the different mechanisms of 
action of antibody targeted therapies. Where possible, the use of antibodies will 
be compared with the use of smaller molecules, e.g. peptides and non-peptides, 
Chapter 1 
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and successes of these different agents will be briefly mentioned for reason of 
comparison.  
The concept of immunotherapy is based on the body's natural defence system. 
One immediate research goal in cancer immunology is the development of 
methods to harness and enhance the body's natural tendency to defend itself 
against malignant tumours. Antibodies have now become part of standard 
cancer treatment. Other examples of immunotherapy remain experimental, e.g. 
cancer vaccines (Scott, 1997; Pardoll, 2002), or involve certain cytokines 
(Hutson, 2005), but are out of the scope of this thesis. 
1.1.1 Monoclonal antibodies 
Köhler and Milstein developed the hybridoma technology in 1976, leading to 
today’s approval of twelve monoclonal antibodies for detection or therapy of 
cancer (Table 1.2) and more than 150 mAbs under clinical investigation. Six 
monoclonal antibodies are used for other diseases than cancer, including 
chronic inflammatory diseases, transplantation and infectious diseases, and for 
cardiovascular medicine (Carter, 2006).   
Monoclonal antibodies, with immunoglobulin G (IgG) the most commonly 
used immunoglobulin, are unique proteins with dual functionality. All naturally 
occurring antibodies are multivalent, with IgG having two binding ‘arms.’ 
Antigen-binding specificity is encoded by three complementarity-determining 
regions (CDRs), while the Fc-region is responsible for binding to serum 
proteins (e.g., C1q complement factor) or cells such as macrophages and 
natural killer (NK) cells (Sharkey and Goldenberg, 2006b) (Fig. 1.2). 
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Fig. 1.2. IgG molecules are tetramers of ~150 kDa, which comprise a pair of identical heavy and 
light chains linked by disulphide bonds (green bars). The heavy chains contain a variable (V) 
domain (the VH domain; green) and three constant (C) domains, the CH1 domain, CH2 domain and 
CH3 domain (purple). By contrast, the light chains contain a V domain (the VL domain; orange) and 
a single C domain (the CL domain; purple). Highly selective binding of antigen (light blue) is a 
common hallmark of antibodies. This is mainly mediated by six loops, which are known as the 
complementarity-determining regions (CDRs), three of which are present in each of the VH and VL 
domains. The interaction of antibody with antigen is exemplified in this figure by the Fab of 
trastuzumab (Herceptin; Genentech, Inc. and F.Hoffman-LaRoche Ltd) in complex with HER2. For 
clarity, only the V domains of trastuzumab and domain IV of HER2 are shown (see inset). The 
remaining portion of the V domains, which are known as framework regions, function mainly as a 
structural scaffold to support the CDRs. Human IgG bound to an antigen on a target cell, 
particularly IgG1 and IgG3, can subsequently interact through its Fc region with IgG receptors 
FcγRs) expressed by effector cells or with complement component 1q (C1q), potentially supporting 
the destruction of target cells through antibody-dependent cell-mediated cytotoxicity (ADCC) or 
complement-dependent cytotoxicity (CDC), respectively. In addition, the Fc region of IgG can bind 
the salvage receptor FcRn after fluid-phase uptake by vascular endothelial cells and other cells, an 
interaction that contributes to the long (21 day) half-life of human IgG. Effector functions (that is, 
ADCC and CDC) require the presence of the Fc-region glycan (dark blue) and are crucially 
influenced by its structure. The N-linked glycan that is attached to the conserved asparagine (Asn) 
residue at position 297 comprises a core structure of N-acetylglucosamine and mannose, plus 
additional carbohydrate residues, which can vary, including fucose, galactose, sialic acid and 
bisecting N-acetylglucosamine. (Cho et al., 2003; Carter, 2006) 
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1.1.2 Unconjugated antibodies 
1.1.2.1 Enhancing cytolytic mechanisms 
There are many different mechanisms of action using monoclonal antibodies in 
cancer patients (von Mehren, 2003). The early models of mAb-based therapies 
focused on enhancing the cytolytic mechanisms against tumour cells (Adams 
and Weiner (2005). 
 
Fig. 1.3. Schematic model of indirect antibody action by immune mechanisms. Antibody-dependent 
cellular cytotoxicity (ADCC) involves the recognition of the CH3 constant region of the antibody by 
immune effector cells such as macrophages and natural killer (NK) cells through FcγRIIIa receptors 
expressed by both effector cells. Target tumour cells become phagocytosed by macrophages or 
undergo cytolysis by NK cells. Complement-dependent cytotoxicity (CDC) involves the recognition 
of the CH2 region of the antibody by the C1q complement factor, which leads to activation of a 
proteolytic cascade of the classical complement pathway and consequently induces the formation 
of a membrane-attack complex (MAC) and lysis of the tumour cell. C3b, which is generated during 
this cascade reaction, functions as an opsonin to facilitate phagocytosis and cytolysis through its 
interaction with the C3b receptor (C3bR) on a macrophage or natural killer (NK) cell; this activity is 
termed complement-dependent cell-mediated cytotoxicity (CDCC). (Imai and Takaoka, 2006) 
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An antibody itself usually is not responsible for killing target cells, but instead 
marks the cells. In that way, other components or effector cells of the body’s 
immune system attack the marked cells. These attack mechanisms are referred 
to as antibody-dependent complement-mediated cytotoxicity (CDC) and 
antibody-dependent cellular cytotoxicity (ADCC) (Sharkey and Goldenberg, 
2006b) (Fig. 1.3). IgG1 and IgG3 can activate the classical complement 
pathway and interact with Fc receptors more potently than IgG2 or IgG4. In 
particular, IgG4 cannot activate the classical complement pathway (Imai and 
Takaoka, 2006). 
The anti-tumour effect of Rituxan (anti-CD20) (Table 1.2) was initially 
attributed to CDC and ADCC. Shan et al. (1998) showed that the anti-CD20 
mAb Rituxan provides also pro-apoptotic signals to B-cell lymphomas, 
offering another mechanism of action of this antibody (Kim, 2003). 
1.1.2.2 Signal transduction interference 
The increasing knowledge of molecular pathways that underlie the cancer 
process has resulted in the use of antibodies in a direct way. These modes of 
action involve blocking the function of target signalling molecules or receptors 
(e.g., blocking ligand binding, inducing regression of angiogenesis, increasing 
internalization of receptors), and stimulating function of target signalling 
molecules or receptors (e.g., inducing apoptosis). Based on these mechanisms 
of action, several monoclonal antibodies as well as small molecules have been 
FDA approved for clinical use (Table 1.2). 
Signal transduction in cancer cells is a sophisticated process involving receptor 
tyrosine kinases (RTKs) that eventually trigger multiple cytoplasmic kinases, 
which are often serine/threonine kinases. Three major signalling pathways that 
have been identified as playing important roles in cancer include the 
phosphatidyl inositol-3-kinase (PI3K)/Akt, protein kinase C (PKC) family, and 
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mitogen-activated protein kinase (MAPK)/Ras signalling cascades (Fig. 1.4) 
(Faivre et al., 2006). Targeting signal transduction involves blocking or 
interfering with the RTKs (C-KIT, EGFR (ERBB1), HER2 (ERBB2), PDGFR, 
VEGFR, FLT3 and RET) or molecules downstream the signal transduction 
cascade (Ras, Raf, MAP, MEK, mTOR, PKC, BCR-ABL) (Faivre, 2006). 
 
Fig. 1.4. Schematic diagram of key signalling pathways leading from receptor tyrosine kinase 
(RTK) activation to cancer development. pY, phosphorylated tyrosine (Marmor et al., 2004; Faivre 
et al., 2006) 
Small-molecule tyrosine kinase inhibitors (TKIs), such as gefinitib, function as 
adenosine triphosphate (ATP) analogues and inhibit the epidermal growth 
factor receptor (EGFR) signalling by competing with ATP binding within the 
catalytic kinase domain of RTKs (Fig. 1.5). As a result, the activation of 
various downstream signalling pathways is blocked. Each TKI has a different 
selectivity for RTKs, and some are dual- or multi-selective, which might 
provide a therapeutic advantage. By contrast, therapeutic monoclonal 
antibodies (mAbs) bind to the ectodomain of the RTK with high specificity (for 
example, cetuximab binds to the L2 domain of EGFR), and thereby inhibits its 
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downstream signalling by triggering receptor internalization and hindering 
ligand-receptor interaction. 
 
Fig. 1.5. Schematic diagram of the structure of receptor tyrosine kinases and the mechanism of 
action of monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) inhibiting these 
receptors. pY, phosphorylated tyrosine kinase (Faivre et al., 2006) 
Both gene amplification and overexpression of EGFR and HER2 are frequently 
observed in breast, lung and colorectal cancers, and the deregulated activation 
of intracellular mitogenic signalling by the ErbB family has been implicated in 
various cancers. Table 1.3 gives an overview of the main clinical investigations 
currently available on targeted signal transduction agents in the treatment of 
non-small cell lung cancer (NSCLC), colon and breast cancer, and other solid 
tumours (Allen et al., 2003; Gridelli, 2004; Maione et al., 2004; Vanhoefer, 
2005; Isobe et al., 2005; Mendelsohn and Balsega, 2006; Massarelli and 
Herbst, 2006). 
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Table 1.3 Main clinical investigations currently available on targeted signal transduction agents in 
the treatment of non-small cell lung cancer, colon and breast cancer, and other solid tumours (Allen 
et al., 2003; Gridelli, 2004; Maione et al., 2004; Vanhoefer, 2005; Isobe et al., 2005; Mendelsohn 
and Balsega, 2006; Massarelli and Herbst, 2006; Steeghs et al., 2006) 
 
Agents Characteristic Tumourtype Stage 
Receptor tyrosine kinase inhibitors 
ErbB-1 (EGFR)     
Antibody Cetuximab 
(Erbitux) 
IgG1κ, chimeric Colon, H&N Marketed 
   NSCLC, 
pancreas 
Phase II/III 
 Panitumumab 
(ABX-EGF) 
IgG2, human Colon, renal, 
H&N 
Phase III 
 Matuzumab (EMD-
72000) 
IgG, humanized H&N, ovarian, 
colon, cervix 
Phase II 
TKI Gefitinitib (Iressa, 
ZD1839) 
Quinozaline, reversible NSCLC Marketed 
   Breast, colon 
and other types 
Phase II 
 Erlotinib (OSI-774, 
Tarceva) 
Quinazoline, reversible NSCLC, 
pancreas 
Marketed 
   Ovarian, H&N, 
glioblastoma 
Phase II 
 EKB-569  Reversible colon Phase II 
ErbB-2 (HER2)     
 Trastuzumab 
(Herceptin) 
IgG1κ, humanized Breast Marketed 
   NSCLC Phase II 
 Pertuzumab IgG, humanized Breast, ovarian, 
prostate, 
NSCLC 
Phase III 
Panerb-B     
 Canertinib  
(CI-1033) 
Quinazoline, irreversible NSCLC, breast Phase I/II 
   SCC, skin Phase II 
 Lapatinib (GW-
572016, Tykerb) 
EGFR/HER2, 
irreversible 
Breast Phase III 
Cytoplasmic  inhibitors 
Protein kinase C 
 Affinitak (ISIS3521, 
LY900003) 
Antisense 
oligonucleotide 
NSCLC Phase I/II/III 
Ras pathway 
 ISIS2503 Antisense 
oligonucleotide 
NSCLC Phase II 
 Lonafarnib (SCH-
66336) 
Non-peptidomimetic, 
reversible 
NSCLC Phase III 
 Tipifarnib 
(R115777) 
Non-peptidomimetic 
quinolone FTI 
NSCLC Phase III 
 BMS214662 Benzodiazepine FTI NSCLC Phase II 
CML, chronic myelogenous leukaemia; GIST, gastrointestinal stromal tumours; H&N, head and neck; 
NSCLC, non-small cell lung cancer;  PDGFR, platelet-derived growth factor receptor; SCC, squamous 
cell carcinoma; VEGFR, vascular endothelial growth factor receptor 
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Tabel 1.4 Main clinical investigations currently available on targeted anti-angiogenesis agents in 
the treatment of NSCLC, colon and breast cancer and other solid tumours (Gridelli, 2004; Maione 
et al., 2004; Rüegg et al., 2004; Isobe et al., 2005; Vanhoefer et al., 2005; Steegh et al., 2006) 
 
Agents Characteristic Tumortype Stage 
VEGF inhibitors     
Antibody Bevacizumab IgG1, humanized Colon Marketed 
   NSCLC Phase 
II/III 
SMKI Zactima (ZD6474) VEGFR, EGFR NSCLC Phase 
I/II/III 
 Sunitib (Sutent, 
SU11248) 
VEGFR-1, PDGF, 
KIT, FLT-3 
RCC, GIST Marketed 
   NSCLC Phase II 
 ZD6474 VEGFR-2 and EGFR 
inhibitor 
NSCLC Phase 
II/III 
 Vatalanib (PTK787, 
ZK 222584) 
VEGFR, PDGFR, c-
KIT 
colon Phase 
II/III 
 Sorafanib (Bay 43-
9006, Nevaxar) 
VEGFR, PDGFR, 
Raf-1 
RCC Marketed 
   Melanoma, 
HCC 
Phase 
II/III 
Angiogenesis     
 Endostatin Cleavage product of 
plasminogen, natural 
anti-angiogenic 
protein 
NSCLC Phase III 
Integrin     
Antibody Vitaxin αvβ3 (IgG1, 
humanized) 
Melanoma, 
prostate 
Phase II 
 CNTO95 αv (IgG1, humanized) Melanoma Phase II 
Peptide Cilengitide Cyclic RGD peptide Glioma Marketed 
   Prostate Phase II 
MMP     
 Prinomastat MMPI (MMP-2, MMP-
9) 
NSCLC Phase III 
(early 
closure) 
 BMS275291 MMPI (MMP-1, -2, -8, 
-9, -13, -14) 
NSCLC, 
prostate 
Phase 
II/III 
 Neovastat Anti-VEGF and MMPI NSCLC Phase III 
EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumours; HCC, 
hepatocellular carcinoma; IgG, immunoglobuline G; MMPI, matrix metalloproteinase inhibitor;  
NSCLC, Non-small cell lung cancer; PDGF, platelet derived growth factor; RCC, renal cell 
carcinoma; RGD,  arginine-glycine-aspartate peptide motive; SMKI, small molecule kinase 
inhibitor; VEGF, vascular endothelial growth factor 
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1.1.2.3 Anti-angiogenesis therapy 
Tumour cells will continue dividing until they reach the diffusion-limited 
maximum size (~2 mm³). At that point, the outer cancer cells have access to 
nutrients, while the inner cells of the tumour will perish because the amount of 
nutrients is insufficient. A steady state tumour size forms. 
To grow beyond this size the tumour must start the process of angiogenesis, i.e. 
new blood vessels must be formed to provide the tumour with nutrients 
essential for expansion. The factors involved in angiogenesis present new 
therapeutic targets (Brannon-Peppas, 2004). Table 1.4 shows some of the most 
important factors under investigation including the vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth 
factor (PDGF), integrin αvβ3 and certain matrix metalloproteinases (MMPs) 
(Kerbel, 2006). 
1.1.2.4 Inducing apoptosis 
Apoptosis, or programmed cell death, is a gene-directed control mechanism by 
which cells die if DNA damage is not repaired (Lowe et al., 2000). Apoptosis 
is also important in controlling cell number and proliferation as part of normal 
development. The genetic basis of apoptosis implies that it can be disrupted by 
mutation. The results of defects in apoptosis lead to immortal clones of cells. 
Defects in the apoptotic regulatory pathways such as p53, the nuclear factor 
kappa B (NFκB), or phosphatidylinositol 3-Kinase (PI3K)/Akt lead to new 
treatments that target them. 
When tumour cells detect DNA damage beyond the repair capabilities of the 
cell, programmed cell death pathways are triggered. Apoptotic cell death can be 
initiated through an extrinsic pathway involving activation of cell surface death 
receptors or by an intrinsic pathway via the mitochondria (Fig. 1.6). 
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Fig. 1.6. Extrinsic (cytoplasmic) and intrinsic (mitochondrial) apoptotic pathways. These are 
regulated by proteins such as p53, the PI3K pathway, NFκB, and the ubiquitin/proteasome system. 
Influence of FDA-approved proteosome inhibitor bortezomib on the nuclear factor (NF) κB survival 
pathway is indicated. Bortezomib (red) binds to the 20S β-subunit, thereby blocking the 
proteasome. As a result, IκB will not be degraded into small peptides. It remains bound to the 
survival protein NFκB, thereby inhibiting NFκB action. Action of antibodies HGS-ETR1, HGS-ETR2, 
and HGS-TR2 (green) stimulate apoptosis by binding the death receptors Dr4 (TRAIL R1, tumour 
necrosis factor-related apoptosis-inducing ligand receptor 1) and Dr 5 (TRAIL R2, tumour necrosis 
factor-related apoptosis-inducing ligand receptor 2) receptor. (Vink et al., 2006 and Ghobrial 2006 –
modified) 
Both pathways lead to activation of effector caspases that trigger a proteolytic 
cascade resulting in fragmentation of intracellular components. Many of these 
are p53 dependent; the p53 gene is mutated in the majority of human cancers, 
resulting in inhibition of apoptosis. 
Monoclonal antibodies (HGS-ETR1 (mapatumumab), HGS-ETR2, and HGS-
TR2) with agonist function at the death receptor (Dr) Dr4 (TRAIL R1, tumour 
necrosis factor-related apoptosis-inducing ligand receptor 1) and Dr5 (TRAIL 
R2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2) sites 
may also induce apoptosis and caspase activation and have shown tumour 
regression in colon tumour xenograft models. Phase I and Phase II trials in 
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patients with advanced non-small cell lung cancer, colon cancer, and non- 
Hodgkin lymphoma are in progress (Ghobrial et al., 2005). Other examples of 
agents active on apoptotic proteins in the extrinsic, intrinsic and common 
pathways or indirect modulators of apoptosis, are given by Ghobrial et al. 
(2005). 
1.1.2.5 Future targets 
Stroma cells contribute to the cancer microenvironment and are essential for 
cancer growth, invasion and metastatic progression. Fibroblasts, often termed 
myofibroblasts or cancer-associated fibroblasts (CAFs), represent the most 
abundant cell type in the tumour stroma. The demonstrated tumour-promoting 
capacities of CAFs have increased the interest to exploit them as drug targets 
for anticancer therapy. Single factors, such as platelet-derived growth factor, 
transforming growth factor-β1, hepatocyte growth factor and matrix 
metalloproteinases have been identified as mediators in the fibroblast tumour 
interaction (Micke et al., 2005). The cell surface serine protease known as 
fibroblast activation protein (FAP) emerges as a promising candidate for 
specifically targeting CAFs (Rettig et al., 1993). FAP is not expressed by 
mature somatic tissues except for activated fibroblasts during wound healing 
and within stroma (Wang et al., 2005). A phase I dose-escalation study with 
sibrotuzumab (an anti-FAP antibody) in patients with advanced colorectal 
carcinoma and non-small cell lung carcinoma showed that sibrotuzumab bound 
specifically to the tumour sites without apparent site effects (Scott et al., 2003). 
Targeting CAFs as therapeutic strategy against cancer is an intriguing concept 
and needs further study (Kalluri and Zeisberg, 2006). Other promising 
unconjugated antibodies or agents in advanced clinical trials are discussed by 
Sawyers (2004) and, Sharkey and Goldenberg (2006b). 
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1.1.3 Conjugated antibodies 
Other modes of action of antibodies are the specific delivery of radioisotopes 
(Goldenberg et al., 2006; Koppe et al., 2005; Milenic et al., 2004; Tolmachev 
et al., 2004; Goldenberg, 2003; Goldenberg, 2002), toxins (Pastan et al., 2006; 
Ross et al., 2003) or drugs (Carter, 2001; Lambert, 2005) to target tumour sites. 
Today, two radioimmunoconjugates and one drug-immunoconjugate are FDA-
approved (Table 1.2). New approaches involve pretargeting strategies and the 
use of immune-modulating bispecific antibodies or recombinant ligand-
antibodies (Pardoll, 2002; Holliger and Hudson, 2005; Waldmann, 2006). 
Pretargeting approaches have been applied to radionuclides (Goldenberg, 2002; 
Boerman et al., 2003; Sharkey and Goldenberg, 2005; Goldenberg et al., 2006) 
and drugs termed antibody-directed enzyme prodrug therapy (ADEPT) 
(Goodwin and Meares, 2001; Sharma et al., 2005). In all these cases, the 
antibody acts as a homing device to carry its payload to the target where the 
latter precipitates a biologic activity with minimum side effects to non-target 
tissue (Kim et al., 2005; Sanz et al., 2005). In the scope of this thesis we will 
only focus on radioimmunotherapy as part of radionuclide therapy. 
Radionuclide therapy differs from radiotherapy in the mechanism of radiation 
delivery to the target tissue, i.e. systemic versus external beam-radiation. In 
radionuclide therapy, specific delivery of radiotoxic agents to tumour lesions 
while sparing normal tissues, depend on physicochemical events (e.g., 131I-NaI 
concentration in thyroid) or is receptor based (interaction of peptides and 
antibodies with tissue-specific receptors). The principal target for ionizing 
radiation is DNA. Several lesions are produced (e.g., single-strand or double-
strand DNA breaks, base damage, DNA-protein cross-links, and multiple 
damage sides) by direct ionization of DNA (direct effect) or by interaction of 
free radicals (mostly hydroxyl radicals). In general, these lesions are repaired 
with high precision by the control mechanisms within each cell. Exceptions are 
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the double strand breaks and multiple damaged sides. After a delay in the 
progression of dividing cells, non repairable cells will undergo apoptosis 
(Kassis and Adelstein, 2005). 
Today, 131I-NaI is the only FDA-approved agent for a solid tumour (thyroid) 
based on targeted radionuclide therapy.  Ibritumomab tiuxetan (Zevalin 
111In/90Y) and 131I-tositumomab (Bexxar) are both monoclonal antibodies 
approved for the localization and treatment of non-Hodgkin’s lymphoma 
(NHL) (Larson and Krenning, 2005). 
An overview of representative radioimmunotherapy trials in NHL and solid 
tumours is given by Koppe et al. (2006). For solid tumours, the most targeted 
malignancies in Phase I/II clinical RIT are epithelial cancers, e.g. colorectal 
cancer, ovarian cancer, medullary thyroid cancer, and to a lesser extent breast, 
prostate and renal cell cancer. The most commonly targeted antigens are the 
carcinoembryonic antigen (CEA, mainly in colorectal, medullary thyroid and 
breast cancer), tumour-associated antigen-72 (TAG-72, mainly in colorectal, 
ovarian and breast cancer), and G250 (renal cell cancer). 131I or 90Y were the 
radionuclides commonly applied, although in some trials 186Re, 188Re, or 177Lu 
were used. In most cases, the radiolabeled antibodies were administered in 
dose-escalating steps to determine the maximum tolerable dose. As a result, in 
most studies suboptimal doses were administered. Most of these patients had 
metastatic, bulky disease, and had been heavily pretreated with chemotherapy 
and/or radiotherapy. Compared to haematological disease, complete responses 
in patients with solid cancers have rarely been reported, although in many 
studies a few patients still experienced minor, partial or mixed responses or 
stabilization of previously progressive disease. 
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1.2 Use of monoclonal antibodies in molecular imaging 
Molecular imaging may be defined as the spatially localized remote sensing of 
molecular and physiological processes in vivo. An alternative definition might 
be that molecular imaging is the minimally invasive depiction, characterization, 
and measurement of biological processes at the cellular and molecular levels in 
living organisms (Hillman and Neiman, 2002). Molecular imaging can be 
useful in four broad categories of applications: screening and early detection, 
diagnosis and staging, guidance for less invasive treatments, drug development, 
and monitoring of treatment response. 
Medical imaging modalities most relevant to cancer research and clinical care 
include ultrasound, x-ray computed tomography (CT), magnetic resonance 
imaging (MRI), nuclear imaging (single photon emission computed 
tomography (SPECT) and positron emission tomography (PET)), and near 
infrared optical imaging (NRI) (Hillman, 2006). A brief and clear overview of 
the principles underlying these modalities is given by Schnall and Rosen 
(2006). Over the past decades, each of these techniques have undergone 
increasing interest for research and improvements regarding sensitivity and the 
development of contrast agents (Bloch et al., 2004; Nelson SJ, 2004; 
Blankenberg, 2004; Pomper and Hammoud, 2004; Mahmood, 2004; Kelloff et 
al., 2005). Previous and today’s clinical practice measures the effect of 
anticancer treatment mainly on the basis of the morphological changes that are 
imaged using structural imaging using CT and MRI. As the size of the tumour 
after therapy is not directly related to the viability of the tumour, these imaging 
techniques have limitations in assessing therapeutic effects. In addition, 
neoadjuvant chemoradiotherapy can produce severe mucositis, edema, scarring 
and granulation tissue, which might interfere with the detection of persistent 
disease using conventional diagnostic methods (Kitagawa et al., 2003). Also, 
with these techniques, sensitivity for early disease is poor. Many diseases are 
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initiated at the molecular and cellular levels, and usually do not cause gross 
abnormalities for an extended period. As a result, functional imaging 
techniques such as PET and SPECT can complement anatomical modalities 
and overcome some of the deficiencies of structural imaging (Alavi et al., 
2004). Nuclear medicine techniques have the capability to detect and serially 
monitor a variety of biologic and pathophysiologic processes, but PET and 
SPECT lack the high anatomical spatial resolution of CT and MRI. The 
development of PET/CT (Townsend et al., 2003), SPECT/CT (von Schulthess, 
2005), and PET/MRI (Gaa et al., 2004; Seemann, 2005) research and clinical 
scanners provide the combination of functional and structural images. Four 
monoclonal antibodies have been approved for imaging including Oncoscint, 
Verluma, Prostascint, and CEA-scan (Table 1.2). 
1.2.1 PET and SPECT: basic principles 
Positron emission tomography (PET) imaging begins with the injection of a 
biological molecule that carries a positron-emitting isotope (e.g., 11C, 13N, 15O, 
or 18F). As the tracer accumulates in an area of the body for which it has a high 
affinity, the isotope decays by positron emission, i.e. a positively charged 
antiparticle of the electron. After travelling a short distance the positron 
combines with an electron to annihilation. As a result, two gamma rays of 511 
keV each are emitted in opposite direction at a 180° angle (Fig. 1.7A). By 
detecting those photons that travel in opposite directions in coincidence within 
several nanoseconds, the projection data required for tomographic 
reconstruction are obtained. If two detectors are in coincidence, the assumption 
is that the positron was emitted along the line that connects them, referred to as 
the line of response (Pomper and Hammoud, 2004). 
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Fig. 1.7. (A) Positron emission tomography (PET) and (B) single-photon emission computed 
tomography (SPECT) detection. The trajectory of the photon is determined by the coincidence 
detection of two photons emitted 180 degrees apart, whereas for SPECT, the collimator determines 
the trajectory of the photons that contribute to the image by filtering out unwanted photons, 
resulting in only a fraction of the possible photons contributing to the image. (Schnall and Rosen, 
2006) 
Single photon emission computed tomography (SPECT) relies on the emission 
of a single photon (e.g. 99mTc, 123/131I, 111In, or 67Ga) by a decaying isotope. The 
origin of the single photon needs to be located. Therefore, a perforated metal 
filter (a collimator) is used to filter out the photons from all but the prescribed 
direction (Fig. 1.7B). This is an inefficient process that results in the majority 
of photons not reaching the detector and less sensitivity compared to PET 
(Schnall and Rosen, 2006). The advantages and disadvantages of PET and 
SPECT are summarized in Table 1.5. 
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Tabel 1.5 Characteristics of human PET and SPECT imaging 
 PET SPECT 
Cost Expensive Less expensive 
Isotopes Cyclotron isotopes: short t½  
(2 min-2 hrs) 
Generator or purchased isotopes: long 
t½ (6 hrs – 8 days) 
Chemistry Physiologic radiotracers Direct or chelation 
Emission energies 511 keV 70-364 keV 
Quantification Semi-quantitative/quantitative Quantitative? 
Resolution High (4-5 mm)  Lower (8-10 mm) 
Sensitivity No collimators: higher sensitivity Collimators: lower sensitivity 
SPECT enables imaging of biological processes with long half-lives because of 
longer physical half-lives of the radionuclides, has more readily available 
radiotracers, employs less expensive equipment and, can simultaneously detect 
isotopes with different emission energies. PET employs physiologic 
radiotracers which can be identical to the biological molecule of interest, lends 
itself more easily to quantification, and is approximately two orders of 
magnitude higher in sensitivity than SPECT. The high resolution of PET is 
limited because of the positron range and the photon non-colinearity effects 
(Pomper and Hammoud, 2004). Further improvement in SPECT resolution is 
possible using high resolution pinhole collimators. Unfortunately, this is not 
generally practical for human imaging (Meikle et al., 2005). 
1.2.2 Molecular imaging targets and probes 
An important application in molecular imaging in oncology is to design and 
implement better drug development. This includes differentiation (i.e. 
inflammation vs. recurrence, sensitive vs. drug resistant) and prediction (i.e. 
selection of patients who are more likely to respond to therapy). The imaging 
probes can facilitate early clinical pharmacokinetic and/or pharmacodynamic 
evaluation particularly in patients where no direct measures of 
pharmacokinetics and/or pharmacodynamics throughout the tissues of the body 
and at the target are available. 
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Tabel 1.6 Imaging probes used to visualize molecular targets and processes in cancer (Kelloff et 
al., 2005) 
Molecular target/process Imaging probes (phase of development) 
Small-molecule probes  
    Proliferation 2-[11C]Thymidine, [18F]-FLT, [18F]FFEAU, [124I]-IdUrd (clinical 
testing) 
    Apoptosis [99mTc]Annexin V, [18F]Annexin V (clinical testing) 
    Hypoxia [18F]FMISO, [18F]-EF5, [18F]FETNIM, [18F], [64Cu]ATSM, [124I]-
IAZG, [123I]-arabinoside, [18F]FAZA (clinical testing) 
    Pharmacokinetics [18F]5-FU, [11C]DACA, [11C]BNCU, [11C]temozolomide, 
[13N]cisplatin (FDA approved) 
    Multidrug resistance [99mTc]sestamibi, [11C]verapamil, [11C]daunorubicin, 
[11C]colchicine, [99mTc]MIBI (FDA approved) 
    Breast cancer (ER) [18F]FES (clinical testing) 
    Prostate cancer (androgen receptor) [18F]FDHT (clinical testing) 
Peptide probes  
    Somatostatin/somatostatin receptor [90Y] DOTATOC, [111In]DTPA-D-Phe-1-octreotide, [90Y]DOTALAN, 
[90Y]DOTAVAP (FDA approved) 
    Vasoactive intestinal peptide/vasoactive 
intestinal peptide receptor-1 
[123I]VIP, [99mTc]TP3654 (clinical testing) 
    Bombesin, gastrin-releasing 
peptide/gastrin-releasing peptide receptor 
[99mTc]Bombesin (clinical testing) 
    Cholecystokinin, gastrin/cholecystokinin 
receptor 
[111In]DTPA-minigastrin (clinical testing) 
    Angiogenesis [18F]RGD peptide targeted to αVß3 integrin (preclinical testing) 
Antibody probes  
    Angiogenesis Paramagnetic nanoparticles using antibodies to integrin αVß3, the 
integrin αVß3 ligand, vascular cell adhesion molecule 1, E-selectin 
(preclinical testing) 
    CEA [99mTc]-Arcitumomab (CEAscan), [111In] Satumomab (FDA 
approved) 
    Prostate-specific membrane antigen [111In]-Capromab pendetide (ProstaScint) (FDA approved) 
    CD20 [131I]-tositumomab (Bexxar), [90Y]-ibritumomab tiuxetan (Zevalin) 
(FDA approved) 
    CD22 [99mTc]-Bectumomab (clinical testing) 
ATSM, diacetyl-bis(N4-methylthiosemicarbazone); BNCU, 1,3-bis(chloroethyl)-1-nitrosourea; CEA, 
carcinoembryonic antigen; DACA, N-[2-(dimethylamino)ethyl]acridine-4-carboxamide; DOTALAN, 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid lanreotide; DOTATOC, DOTA-Tyr3-octreotide; DOTAVAP, 
DOTA-vapreotide; EF5, 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide; ER, estrogen 
receptor; FAZA, fluoro-azomycin-arabino-furanoside; FDHT, 16β-fluoro-5α-dihydrotestosterone; FES, 16α-
fluoroestradiol-17β; FETA, fluoroetanidazole; FETNIM, fluoroerythronitroimidazole; FFEAU, 2′-fluoro-2′-deoxy-
1-β-D-arabinofuranosyl-5-(2-fluoroethyl)-uracil; FLT, 3’-deoxy-3’-fluorothymidine; FMISO, fluoromisonidazole; 
5-FU, 5-fluorouracil; IAZG, iodo-azomycin-galactoside; IdUrd, iododeoxyuridine, MIBI, methoxyisobutylisonitrile; 
RGD, arginine-glycine-aspartic acid peptide,VIP, Vasoactive intestinal peptide 
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An application of this strategy can be comparing lead candidates interacting 
with the same target in an early phase of drug development. Also, imaging 
probes can act as biomarkers of tumour response; imaging end points at the 
molecular level (i.e., apoptosis, proliferation, angiogenesis, etc.) can speed up 
the evaluation of therapeutic success (Smith-Jones et al., 2004; Kelloff et al., 
2005). 
Although the introduction of [18F]-fluorodeoxyglucose (FDG)-PET has offered 
a revolution in oncology imaging (Alavi et al., 2004), the complexity of cancer 
progress and unique capabilities of PET and SPECT, lead to the increased 
development of new tracers, both for PET and SPECT applications. The most 
important molecular imaging targets and probes are given in Table 1.6. 
Analogously to targeted therapeutics, the target of choice in molecular imaging 
plays an important role in tumour biology or the physiological mechanisms of 
oncogenesis. Prominent examples of targets include specific kinases, cellular 
receptors, and signalling molecules. Imaging of neoplastic processes includes 
proliferation, angiogenesis, apoptosis and, hypoxia (Table 1.6). The probes 
used are small molecules, peptides and monoclonal antibodies labeled with 
radionuclides (e.g., 11C, 18F, 99mTc, and 123I) or magnetic ligands (Kelloff et al., 
2005). Each category has been intensively investigated and reviewed over the 
last decade (Blankenberg et al., 2000a-b; Welch and Redvanly, 2003; Alavi et 
al., 2004; Blankenberg, 2004; Schuster and Halkar, 2004; Czernin et al., 2006; 
Yang et al., 2006). 
CEA was one of the earliest targets for radioimmuodetection and radiotherapy. 
Extensive work in the late 1970s and early 1980s used a variety of antibodies 
primarily labeled with iodine radionuclides (Goldenberg et al., 1978; Mach et 
al., 1980). Despite high rates of detection, and a lot of improvements over the 
years (e.g., genetic engineering, pretargeting) radioimmunodetection is still not 
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considered a routine procedure in the clinic. Table 1.7 lists some of the factors 
discussed by Bischof Delaloye (2000) possibly impeding its overall acceptance. 
Tabel 1.7 Factors impeding overall acceptance of radioimmunodetection (Bischof Delaloye, 2000) 
Costs 
Complexity of procedure 
Difficulty of penetration 
Human anti-mouse antibodies 
Lack of interest from clinicians 
Lack of large clinical trials 
Lack of pertinence of the method 
Lack of support from the industry 
Competing methods 
Two of the most important factors are the success of FDG-PET and the 
refinement of the anatomic imaging methods, which have reduced the unclear 
cases in which functional imaging often allows a clarification of the diagnosis. 
However, one limitation of FDG is that its uptake is related to increased 
glucose metabolism and not a specific metabolic feature. False positive results 
have been described in cases of active inflammatory/infection lesions 
(Sugawara et al., 1998; Lim et al., 2005; Jacene et al., 2006). Improved 
imaging methods, such as immuno-PET, offer possible advantages (Larson et 
al., 1992, Lovqvist et al., 2001; Sundaresan et al., 2003), and rapid imaging 
using pretargeting and other techniques could enable application of PET 
radionuclides with short half-lives (e.g., 18F and 68Ga) labeled to antibodies. A 
spectrum of antibodies and antibody derivatives, including minibodies and 
diabodies (Sundaresan et al., 2003; Olafsen et al., 2004), are now available 
based on advanced molecular engineering techniques, and these forms are 
likely to have targeting advantages when optimized. These new antibody forms 
are also likely to lack immunogenicity, permitting repeated diagnostic use, or 
therapeutic administration (Winter and Harris, 1993). 
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These diverse advances in the technology of imaging and radiolabeling, and in 
molecular engineering of antibodies, will together provide opportunities to 
develop increasingly effective molecularly agents for imaging. 
1.3 Advances in radioimmunodetection and -therapy 
Monoclonal antibodies account for an increasing portion of marketed human, 
biological therapeutics. Since the mid-1990s, antibodies have emerged as an 
important new drug class. 
 
Fig. 1.8. The first step in the generation of antibody therapeutics, which is one of the most difficult 
steps, is the selection of a target antigen. A concept for therapeutic intervention using an antibody 
is then devised, ideally on the basis of knowledge about the target, including its role in the 
pathobiology of disease. This therapeutic concept leads to the antibody design specification: that 
is, a list of crucial or desirable properties that are predicted to achieve the desired clinical outcome. 
The design specification guides the method of antibody generation, as well as the reagents and 
assays that are needed to identify antibodies with the desired properties. Panels of antibodies are 
evaluated in vitro and then in vivo to test the therapeutic concept and to rank the antibodies for 
potency and safety. Antibody optimization might be necessary or desirable to meet the design 
goals and can be guided by existing antibody drugs, in terms of favourable attributes to emulate 
and limitations to overcome. Revision of the design specifications might be required in light of in 
vitro and in vivo data. The antibody clinical candidate is then subjected to further preclinical and, if 
warranted, clinical development. Clinical-trial data — particularly if they validate the target through 
to the drug-approval stage — might provide the impetus for the whole process to begin again, to 
generate an improved drug (Carter, 2006). 
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Eighteen antibodies have now been approved (17 have been marketed, and 1 
withdrawn) for imaging and therapeutic use. Twelve of these antibodies are 
used in oncology of which half of them are radioimmunoconjugates.  The other 
antibodies are used in chronic inflammatory diseases, transplantation, 
infectious diseases and cardiovascular medicine (Carter, 2006). Selection, 
design, and engineering of these antibodies not only expanded in the past two 
decades but are now becoming important competitive factors. In his latest 
review, Carter (2006) depicts the development of an antibody drug as an 
iterative design process (Fig. 1.8). From this design process, it is clear why 
antibody drugs are expensive. One of the many factors includes the large 
expense of drug development in general and high costs of intellectual property 
associated with the generation, optimization and production of antibodies.  
The success of both radioimmunodetection (RID) and radioimmunotherapy 
(RIT) depends on intrinsic factors of the antibody, the radionuclide, and the 
target. A key strength of antibodies is that their clinical potential can readily be 
increased by improving their existing properties, as will be discussed below. 
Many authors review the pros and contras concerning these evolving steps 
made in the past five years. Most progresses have been made in the field of 
genetic engineering and pretargeting (Bischof Delaloye, 2000; Blankenberg, 
2000; Illidge and Brock, 2000; Maynard and Georgiou, 2000; Verhaar-
Langereis et al., 2000; Banerjee et al., 2001; Carter, 2001; Reff and Heard, 
2001; Todorovska et al., 2001; Allen, 2002; Batra et al., 2002; Carlsson et al., 
2002; Goldenberg, 2002; Boerman et al., 2003; Brekke and Sandlie, 2003; 
Carlsson et al. 2003; Goldenberg, 2003; von Mehren et al., 2003; Bethge and 
Sandmaier, 2004; Carter 2004; Huchalov and Chester, 2004; Mertens et al., 
2004; Milenic et al., 2004; Mirick et al., 2004; Penichet and Morrison, 2004; 
Robinson et al., 2004; Tolmachev et al., 2004; Van De Wiele et al., 2004; 
Adam and Willbur, 2005; Adams and Weiner, 2005; Kelloff et al., 2005; 
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Koppe et al., 2005; Pavlou and Belsey, 2005; Sharkey and Goldenberg, 2005; 
Wu et al., 2005; Carter, 2006; Goldenberg et al., 2006; Pohlman et al., 2006; 
Sharkey and Goldenberg, 2006a; Sharkey and Goldenberg, 2006b; Weiner, 
2006). 
1.3.1 Antibody parameters 
1.3.1.1 Binding affinity 
The longer the time the radionuclides stay in or near the targeted cell the higher 
the fraction of the total radioactivity that can be utilised for imaging or therapy, 
and the higher the dose will be delivered per targeting event. Increased 
retention can be achieved by a targeting process that gives a high affinity and 
stable binding (Carlsson et al., 2003). Affinity is often expressed by the 
dissociation constant (Kd = koff/kon). In general a high affinity antibody is one 
which requires a very low concentration (typically 10-7 – 10-12 mol/l) of free 
antibody to acquire half of the saturating antibody level (Morris, 1995). 
However, it remains an interesting question whether the affinity of the antibody 
for its receptor should be high or low. There is some evidence that with solid 
tumours, decreased tumour penetration can occur when the affinity is too high 
because of the ‘binding site barrier’ (Weinstein and van Osdol, 1992). 
Consequently, high affinity antibodies bind to the first targets encountered but 
fail to diffuse further into the tumour (Adams et al., 2001). On the contrary, 
with readily accessible cancer cells, e.g. tumour vasculature and 
haematological malignancies, high binding affinity might be desirable (Allen, 
2002). 
Ong and Mattes (1993) demonstrate that an antibody has a spectrum of 
functional affinities depending on the experimental conditions applied. 
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1.3.1.2 Antibody fragments 
The long persistence of monoclonal antibodies in circulation exhibits toxic 
radiation to normal tissues with limited quantities delivered to the tumours 
(Carter, 2006). Furthermore, intact mAbs show poor diffusion from the 
vasculature into and through the tumour (Jain, 1987; Goel et al., 2000). While 
micrometastases offer an interesting target for RIT, these lesions often show 
high interstitial pressure and low vascularization, in which only low 
sensitivities have been observed (Bock et al. 1992; Vijayakumar et al. 1993, 
Goldenberg et al. 2002). To minimize these limitations of intact mAbs, many 
efforts of various groups have been undertaken in increasing the tumour-to-
background ratio and increase tumour penetration. A common approach is the 
development of smaller antibody fragments by enzymatic cleavage (papain, 
pepsin or ficin) and genetically engineered single-chain Fv (scFv) constructs of 
antibody molecules (Reff ME, 2001; Goldenberg DM, 2002; Batra SK et al., 
2002). 
Enzymatic derived bivalent F(ab')2 and monovalent Fab fragments have shown 
promising tumour penetration and good therapeutic results in animals (Wahl et 
al., 1983; Sharkey et al., 1990; Hansen et al., 1990; Blumenthal et al., 1992; 
Behr TM , 2000) and clinical studies (Murray et al., 1994; Willkomm et al., 
2000; Libutti et al., 2001; Goldenberg, 2002). Disadvantages seen with these 
fragments are lower tumour uptake and high renal uptake particularly when a 
radiometal is used, which raises concern for renal toxicity. However, studies 
have shown that a high predose of cationic amino acids (e.g. L-lysine) could 
significantly reduce renal tubular reabsorption of radiometal-labeled Fab (Behr 
et al., 1995; Behr et al., 1998). 
Genetic engineering provides powerful tools for manipulating the structure and 
pharmacokinetic properties of antibodies. One useful strategy has been the 
production of single chain fragments (scFv) containing the variable regions of 
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the immunoglobulin heavy chain and light chain, covalently connected by a 
flexible peptide linker (Colcher et al., 1990). Several scFvs have been 
evaluated for their specific in vivo tumour targeting to antigens such as TAG-
72, carcinoembryonic antigen (CEA) and the HER2/neu receptor. They 
demonstrated more rapid clearance and higher tumour-to-normal tissue ratios 
than the corresponding IgG or Fab fragments (Milenic et al., 1991; Adams et 
al., 1993; Wu et al., 1996). Furthermore, penetration of scFv into a tumour 
from the vasulature demonstrated with autoradiography, was superior to that of 
corresponding intact IgG, F(ab’)2 or Fab (Yokota et al., 1993). 
 
Fig. 1.9. Alternative antibody formats with a molecular-weight range of at least 12–150 kDa and a 
valency (n) range from monomeric (n = 1), dimeric (n = 2) and trimeric (n = 3) to tetrameric (n = 4). 
The building block that is most frequently used to create novel antibody formats is the single-chain 
variable (V)-domain antibody fragment (scFv), which comprises V domains from the heavy and 
light chain (VH and VL domain) joined by a peptide linker of up to ~15 amino-acid residues. 
Constant (C) and V domains, inter-chain disulphide bonds (green bars) and glycosylation are 
depicted. Peptide and chemical linkers are shown as orange and red lines, respectively. CH, C 
domain of immunoglobulin heavy chain; CL, C domain of immunoglobulin light chain; dsFv, 
disulphide-stabilized scFv. (Carter, 2006) 
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Because of the rapid clearance of 25 kDa proteins from the blood pool, the 
absolute tumour uptake of a monomeric scFv is limited. Multivalent antibody 
constructs have demonstrated improved tumour uptake with the corresponding 
form and demonstrate intermediate blood clearance ratios compared with scFv 
and intact antibodies. Different strategies have been described in literature for 
the formation of multivalent antibodies with altered pharmacokinetics and 
improved tumour uptake. Adams et al. (1993) described an improvement in in 
vivo tumour targeting using divalent forms of anti-neu-scFv with a C-terminal 
Gly4Cys joined by a disulfide bond (Huston et al., 1994). Another antibody 
fragment, a minibody, was produced by fusion of T84.66 anti-CEA scFv to the 
human IgG1 CH3 domain (Hu et al. 1996). Others have fused scFvs to protein 
domains capable of multimerization, e.g., leucine zipper proteins (Kostelny et 
al., 1992), streptavidin (Dubel et al., 1995), or the κ-constant region (McGregor 
et al. 1994). The easiest approach for the production of dimeric scFvs is based 
on spontaneous formation of noncovalent dimers such as 50 kDa diabodies 
(Holliger, 1993). Figure 1.9 shows a recent overview of alternative antibody 
formats based on the scFv as building block given by Carter (2006). 
Tabel 1.8 Targeting properties of monoclonal antibody and alternative antibody formats 
(Goldenberg et al., 2006) 
 
IgG F(ab’)2 CH2-deletion Minibody Fab Diabody scFv 
Physical properties        
Approximate molecular weight 
(kDa) 
150 100 120 80 50 40-50 20-25 
Biological properties        
Approximate biological t½ blood† 2-3 d 1 d Hours Hours Hours Hours Hour 
Target organ Liver Liver Liver Liver Kidney Kidney Kidney 
Tumour binding properties        
Relative uptake‡ 1 2 2-3 2-3 3 3 4 
Time to optimum accumulation Day(s) Day Hours Hours Hours Hours Hour 
Relative duration‡ 1 2 2-3 2-3 3 3 4 
† Estimated time for 50% of the antibody to clear from the blood 
‡ From the highest (1) to the lowest (4) 
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Table 1.8 shows the changes in targeting properties of some engineered 
antibody fragments. New molecular constructs are being developed with 
properties that enable good uptake in tumours, with minimal accumulation and 
retention in normal tissue, but it is possible that at least for some of these 
constructs, the choice of radionuclide may be limited. 
1.3.1.3 Immunogenicity 
Except for altering pharmacokinetics, genetic engineering has another 
advantage. Mouse monoclonal antibodies have shown limited use as 
therapeutic agents in humans as a result of the production of human anti-
mouse-antibodies (HAMA response). 
 
Fig. 1.10. Advances in genetic engineering techniques have contributed to the development of 
humanized therapeutic mAbs. The fundamental structure of an intact, single immunoglobulin G 
(IgG) molecule has a pair of light chains (orange/red) and a pair of heavy chains (yellow/pink). Light 
chains are composed of two separate regions (one variable region (VL) and one constant region 
(CL)), whereas heavy chains are composed of four regions (VH, CH1, CH2 and CH3). The 
complementarity-determining regions (CDRs) are found in the variable fragment (Fv) portion of the 
antigen-binding fragment (Fab). Chimeric mAbs such as cetuximab and rituximab are constructed 
with variable regions (VL and VH) derived from a murine source and constant regions derived from 
a human source. Humanized therapeutic mAbs are predominantly derived from a human source 
except for the CDRs, which are murine. There are currently four approved humanized mAbs. Both 
murine and human mAbs are entirely derived from mouse and human sources, respectively. 
Panitumumab (ABX–EGF) is a fully human anti-epidermal growth factor receptor (EGFR) mAb, but 
has not yet been approved. (Imai and Takaoka, 2006) 
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In an attempt to reduce the immunogenicity of mouse antibodies, genetic 
engineering was also used to generate chimeric antibodies, that is, antibodies 
with human constant regions and mouse variable regions. However, anti-
chimeric antibody responses (HACAs) have been observed. Further 
minimization of the mouse component of antibodies can be achieved through 
complement determining region (CDR) grafting. In these humanized 
antibodies, only the CDR loops are inserted into the human variable framework 
(Fig. 1.10) (Imai and Takaoka, 2006). 
1.3.1.4 Pretargeting 
Pretargeting is a process in which the antibody and radionuclide targeting steps 
are separated. Recently, Sharkey (2006a) and others (Goodwin and Meares, 
2001; Boerman et al., 2003) reviewed the advances made in pretargeting 
strategies. There are basically 3 types of pretargeting methods used for 
radionuclides: those that use a bispecific antibody (bsMAb); those based on 
streptavidin/avidin and biotin; and a new model that is evaluating the 
possibility for using complementary DNA analogues. The steps commonly 
used in these pretargeting methods are illustrated in Figure 1.11. 
Pretargeting procedures permit a very rapid uptake of radioactivity in tumours, 
thereby increasing the radiation dose rate, which could be important for 
improving therapeutic responses. Data from animal models and recent clinical 
studies suggest that pretargeting can deliver more radioactivity to tumours than 
a directly radiolabeled whole IgG. All pretargeting procedures could be 
adapted for use with different radionuclides that would be best suited for a 
variety of clinical indications and settings. Therefore, pretargeting has 
potentially important advantages over directly radiolabeled antibodies for 
future therapeutic applications. 
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Fig. 1.11. Most commonly used pretargeting methods for radioimmunotherapy (Sharkey and 
Goldenberg, 2006a) AES, affinity enhancing system; gal, galactose; IgG, immunoglobulin G 
1.3.2 Choice of Radionuclides 
1.3.2.1 Radionuclides for radioimmunotherapy 
In RIT, potentially therapeutic radionuclides are transported to the desired site 
of action by target-selective vehicles. As a consequence, any consideration of 
the optimal properties of such nuclides must take into account the nature and in 
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vivo behaviour of the respective vehicle. Despite this obvious limitation, some 
generalizations can be made about the required physical characteristics of 
therapy nuclides, and these have formed the basis of numerous publications 
(e.g. Wessels and Rogus (1984) and Andres and Schubiger (1987)). Several 
types of radionuclides are suitable for therapy. Table 1.9 lists some of the more 
commonly used radionuclides conjugated to antibodies for RIT. 
Tabel 1.9 Physical properties of some radionuclides of therapeutic interest in RIT 
Radionuclide Emission  Half-life  Range  
Approximate # 
Cell Diameters 
131Iodine β 8.0 d 0.08–2.3 mm 10 to 230 
90Yttrium β 64.1 h 4.0–11.3 mm 400 to 1100 
177Lutetium β 6.7 d 0.04–1.8 mm 4 to 180 
188Rhenium β 17.0 h 1.9–10.4 mm 200 to 1000 
67Copper β 61.9 d 0.05–2.1 mm 5 to 210 
211Astatine α 7.2 h 60 µm 6 
213Bismuth α 46 min 84 µm 8 
125Iodine Auger 60.5 d <100 nm (1) 
111Indium Auger  3.0 d <100 nm  (1) 
The three major groups are those emitting therapeutically adequate amounts of 
β particles, Auger electrons or α particles. Important factors influencing the 
choice of an isotope are the nature of the associated radiation, the penetration 
range, the physical half-life (t1/2) of the nuclide, the stability of any daughter 
nuclides formed, cost, availability, linear energy transfer (LET), specific 
activity, feasibility of radiochemistry, substitution index, internalization and 
cellular metabolism. Tumour size is the primary consideration (Goldenberg, 
2002; Carlsson et al., 2003; Adam et al., 2005; Milenic et al., 2004; Sharkey 
and Goldenberg, 2006b). 
High energy β particles (e.g., 90Y, Emax 2.3 MeV; 188Re, Emax 2.1 MeV) are not 
efficient for killing single disseminated cells or small metastases, since only a 
small fraction of the electron energy will be deposited in such small targets. 
Most of the energy will instead be absorbed in surrounding tissues. On the 
other hand, they might be important for treatment in case of a non-uniform 
Introduction 
 37
radioactivity distribution in larger tumour areas to kill across several hundred 
cells, referred to as ‘bystander effect’ or ‘crossfire effect’. Irradiation from the 
targeted cells will then enable a more uniform dose-distribution and give 
therapeutic effect also to non-targeted tumour cells (O’Donoghue et al., 1995). 
This is considered a significant attribute for radioconjugates compared with 
other immunoconjugates, since they can be therapeutically active even if 
heterogeneous antigen expression, tumour architecture, or other factors impede 
targeting of every cell (Carlsson et al., 2003; Sharkey and Goldenberg, 2006b). 
Radionuclides emitting α particles are more appropriate for metastatic disease 
or applications where single cells are targeted. These high-energy particles (4-9 
MeV) travel short distances (40-100 µm). They are characterized by dense 
emission path lengths of high LET, which is approximately 400 times greater 
than β- emitters (80 versus 0.2 keV per µm). While it is estimated to take 
several hundred β- particle emitting radionuclides (e.g., > 400) on a single cell 
to kill that cell, only few hits of α particles (e.g., 1-14) are necessary (Mattes, 
2002; Milenic et al., 2004). 
The low energy Auger electrons deposit their energy in a very short distance 
(e.g. a few Å), which makes it high LET. Auger electron emitters are only 
suitable if nuclear localisation is possible (Hofer, 2000). Despite this limitation, 
studies have demonstrated that Auger emitters might have a significant role as 
therapeutics, even if their clinical use might be limited to eradication of 
microscopic residual disease (Mattes, 2002; Michel et al., 2003; Milenic et al., 
2004). 
The physical half-life of the radionuclides should preferably be in the same 
order of magnitude as the biological half-life. A too long physical half-life 
increases the necessary amount of radionuclides to be delivered to the tumour 
cells to allow for reasonable amounts of decays before excretion. A too short 
physical half-life will not give enough time for the targeting process to take 
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place. It seems reasonable to assume that the most suitable physical half-life 
ranges from a few hours up to some days when targeting of disseminated cells 
is considered. Longer physical half-lives (up to one or a few weeks) might be 
desirable if high uptakes in solid tumour masses are needed (Carlsson et al., 
2003). 
1.3.2.2 Radionuclides for radioimmunodetection 
The most studied radionuclides for radioimmunodetection are iodine-131 (131I), 
indium-111 (111In), iodine-123 (123I), and technetium-99m (99mTc) (Table 1.10). 
Early studies were performed with 131I (364 keV), but gamma rays emitted by 
123I (159 keV) or 99mTc (140 keV) are superior for imaging with a conventional 
gamma camera or SPECT. 99mTc is the most widely used radioisotope for 
diagnostic imaging.  
Tabel 1.10 Most common radionuclides used in radioimmunodetection 
Radionuclide Emission Half-life 
SPECT   
131Iodine γ 8.0 d 
123Iodine γ 13.1 h 
99mTechnetium γ 6.0 h 
111Indium γ 62 h 
PET   
64Copper β+ 12.7 h 
18Fluorine β+ 1.8 h 
89Zirconium β+ 3.27 d 
124Iodine β+ 4.18 d 
Labeling strategies for radiometals require bifunctional chelating agents (BFC), 
which consist of a chelator to complex the radiometal and a functional group 
for linkage with amine or thiol groups on proteins and peptides (Schubiger et 
al., 1996). The first BCFs were analogues of (ethylenediaminetetraacetic acid) 
EDTA and diethylenetriaminepentaacetic acid (DTPA) (Hnatowich et al., 
1983). Many improvements have been made and commonly used BCFs for 
copper, technetium and indium have been reviewed (Hnatowich, 1994; 
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Schubiger et al., 1996; Zalutsky and Lewis, 2003; Yang et al., 2006). Several 
review articles discuss the various direct protein labeling methods for 99mTc and 
rhenium isotopes (Griffiths et al., 1992; Hnatowich, 1994). The labeling 
strategies for radiohalogen radionuclides were recently reviewed by Adam and 
Wilbur (2005). Different labeling strategies with radioiodine isotopes are 
reviewed by Zalutsky and Lewis (2003). The most frequently used methods for 
generating the electrophilic radioiodinating species involve the oxidants Iodo-
Gen (Fraker and Speck, 1978) or chloramine-T (Hunter and Greenwood, 1962). 
Feasibility of immuno-PET has been established with 124I- or 64Cu-labeled 
monoclonal antibodies and more alternative PET tracers have been examined 
(Pagani et al., 1997; Lewis et al., 2003; Verel et al., 2004). Increased sensitivity 
has been documented relative to CT or magnetic resonance imaging (MRI). 
Limited availability of antibodies labeled with these isotopes has hindered 
development of immuno-PET and much effort has focused on the more readily 
available 18F-labeled reagents. Due to the short half-life of 18F, studies have 
been limited to small antibody fragments that can be rapidly cleared from the 
circulation. A possible solution to the search of a long-lived metallic PET 
isotope in the form of 89Zr for labeling antibodies is described by Verel et al. 
(2003a-b). A possible limitation of this tracer can be the concomitant high 
gamma emission at 909 keV, which may limit the radioactive dose that can be 
administered and affect image quality and quantitative aspects of imaging 
(Eary, 2001). 
1.3.3 Antigen parameters 
1.3.3.1 Antigen/Receptor expression 
Identifying a molecular or cellular target critical to the pathophysiology of 
cancer is a basic step in drug development. It is anticipated to be a necessary 
but not sufficient condition for successful tumour targeting with an antibody. 
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An ideal expression profile is abundant and homogeneous on the external 
surface of all tumour cells for multiple tumour types, with the majority of 
patients for each tumour type, and absent from normal tissue. It is not 
necessary to fully satisfy all of these criteria as evidenced by clinical approval 
of antibodies targeting HER2 (Herceptin), CD20 (Rituxan, Zevalin and 
Bexxar), CD33 (Mylotarg), CD52 (Campath) and epidermal growth factor 
receptor (EGFR) (Erbitux). Table 1.11 gives an overview of the most important 
antigen expression characteristics that need to be investigated during 
identification and validation of new antibody targets (Carter et al., 2004). 
Tabel 1.11 Antigen expression characteristics suitable for antibody targeting (Carter et al., 2004) 
• Associated with advanced disease; present in tumours at all stages of disease, including 
metastatic foci; causally involved in disease pathogenesis; no downregulation 
• Homogeneous expression; heterogeneous expression may necessitate bystander effect 
• Lower limit and upper limit of antigen expression are not known; dependent non-solid tumour 
versus solid tumour; dependent conjugated versus unconjugated; 5 000 to 1 000 000 copies  
• Limited, preferably no expression on vital normal tissue; less problematic on non-vital tissue 
e.g. CD20, CD33 and CD52 
• Target is not shed or shed at low levels (<500 ng/ml) 
Ideally, the target is preferentially expressed and/or activated in cancer cells at 
all stages of disease, including metastatic foci. Minimally, it should be present 
in advanced disease and preferentially causally involved in the pathogenesis to 
reduce the probability that tumours will escape from antibody therapy by down 
regulation. Target cells should not show a high degree of heterogeneity in 
antigen expression. However, using radionuclides, the targeted treatment might 
lead to toxicity against antigen-negative cells, called the bystander effect, 
which are in close proximity of the actual target. In that case, some 
heterogeneity might be tolerated (Carter, 2001; Milenic, 2002; Presta, 2002; 
Ross et al., 2003). The targeted antigen should ideally have a high density (100 
000 targets/cell) on the tumour cell, although it depends on several parameters 
Introduction 
 41
such as treatment of non-solid tumour versus solid tumour, use of 
immunoconjugates versus non-conjugates (Tanimoto et al., 1989). The antigen 
should not be shed or downregulated. Circulating shed antigen will compete 
with targets at the cancer cells for binding of the targeted therapeutics, resulting 
in acceleration of antibody clearance and decrease of antibody localization. 
Using radioimmunoconjugates this might lead to increasing the toxicity to 
normal tissues. Ideally the target antigen is not shed (e.g. CD20, Einfeld et al. 
1988) or shed at only low (<500 ng/ml) and antibody-titratable levels in the 
majority of patients (e.g. HER2, Baselga et al. 1996, Cobleigh et al. 1999). 
Genomic instability is sometimes referred to as a consequence of the multistep 
carcinogenesis in which defect onco-, supressor-, cell cycle- and apoptosis 
regulating genes allow the tumour cells to pass the cell cycle and divide in spite 
of non-repaired DNA damage. The genomic instability may give rise to unique 
tumour cell epitopes suitable for targeting. However, if an efficient therapy 
based on targeting of new epitopes is carried out, a selection will be created 
and new subclones with no or only low amounts of the epitope might appear. 
Furthermore, the treatment with radioactivity itself will create DNA damages 
and thereby possibly make the selection process more extensive. By choosing 
appropriate targets for radionuclide therapy it might be possible to minimise 
the risk for adverse effects due to genomic instability. For example, it is known 
that the expression of the oncogene HER2 is surprisingly stable when 
comparing primary tumours with the corresponding metastases (Niehans et al., 
1993; Tewari et al., 2000; Carlsson et al., 2003). 
Tumour progression depends upon a variety of non-cancerous cells (e.g. 
endothelial cells, stromal cells) and factors associated directly or indirectly 
with them (e.g., matrix metalloproteinases, growth factors). Consequently, non-
cancerous cells and these associated factors should also be considered as a 
source of cancer therapy targets. The recent approval of an anti-VEGF 
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antibody, bevacizumab (Avastatin), as anti-angiogenic treatment is an example 
of such approach. 
1.3.3.2 Internalization 
The binding of some ligands to their receptor can cause receptor-mediated 
internalization and influence the metabolism of radiolabeled antibodies (Sands 
and Jones, 1987). Depending on the type of radiotargeted therapy, this may be 
desired or should not at all occur. One critical factor is the high cellular 
retention of the radionuclides. For therapies with radiolabeled antibodies, 
internalization might be advantageous for α-emitting radionuclides. Because of 
the very short range of α-particles, they should ideally be produced in the 
proximity of the DNA. For radioiodinated tracers, internalization may lead to 
metabolization and also excretion of iodo-tyrosine from the lysosomes. Hereby, 
cell-associated radioiodine decreases rapidly from the cells followed by 
diffusion and elimination of the radionuclide (Geissler et al., 1991; Shih et al., 
1994a; Shih et al., 1994b).  
Different approaches have been developed for residualizing radioiodine activity 
in tumour cells after mAb internalization: oligosaccharide conjugates, 
positively charged templates, and D-amino acid peptides (Ram and 
Buchsbaum, 1994; Thorpe et al., 1993; Reist et al., 1995; Stein et al., 1995; 
Reist et al., 1996; Mattes et al., 1997; Govindan et al., 1999; Foulon et al., 
2000; Zalutsky and Lewis, 2003; Stein et al., 2003; Govindan et al., 2004; 
Schaijk et al., 2005).  
Radiometals, e.g. indium and technetium, are trapped within the lysosomes 
after catabolization (Duncan and Welch, 1993; Mattes et al., 1994). Therefore, 
tumour uptake can be increased when using radiometals instead of halogens 
when internalization of mAb-receptor occurs. However, kidney uptake of 
radiometals is increased by the same internalization effect, especially when 
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smaller antibody fragments are used. Therefore, different strategies have been 
tested to reduce kidney uptake of radiometals using basic amino acids (e.g., 
Lysine), amino sugars, and basic polypeptides. The effect seems to rely 
essentially on the presence of a positively charged amino group (Behr et al., 
1998). 
Some evidence is given that multivalency is required for internalization, e.g. 
when monovalent Fab fragments of several anti-HER2 antibodies were tested 
for internalization, the monovalent Fab fragments were not internalized 
(Srinivas et al., 1993). 
1.3.3.3 Haematological cancers versus solid tumours 
Despite the success of RIT in the treatment of non-Hodgkin’s lymphoma, 
therapeutic success in solid tumours has been modest. Immunotherapeutics are 
often administrated via intravenous injection and distribution to the target cells 
occurs by the bloodstream. Therefore, haematological cancers are more 
accessible than solid tumours, e.g. malignant B or T cells, metastatic cells 
distributed in the bloodstream, or the cells of the tumour vasculature. Targeted 
therapeutics can rapidly bind these cells and long circulation times may not be 
necessary. On the contrary, in the case of solid tumours it is important that the 
radioimmunoconjugates circulate for sufficient time to obtain sufficient tumour 
uptake. Higher penetration is obtained when smaller antibody fragments are 
used, however, their size need to be above the exclusion limit for kidney 
filtration in order to circulate enough time in the bloodstream (Allen, 2002). 
Solid tumours have substantial physical barriers composed by the 
microvascular endothelium, the tumour stromal and interstitial structures as 
well as the excessive interstitial pressure associated with a high cell density 
(Christiansen and Rasjeskaran, 2004). The affinity of the antibody is probably 
critical, and if it is too high, its ability to penetrate a tumour mass will be 
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further restricted (Adams et al., 2001; Graff and Wittrup, 2003). Various 
solutions to these problems have been considered, including the use of smaller 
antibody fragments, intratumour injection of antibody and the targeting of 
tumour vasculature with agents that increase permeability such as TNFα (Hale, 
2006). 
1.3.4 Future challenges 
One of the initial goals of targeted strategies is defining targets early in cancer 
development, to intervene in early stages of cancer. Has radioimmunotherapy 
potential in targeting early steps of cancer development? Carter (2004) suggests 
that antigen expression restricted to early stage cancer appears impractical for 
antibody drug development for the following reasons. First, there is a risk that 
diagnosis of cancer will not occur until after antigen expression has been lost. 
Secondly, patients with early stage disease will often have established treatment 
options that preclude the use of an unproven experimental drug (Carter et al., 
2004). However, very encouraging results of first-line treatment of lymphoma 
patients with radiolabeled antibodies were published (Kaminski et al., 2005). 
Seventy-six previously untreated patients received Bexxar. The overall 
response rate was as high as 95%, of which fifty-seven patients achieving a 
complete response (Kaminski et al., 2005). On the contrary, in solid cancers 
patients eligible for phase I/II RIT trials almost invariably have metastatic and 
bulky disease, and have been heavily pretreated with chemotherapy and/or 
radiotherapy (Koppe et al., 2005). 
Perhaps the most challenging problem with RIT remains its inability to deliver 
a sufficient amount of radioactivity to kill solid tumours, especially when >5 
cm, at tolerable doses to other organs. Interestingly, Sharkey (2006) discusses 
the potential of RIT in targeting the tumour vasculature, rather than to breach 
the tumour vasculature to deliver the radiotoxicity to the individual tumour 
cells. Vascular targets have received increasing attention over the past decade, 
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with a variety of agents, including antibodies, being used to inhibit 
neovascularization (Cardones and Banez, 2006; Folkman, 2006; Mitra et al., 
2006). Some of these agents act on substances found on the endothelial cells of 
the blood vessels, but others, such as inhibitors of the vascular endothelial 
growth factor, act indirectly by binding to substances required to activate blood 
vessel formation (Folkman, 2006). Tijink et al. (2006) used a recombinant 
engineered antibody, L19-SIP, that binds to an isoform of fibronectin found 
primarily on  blood vessels formed within the tumour, and thus the antibody 
does not have to overcome the barriers that inhibit migration to the individual 
tumour cells (Borsi et al., 2002). In addition to revaluating the conditions 
where RIT should be best applied, careful consideration also needs to be given 
to choosing solid tumours that, like NHL, will be more susceptible to radiation. 
In this regard, head and neck cancers are noted for their relative sensitivity to 
radiation, and therefore this would be an excellent indication for the 
development of a targeted radionuclide therapy (Sharkey, 2006). 
Exploring the combinations of all new targeted strategies and optimizing the 
role of RIT in these combinations offers another big challenge for the future. 
Enhancement of immunotherapy and radioimmunotherapy has recently been 
demonstrated by the use of combined molecular targeting. The efficacy of 
radioimmunotherapy with an anti-LewisY monoclonal antibody was enhanced 
by the use of a tyrosine kinase that inhibited signalling of the epidermal growth 
factor receptor during RIT in animals (Lee et al., 2005). Several other studies 
support the possibility of synergy when combining targeted strategies (Burke 
and Denardo, 2001; Burke et al., 2002; Denardo, 2006). Also, in clinical trials 
highly selective or specific blocking of only one of the kinases involved in the 
signalling pathways has been associated with limited or sporadic responses. 
Many authors suggest that optimal targeting may involve targeting multiple 
molecules found in both the tumour and supportive tissue (Faivre et al., 2006; 
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Imai and Takaoka, 2006). Agents that target multiple pathways may increase 
the treatment-related toxicities (Kim, 2003). Also, the combination of small 
molecules and monoclonal antibodies may enhance the therapeutic efficacy, 
e.g. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab 
(Herceptin) in HER-2-positive breast cancer cells in a synergistic manner 
(Cardoso et al., 2006). 
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2.1 Scope of the thesis 
In 2004 in Europe, there were an estimated 2 886 800 incident cases of cancer 
diagnosed and 1 711 000 cancer deaths. The most common incident form of 
cancer was lung cancer (13.3% of all incident cases), followed by colorectal 
cancer (13.2%) and breast cancer (13%). Lung cancer was also the most 
common cause of cancer death (341 800 deaths), followed by colorectal (203 
700), stomach (137 900) and breast cancer (129 900) (Boyle et al., 2005). In 
the United States the estimates of new cancer cases and deaths follow these 
European trends (Jemal et al., 2005). 
Once patients have been diagnosed with cancer, they are treated with the 
various modalities of surgery, radiation therapy, chemotherapy, immuno-
therapy, or other treatments directed at the eradication of detectable lesions. 
Despite some spectacular successes in the treatment of relatively rare cancers, 
this approach has not yet led to a significant decrease in cancer mortality 
resulting from the common forms of many metastatic epithelial cancers, such 
as carcinoma of the lung, breast, colon, prostate, pancreas, and other sites. A 
key explanation in these often disappointing results is that once patients have 
been diagnosed with cancer, the disease is already in an advanced stage. 
Therefore, it is needed to intervene with anti-invasive and anti-metastasis 
diagnosis and therapies much earlier in the cancer progress. 
Surgery and external radiation therapy are the major treatment modalities for 
primary tumours and large metastases. The development and evolution of 
modern chemotherapy during the second half of the twentieth century has 
improved the clinical outcome of patients with various forms of cancer. Still, 
in the far majority of malignancies the efficacy of chemotherapy is very 
limited. The concept of chemotherapy is non-specific and systemic and is 
based upon the observation that malignant cells divide at a more rapid rate 
than the normal cells leading to undesirable side effects. For this reason the 
Chapter 2 
 64
feasibility and efficacy of various forms of targeted therapies have been the 
subject of investigation on both preclinical and clinical research. These 
strategies have in common that they start from a target identified as playing an 
important role in tumour biology and oncogenesis. The targeted agents include 
monoclonal antibodies (mAbs), small molecules, peptide mimetics and 
antisense oligonucleotides. 
In search of new antibody therapeutics for inhibition of metastatic breast 
cancer, De Potter et al. (1994) developed several mouse monoclonal antibodies 
(mAbs) against epitopes on the extracellular membrane of SK-BR-3 human 
breast cancer cells. In this study, we will focus on one of these mAbs, the IgG1 
mAb 14C5, which is possibly involved in the cell-substrate adhesion and 
invasion of metastatic cancer cells (De Potter et al., 1994; Coene et al., 1997). 
2.2 Aims 
Our concept of choice is the use of radioiodinated mAb 14C5 as a potential 
agent for radioimmunodetection (RID) and –therapy (RIT) of lung, colon and 
breast cancer. As is apparent from the literature, the development of a new 
antibody drug can be depicted as an iterative design process. Key steps in the 
development of radioiodinated mAb 14C5 are: target identification and 
characterization, investigation of the radioiodinated mAb 14C5 properties and 
synthesis and evaluation of radioiodinated mAb 14C5 derivatives. 
2.2.1 Identification and characterization of antigen 14C5 
The objective of the first part of the thesis is to identify and characterize the 
antigen 14C5 (Ag 14C5) by affinity chromatography studies and comparative 
antigen expression analysis. De Potter et al. (1994) and Coene et al. (1997) 
already suggested that Ag 14C5 could be related to the family of integrins. 
Therefore, we will compare the expression of Ag 14C5 with the expression of 
eight different integrin subunits (α1, α2, α3, αv, β1, β2, β3, and β4) and three 
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different integrins (αvβ3, αvβ5, and α5β1) by flow cytometry, which possibly 
could show one integrin which shows high similarity with antigen 14C5 
expression. In that case, the integrin similar to antigen 14C5 will be transfected 
in an Ag 14C5–negative cell line, Colo16. In addition, blocking experiments 
will be used to show specific Ag 14C5 binding of selected anti-integrin 
antibodies. These studies are presented in chapter 3. 
Coene et al. (1997) demonstrated abundant expression of Ag 14C5 on the 
tumour surface of in situ and invasive breast cancer tissue. Because lung, colon 
and breast cancer are the most common forms of cancer and causes of cancer 
deaths, we will further investigate the spectrum of tumour types which might 
be considered for mAb 14C5 based diagnostic or therapeutic applications. We 
will analyse different human cancer cell lines for Ag 14C5 expression by 
immunocytochemistry and flow cytometry. Immunohistochemistry will be 
performed with human lung cancer and colon cancer tissues. The studies are 
described in chapter 4. 
2.2.2 Targeting properties of radioiodinated monoclonal antibody 14C5 and 
its fragments Fab and F(ab’)2  
Potentially suitable for antibody targeting, the second part of the thesis will 
address the in vitro and in vivo targeting properties of radioiodinated mAb 
14C5, including the development of mAb 14C5 fragments (Fab and F(ab’)2), 
and investigating the process of internalization. Binding affinities will be 
estimated in a saturation binding assay using radioiodinated antibodies. For 
blood clearance and tumour uptake, biodistribution of a tumour-bearing mouse 
model and planar gamma camera imaging studies will be performed. These 
studies are presented in chapter 5 and chapter 6. 
The most important factor influencing the choice of a radionuclide apart from 
its purpose (i.e. diagnostic or therapeutic) is probably the fate of the target 
antigen after the labeled mAb-antigen complex is formed. Depending upon 
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whether the antigen-antibody complex remains on the cell membrane, is shed 
into the circulation, or is internalized into the tumour cell, the labeled mAb 
14C5 will be exposed to different catabolic processes, necessitating different 
labeling strategies. Therefore, internalization of mAb 14C5 and its fragments 
will be studied by confocal laser scanning microscopy. Secondly, we will 
evaluate the fate of radioiodinated mAb 14C5 and its fragments Fab and 
F(ab’)2 in an in vitro binding assay. Chapter 7 describes the internalization 
studies done with these three antibody molecules.  
2.2.3 Optimizing the structure of monoclonal antibody 14C5: cloning and 
sequencing of its variable heavy and light chain genes 
In the last part of the thesis, we will continue the process of optimizing the 
structure of mAb 14C5 in order to obtain improved targeting properties and to 
reduce the immunogenicity of this murine mAb 14C5. The variable heavy 
(VH) and light chain genes (VL) of mAb 14C5 will be cloned and sequenced, 
thereby facilitating further development of multivalent antibody formats of 
mAb 14C5 with less immunogenicity and more suitable targeting properties. 
These studies are presented in chapter 8. 
2.3 References 
Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-8. 
Coene E, Schelfhout AM, De Ridder L, De Potter C. Generation of a monoclonal antibody 
directed against a human cell substrate adhesion molecule and the expression of the antigen in 
human tissues. Hybridoma. 1997;16:77–83. 
De Potter C, Schelfhout AM, De Smet FH, et al. A monoclonal antibody directed against a 
human cell membrane antigen prevents cell substrate adhesion and tumor invasion. Am J 
Pathol. 1994;144:95–103. 
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30. 
 67
 
 
Chapter 3 
 
IDENTIFICATION OF ANTIGEN 14C5 
 
 
۞۞۞ 
 
Burvenich I, Schoonooghe S, Coene E, Mertens N, De Vos F and Slegers G 
 
In preparation 
 
 
 
 
 
 
 
Identification of antigen 14C5 
 
 69
3.1 Introduction 
The spread from primary tumours to organs is the life-limiting aspect of most 
malignant diseases (Ellis et al., 1998; Enns et al., 2005). Having metastasis, the 
patient can no longer be cured by local treatment. Early detection of metastasis 
or metastatic potential prior to development of occult disease still lags. 
Moreover for a physician, being able to detect the metastatic potential is not 
enough. Offering a patient with a poor prognosis an adequate treatment is 
mandatory. 
Metastatic potential is influenced by the local microenvironment, 
angiogenesis, stroma-tumour interactions, elaboration of cytokines by the local 
tissue, and by the molecular phenotype of the tumour and host cells. This 
underscores the importance of understanding the molecular events of the 
metastatic process. Using that understanding, biomarker panels can be 
identified to predict presence and location of metastases, and to identify and 
develop therapeutic targets (Liotta and Kohn, 2003). Investigation of the 
molecular basis of invasion can lead to strategies for delaying progression of 
pre-invasive carcinoma and treatment of primary tumours and established 
metastasis. Although tumour cell invasion might not be rate limiting for the 
increase of metastasis, anti-invasive agents can block tumour angiogenesis and 
thereby indirectly block metastasis. Two classes of molecular anti-invasion 
targets exist: (a) cell surface and extracellular matrix proteins, which mediate 
sensing, adhesion, and proteolysis; and (b) signal transduction pathways, 
which regulate invasion, angiogenesis, and proliferation (Kohn and Liotta, 
1995). 
The extracellular matrix (ECM) consists of a complex network of 
macromolecules, such as collagens, glycoproteins, and proteoglycans, which 
surrounds the connective tissue cells and is mainly being secreted by 
fibroblasts or other members of the fibroblast family, such as chondroblasts 
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and osteoblasts (Alberts et al., 1994; Kreis and Vale, 1999). Apart from 
intercellular adhesion (i.e., cell-to-cell adhesion), the organization of cells 
within connective tissue is based on adhesion of these cells to ECM 
components (i.e., cell substrate adhesion) (Jockusch et al., 1995). 
Subsequently, cell substrate adhesion molecules are considered as essential 
regulators of cell migration, differentiation, and tissue integrity. They play a 
role in inflammation, but they also participate in the process of invasion and 
metastasis of malignant cells in the host tissue (Albelda, 1993; Jiang et al., 
1994; Cavallaro and Christofori, 2001). Cell substrate adhesion is a 
prerequisite for tumour invasion in normal mesenchymal tissue. Invasive 
tumour cells adhere to the ECM components, such as type IV collagen, 
laminin, chondroitin and, heparan sulfate proteoglycans, and are guided by 
them during their permeation through the basal lamina and underlying 
interstitial stroma of the connective tissue (Anderson, 1992; Yurchenco, 1994). 
Several ECM adhesion molecules and their protein receptors have been studied 
extensively for their involvement in tumour invasion and metastasis, including 
the integrins, lectins, selectins, and cadherins (Dedhar and Saulnier, 1990; 
Takeichi, 1990; Pignatelli et al., 1992; Behrens, 1993). 
In search of new antibody therapeutics for inhibition of metastatic breast 
cancer, De Potter et al. (1994) developed several mouse monoclonal antibodies 
(mAbs) against epitopes on the extracellular membrane of SK-BR-3 human 
breast cancer cells. One of these mAbs is the IgG1 mAb 14C5, which 
recognizes an extracellular plasma membrane antigen expressed on SK-BR-3 
and MCF-7 human breast cancer cells (De Potter et al., 1994; Coene et al., 
1997). The antibody is capable of reversibly inhibiting the adhesion of SK-BR-
3 cells on both culture-treated plastic and on pronectin-, fibronectin-, 
osteopontin-, and vibronectin-precoated culture plates. Furthermore, mAb 
14C5 has been shown to prevent invasion and, subsequently, metastasis of SK-
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BR-3 and MCF-7 cells on host tissue in vitro (De Potter et al., 1994). In 
addition, Giffels et al. (1997) and Wagner et al. (1999) demonstrated that the  
anti-idiotypic counterpart mAb ACA 14C5 significantly inhibits tumour 
growth in a dose-dependent way in Sprague–Dawley rats bearing HH-16 clone 
1/2 adenocarcinomas or fibrosarcomas overexpressing the antigen 14C5. 
Therefore, antigen 14C5 offers an interesting target for anti-invasion, anti-
angiogenesis or other antibody-based targeted strategies like 
radioimmunotherapy. 
In the past, different studies have failed to identify the antigen 14C5. 
Immunoprecipitation of the antigen from MCF-7 cells was performed using 
mAb 14C5 (De Potter et al., 1994). Analysis by SDS-PAGE in the presence of 
reducing agent demonstrated that mAb 14C5 recognizes two protein fragments 
with molecular sizes of 50 kDa and 90 kDa respectively. The ratio of both 
fragments changed from purification to purification, but the 90 kDa fragment 
was always the predominant fragment, indicating that the latter was recognized 
by the antibody, whereas the lower molecular weight component was 
gradually lost during the immunoprecipitation procedure and a substantial 
amount of the 50 kDa band consisted of the heavy chain of the mAb 14C5, 
leaking from the column (Coene et al., 1997). Without reducing agent, SDS-
PAGE showed a 120 kDa protein band. After transfer of the proteins of the 
cell lysates and of the immunoprecipitated protein complex on a nitrocellulose 
membrane and subsequent detection of antigen with mAb 14C5, there was no 
detection of any interacting component. Immunoprecipitation of radioactive 
labeled lysate of SK-BR-3 breast cancer cells showed a triplet of 
approximately 50 kDa and one singlet of approximately 200 kDa (Vanholme, 
2000). A similar immunoprecipitation study at the University of Nottingham 
with biotin-labeled membrane proteins of 719T cells was performed. Two 
protein fragments of 66 kDa and 70 kDa were purified (data not published). 
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These contradictory results lead to the investigation of a lambda gt11 cDNA 
library of SK-BR-3 cells. After prokaryotic expression in E. coli, the first 
screening showed four positive clones. Finally after several screening rounds, 
one clone was selected for sequencing. The sequence matched the protein 
proteoglycan decorin, but decorin did not match the expression pattern of the 
antigen 14C5 (Burvenich, 2001). 
The objective of this study was to identify the antigen 14C5 by affinity 
chromatography studies and comparative antigen expression analysis. 
3.2 Materials and methods 
3.2.1 Antibodies 
The 14C5 antibody-producing hybridoma cells produced mAb 14C5 in Integra 
CL 350 flasks (Elscolab, Kruibeke, Belgium) containing protein-free 
hybridoma medium (Invitrogen, Merelbeke, Belgium). MAb 14C5 was protein 
G purified (Amersham Biosciences Europe, Roosendaal, the Netherlands) from 
concentrated supernatant and dialyzed against PBS (pH 7.4). The purity of the 
antibody was evaluated by SDS-PAGE using reducing and non-reducing 
conditions. Anti-mouse kappa IgG, anti-IgG conjugated to alkaline phosphatase 
(AP) (1:1000, anti-mouse, Intec ITK diagnostics, Antwerpen, Belgium; 1:7500, 
anti-goat, Sigma, Bornem, Belgium) were used during western blotting. The 
9E10 mAb (anti-c-myc, mouse IgG1, Becton Dickinson, BD, Erembodegem-
Aalst, Belgium) was used as a control for aspecific Fc-receptor binding during 
flow cytometric analysis. Alexa Fluor 488-conjugated goat anti-mouse IgG 
antibody (Invitrogen) was used during flow cytometry. Integrin antibodies 
(Millipore, Brussels, Belgium) used in flow cytometric analysis were anti-α1 
(FB12, mouse IgG1), anti-α2 (P1E6, mouse IgG1), anti-α3 (ASC-1, mouse 
IgG1), anti-αv (P3G8, mouse IgG1), anti-β1 (P4G11, mouse IgG1), anti-β2 
(P4H9-A11, mouse IgG3), anti-β3 (25E3, mouse IgG2a), anti-β4 (ASC-3, 
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mouse IgG1), anti-α5β1 (HA5, mouse IgG2b), anti-αvβ3 (LM609, mouse 
IgG1) and anti-αvβ5 (P1F6, mouse IgG1). Anti-β5 (B5-IVF2, mouse IgG1) 
was obtained from Sigma. 
3.2.2 Cell lines 
HT-29, Capan-2, and C32 were a kind gift of J&J Pharmaceutical Research & 
Development (Beerse, Belgium). HT-1080, A2058, and A549 were obtained 
from the Laboratory of Tumor and Developmental Biology (University of 
Liège, Belgium). SK-BR-3, Colo16, and MOLT-4, were obtained from the N. 
Goormaghtigh Institute of Pathology, University of Ghent (Ghent, Belgium). 
All cell lines were cultured in standard medium with supplements according to 
the American Type Culture Collection (Manassas, VA) recommendations, 
except for Colo16, and MOLT-4 grown in RPMI1640 medium containing 10 
mmol/l HEPES and 10% fetal bovine serum (Cambrex, Verviers, Belgium). All 
cells were cultured at 37 °C in a 5% CO2 humidified incubator and passaged 
with 0.05% trypsin-0.02% EDTA.  
3.2.3 MAb 14C5-affinity chromatography 
SK-BR-3 or HT-1080 cells were grown in 500 ml flasks (850 cm2) to 
confluence, washed with PBS, detached with cell dissociation buffer 
(Invitrogen, Merelbeke, Belgium), and washed with PBS. Cells are 
resuspended in 25 ml NP40 lysis buffer (0.5 % NP40, 50 mM Tris, pH 7.6, 300 
mM NaCl, 1 tablet per 10 ml buffer of protease inhibitor cocktail Mini-
Complete Roche) following a 30-minute incubation on ice. Lysate is pipetted 
onto a QIAshredder column sitting in 2 ml collection tube (Qiagen, Venlo, The 
Netherlands) and centrifuged for 2 min at 14000 rpm to homogenize. 
The mAb 14C5 antibody affinity column was prepared using a HiTrap NHS-
activated HP column system (GE Healthcare, Brussels, Belgium) according to 
the directions of the manufacturer. The lysate was diluted (1:2) in PBS before 
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applying to the column and filtered through a 0.45 µm filter. After passing the 
clear lysate through the mAb 14C5-HiTrap NHS-activated HP column, the 
column was washed with 5 ml PBS buffer containing 500 mM NaCl and 0.25 
% NP40, followed by 5 ml PBS buffer containing 500 mM NaCl and 0.1 % 
NP40. The antigen was then eluted from the column with 0.1 M glycine-HCl, 
pH 2.5, 0.1 % NP40. Fractions were collected in 1 M Tris buffer (pH 9.0) to 
raise the pH to 7.5. 
Prior to SDS-PAGE analysis, antigen was precipitated using 10 % tri-
chloroacetic acid and 0.06 % deoxycholate for 1 hour at -20 °C. After 
centrifugation (20 min, 14000 rpm), pellets were washed twice with 100 % 
acetone and once with 70 % ethanol. The pellet was re-suspended in Laemmli 
sample buffer and boiled for 5 min. 10 % SDS-PAGE was performed and the 
gel was stained with Silver stain and a duplicate gel was blotted and analysed 
with mAb 14C5 or anti-kappa IgG1 for specific or non-specific protein bands. 
Anti-IgG conjugated to alkaline phosphatase (AP) (1:1000, anti-mouse; 1:7500, 
anti-goat) was added, as secondary antibody, and staining was carried out with 
nitro-blue tetrazolium chloride- 5-Bromo-4-Chloro-3'-Indolylphosphate p-
Toluidine Salt (NBT-BCIP, Roche, Vilvoorde, Belgium). 
3.2.4 Antigen quantification by BiaCore 
Concentration of antigen in crude and purified lysate was analysed using 
Biacore 2000. MAb 14C5 (1.9 µg in 100 µl of 40 mmol/l sodium acetate, pH 
4.5) and an irrelevant mAb 9E10 (8 µg in 100 µl of 40 mmol/l sodium acetate, 
pH 4.5) were immobilized on a CM5 sensor chip using the amine coupling kit 
(Biacore, Breda, The Netherlands). The dextran layer of the sensor chip was 
activated by injecting 50 µl 0.05 mol/l N-hydroxysuccinimide and 0.2 mol/l N-
ethyl-N(3-diethylaminopropyl) carbodiimide. Subsequently, antibodies in 40 
mmol/l sodium acetate buffer (pH 4.5) were injected until 1499 resonance units 
(RU) for mAb 14C5 and 1357 RU for mAb 9E10 were realized. Excess 
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reactive groups were then blocked by injection of 50 µl of 1 mol/l 
ethanolamine/HCl (pH 8.5). Binding analyses were performed in HBS buffer 
(10 mmol/l (N-[2-hydroxyethyl]piperazine-N´-[2-ethane sulfonic acid]) 
(HEPES) (pH 7.4), 0.15 mol/l NaCl, 3 mmol/l EDTA, 0.005% surfactant 
Tween-20) at a flow rate of 10 µl/min. The surface was regenerated with 0.01 
mol/l glycine (pH 2).  
3.2.5 Flow cytometry 
Confluent cells were harvested using cell dissociation buffer (Invitrogen). 
Aliquots of 2 × 105 cells were incubated with mAb 14C5 or integrin antibodies 
under saturating conditions (67 nmol/l) in PBS-0.5% BSA-0.02% (w/v) sodium 
azide (Sigma) (w/v) on ice for 2 hours. After washing the cells with PBS-0.5% 
BSA-0.02% sodium azide, cells were incubated with Alexa Fluor 488-
conjugated goat anti-mouse on ice for 1 hour. Again, cells were washed with 
PBS-0.5% BSA-0.02% sodium azide and suspended in a final volume of 300 
µl of PBS-0.5% BSA-0.02% sodium azide. In control samples, the primary 
antibody was omitted. For isotype control, mAb 9E10 (67 nmol/l) was used 
instead of mAb 14C5. 
Flow cytometric analysis was done using a FACScan flow cytometer (Becton 
Dickinson). Tumour cell populations were gated based on forward and side 
scatter variables. Data analysis was done using WinMDI (Joseph Trotter). 
3.2.6 Nucleotide sequence analyses and quality control of cDNA clones 
Full length cDNA encoding the human αv (OriGene Technologies, Maryland, 
United States) and the human β5 (RZPD, Berlin, Germany) integrin subunits 
were amplified and purified. cDNA sequences were screened with PCR using 
5’ and 3’ primers delivered with the cDNA clones. Nucleotide sequencing was 
performed by the dideoxynucleotide chain-termination method using a DNA 
sequencing kit (Big Dye Terminator version 3.1 cycle sequencing) and 
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nucleotide sequence homology analyses were performed using Clone Manager 
8.0 (Scientific & Educational Software, NC, USA).  
Control digests were performed in mixtures of 20 µl, incubated at 37 °C for 2 h 
containing 2 µl DNA (0.5 µg/µl), 2 µl buffer, 0.5 µl BSA, 1 µl enzyme (Table 
3.1). Digests were subjected to 1 % agarose gel electrophoresis, and photo-
graphed using an instant positive film (Polaroid Black and White Film Type 
667, Sigma). 
Tabel 3.1 Restriction digests of human αv or β5 cDNA clones 
cDNA  clone Enzyme Buffer Restriction fragments (kb)† 
αv ScaI buf K 5600, 2300, 951, 475 
 BsaI NEB3 4165, 3218, 1041, 902 
 PvuII buf B 5520, 1640, 1069, 1097 
β5 ScaI buf K 2237, 1689, 1265 
 BglA buf D 3628, 1389, 174 
 BamI NEB2, 65°C 2247, 1529, 1008, 407 
 NspI NEB2 4021, 1328, 747, 575, 460, 123 
 PstI buf O 2233, 1457, 1090, 222, 189 
†Restriction fragments formed in restriction digests depending the used enzyme and buffer 
(Fermentas or New England Biolabs) 
3.2.7 cDNA transfection of Colo16 cells 
Full length cDNA encoding the human αv integrin (OriGene Technologies) 
was ligated into the expression vector pES31 adjusted with a neomycin 
selection. The neomycin site was derived from a pcDNA3 expression vector by 
BamHI/PvuI and XhoI restriction digest. Full length cDNA encoding the 
human β5 integrin (RZPD) was ligated into the expression vector pES31 
containing a zeomycin selection site. Full human αv clone was amplified by 
PCR using ALPHAV F (sense) and ALPHAV B (anti-sense) primers, and 
human β5 clone was amplified using BETA5 F and BETA5 B primers (Table 
3.2). 
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The sense-primers were designed to contain an EcoRI site and Kozak 
consensus, the anti-sense primers contained a BamHI restriction site. PCR was 
performed in 2 % DMSO and 2 mmol/l MgSO4 conditions. After ligation and 
transformation in E. coli, full sequences of selected clones were analysed with 
primers (αv: NM101, 105, 87, ALPHAV F and ALPHAV B;  β5: NM101, 105, 
87, BETA5 F, BETA5 B, BETA5SEQ B1-B4 and F1-F4) by the 
dideoxynucleotide chain-termination method and nucleotide sequence 
homology was analysed (Table 3.2). Control digests with ScaI, BsaAI and 
PvuII for αv, and NspI and PstI for β5 were performed in mixtures of 20 µL, 
incubated at 37°C for 2 h according to the manufacturer’s instructions (Table 
3.1). Digests were subjected to 1 % agarose gel electrophoresis, and photo-
graphed using an instant positive film (Sigma). 
Tabel 3.2 Primer and primer sequences 
Primer Sequence (5’ to 3’) 
ALPHAV F ATGAATTCGCCACCATGGCTTTTCCGCCGCGGCGACG 
ALPHAV B ATGGATCCTTAAGTTTCTGAGTTTCCTTCACCATTTTCATGAG 
BETA5 F ATGAATTCGCCACCATGCCGCGGGCCC 
BETA5 B ATGGATCCTCAGTCCACAGTGCCATTGTAGGATTTGTTG 
BETA5SEQ B1 AAATCCCAACCGGAAGTTGC 
BETA5SEQ B2 ACCGTTGTTCCAGGTATCAG 
BETA5SEQ B3 CGGCACAGGTTCTGGTACAC 
BETA5SEQ B4 CAGCCTCCTGGTCATCTTTC 
BETA5SEQ F1 CCGAGCCTGGGCACCAAAC 
BETA5SEQ F2 GAGAAATTGGCAGAGAACAAC 
BETA5SEQ F3 GGTGCGAGTGCCAGGATG 
BETA5SEQ F4 AGACCTGCCACAGCCTATGC 
NM101 CAACGTGCTGGTTATTGTGCTGTC 
NM105 TCGAGCCACCATGGGTTGGAGCTG 
NM87 CAACAGATGGCTGGCAACTAGAAG 
         ,EcoRI restriction site,         ,Kozak consensus,          ,BamHI restriction site 
Transfection into antigen 14C5-negative Colo16 squamous carcinoma cells was 
done using the Saint-Mix lipofectamine reagent (Synvolux Therapeutics, The 
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Netherlands) according to the manufacturer’s instructions. Transfections were 
done in 6-well dishes with 1 µg DNA per well (1 µg vector containing αv, 1 µg 
vector containing β5 or 0.5 µg of both αv and β5 containing vectors). After     
48 h, flow cytometry analysis was performed using anti-αv (P3G8), anti-β5 
(B5-IVF2), and anti-αvβ5 (P1F6) specific antibodies. Selection was performed 
in duplicate dishes in 800 µg/ml neomycin, zeomycin or, neomycin and 
zeomycin containing medium. 
3.2.8 Blocking experiment 
Blocking studies were done with mAb 14C5 or anti-αvβ5, both radio-iodinated 
with 123I by the Iodo-Gen method. Unbound radio-iodine was removed by gel 
filtration over a PD-10 desalting column previously equilibrated with 0.5% 
BSA in PBS. The blocking assay was performed by monitoring loss of the 
ability of 123I-labeled anti-αvβ5 to bind to target cells in the presence of excess 
of unlabeled mAb 14C5. Washed target cells (A549, 0.5 × 106) were incubated 
with 300 nmol/l of the unlabeled mAb 14C5 to block antigen 14C5. Test 
solutions containing increasing amounts of 123I-labeled mAb 14C5 or 123I-
labeled anti-αvβ5 in a total volume of 1 ml cell medium were incubated at 4°C 
for 2 hours. Then, supernatant was removed by centrifugation (8 minutes, 1200 
rpm, 4°C) and cells were washed twice with 1 ml ice-cold PBS and peletted for 
8 min at 1200 rpm. For each sample, total binding was determined in the 
absence of unlabeled mAb 14C5. Radioactivity was counted by a gamma 
counter (Cobra II, Perkin-Elmer, Jügesheim, Germany). Incubations were 
performed in triplicate. 
3.2.9 Statistical analysis 
A nonparametric Mann-Witney test was used for comparisons. 
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3.3 Results 
3.3.1 Isolation of antigen 14C5 by mAb 14C5-affinity chromatography 
We tried to purify the antigen 14C5 from HT-1080 fibrosarcoma and SK-BR-3 
breast cancer cells (approximately 109 cells) by mAb 14C5-affinity-column 
chromatography. By SDS-PAGE and western blot analyses with anti-kappa and 
anti-Fc antibodies, only 14C5 antibody fragments leaking from the column 
could be detected. Therefore, purified lysate was passed over a protein G 
column (Amersham) to reduce Fc-containing fragments. However, western blot 
analysis of protein G purified lysate did not show specific protein bands. 
The affinity-column protocol was adjusted with three eluting steps prior to 
loading of crude lysate sample to the column. After three eluting steps, no 
leaking of mAb 14C5 was detected by SDS-PAGE analysis. However, no 
specific protein bands attributable to the antigen 14C5 could be detected after 
western blot analysis. 
The amount of soluble antigen in the crude and purified SKBR-3 lysate was 
determined by Biacore. MAb 14C5 (1499 resonance units, RU) was coated on 
a CM5 sensor chip. An irrelevant IgG, mAb 9E10 (1357 RU) was coated as 
negative control. In crude lysate, no interaction with mAb 14C5 was detected. 
In mAb 14C5 affinity-column purified SKBR-3 lysate, 141 RU bound to the 
mAb 14C5, whereas only 37 RU interacted with mAb 9E10. 
3.3.2 Comparative flow cytometry analysis with integrin antibodies 
A comparison of mAb 14C5 and eleven integrin antibodies (anti-α1 (FB12, 
mouse IgG1), anti-α2 (P1E6, mouse IgG1), anti-α3 (ASC-1, mouse IgG1), 
anti-αv (P3G8, mouse IgG1), anti-β1 (P4G11, mouse IgG1), anti-β2 (P4H9-
A11, mouse IgG3), anti-β3 (25E3, mouse IgG2a), anti-β4 (ASC-3, mouse 
IgG1), anti-α5β1 (HA5, mouse IgG2b), anti-αvβ3 (LM609, mouse IgG1) and, 
anti-αvβ5 (P1F6, mouse IgG1)) was performed by flow cytometry analysis.  
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Fig. 3.1. Flow cytometry analysis showing binding of irrelevant anti-c-myc IgG1 (open histograms), 
mAb 14C5 (blue line) or integrin antibodies (grey filled histograms) under saturating conditions to 
(A) SKBR-3 breast cancer cells and (B) Colo16 squamous carcinoma cells. 
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Fig. 3.2. Flow cytometry analysis showing binding of irrelevant anti-c-myc IgG1 (open histograms), 
mAb 14C5 (blue line) or integrin antibodies (grey filled histograms) under saturating conditions to 
A549, A2058, C32, Capan-2, Colo16, HT-1080, HT-29, and SKBR-3 cancer cells. (A) Comparison 
between anti-αv and mAb 14C5. (B) Comparison between anti-αvβ5 and mAb 14C5. 
A total of eight human cell lines were analysed under saturating conditions for 
a comparison of the reactivity of mAb 14C5 and the eleven anti-integrin 
antibodies. Figure 3.1A shows the reactivity of mAb 14C5 and anti-integrin 
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antibodies with the positive control, the SK-BR-3 breast cancer cell line. 
Figure 3.1B shows the reactivity with the negative control, the Colo16 
squamous carcinoma cell line. The expression patterns of the other six cell 
lines (A2058 skin melanoma, A549 lung carcinoma, C32 melanoma, Capan-2 
pancreas carcinoma, HT1080 fibrosarcoma, HT29 colon carcinoma) are shown 
in the appendix at the end of this chapter. 
Two antibodies showed similar reactivity as mAb 14C5, namely anti-αv and 
anti-αvβ5. However, expression levels of anti-αv differed from expression 
levels of mAb 14C5 in A2058 and C32 cells (Fig. 3.2A), whereas anti-αvβ5 
showed equal reactivity in all tested cell lines (Fig. 3.2B). All other integrin 
antibodies showed differences in expression levels in more than two cell lines. 
3.3.3 Eukaryotic expression of αvβ5 integrin in Colo16 cells 
To determine whether antigen 14C5 is in fact the integrin αvβ5 receptor, 
Colo16 cells were transfected with two expression vectors. One expression 
vector contained cDNA encoding the human αv integrin subunit and a gene 
encoding neomycin resistance, a second expression vector contained cDNA 
encoding the β5 integrin subunit and a gene encoding zeomycin resistance. 
After drug selection, no stable transfectant sub-lines were established. 
However, as shown in figure 3.3, after transfection of Colo16 cells with αv, β5 
or co-transfection of αv and β5, ~30% of transfected cells showed expression of 
respectively the αv subunit, the β5 subunit or αvβ5. Some overlap is seen 
between mAb 14C5 binding and the anti-αv sub-unit or anti-β5 sub-unit alone. 
Only when both integrin sub-units were co-transfected, the expression of mAb 
14C5 matched completely with anti-αvβ5 expression levels. These results show 
that after co-transfection of both αv and β5 genes, the positive transfectant 
subpopulation binds anti-αvβ5 specific antibody and mAb 14C5 at equivalent 
levels. 
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Fig. 3.3. Flow cytometry analysis of Colo16 transfected cells with human αv (αv+/β5-), β5 (αv-
/β5+), or αvβ5 (αv+/β5+). Cell surface expression was analyzed using anti-αv (P3G8, red line), anti-
β5 (B5-IVF2, blue line), and anti-αvβ5 (P1F6, green line) specific antibodies and compared with 
mAb 14C5 (grey filled histograms) binding. (A) Positive and negative transfectant populations are 
shown. (B) Positive transfected cells were gated. 
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3.3.4 Blocking experiment with 123I-labeled mAb 14C5 and anti-αvβ5 
To confirm that integrin αvβ5 is indeed antigen 14C5, a blocking experiment 
was performed with 123I-labeled mAb 14C5 and 123I-labeled anti-αvβ5 specific 
antibody. The blocking agent used in the study represents a 10-fold excess of 
saturating levels obtained in flow cytometry analysis with mAb 14C5 (300 
nmol/l). Figure 3.4 shows the total binding of 123I-labeled mAb 14C5 and anti-
αvβ5. 
 
Fig. 3.4. Blocking of αvβ5 specific binding by mAb 14C5. (A) Total binding of 123I-labeled mAb 
14C5 (filled squares, blue) and anti-αvβ5 (filled triangle, grey) and non-specific binding of 123I-mAb 
14C5 (open squares, blue) and 123I-anti-αvβ5 in the presence of 300 nmol/l of unlabeled mAb 14C5 
to SKBR-3 cells is shown. (B) The amount of total binding blocked by unlabeled mAb 14C5 of 123I-
labeled anti-αvβ5 (grey) and 123I-labeled mAb 14C5 (blue) expressed as percentage of total 
binding. Bars, SD (n = 3); *, P < 0.05, significant binding differences between mAb 14C5 and αvβ5 
In the presence of 300 nmol/l unlabeled mAb 14C5, this binding was reduced 
to non-specific binding both for mAb 14C5 and anti-αvβ5 (Fig. 3.4A). The 
amount of 123I-labeled anti-αvβ5 total binding blocked by unlabeled mAb 14C5 
is significant lower than the amount of 123I-labeled mAb 14C5 blocked when 
non-saturating amounts of radiolabeled antibodies were added to the SKBR-3 
cells (n = 3, P < 0.05). On the contrary, at saturating levels (i.e., starting at 
approximately 5 nmol/l as shown in Fig. 3.4A) there were no significant 
differences in blocking percentages between mAb 14C5 and anti-αvβ5 specific 
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antibody (Fig. 3.4B). These results confirm that mAb 14C5 binds to the αvβ5 
integrin, probably with higher affinity than anti-αvβ5 specific antibody, which 
could explain the significant differences in blocking percentages at low 
antibody concentrations. 
3.4 Discussion 
The data presented in this chapter reveal for the first time the identity of 
antigen 14C5 as the integrin αvβ5. In the past, many immunoprecipitation 
studies failed to purify the antigen and consequently could not deduce the 
identity of Ag 14C5 by sequence analysis (De Potter et al., 1994; Coene et al., 
1997). The studies presented here show that purification of antigen 14C5 by 
mAb 14C5 affinity-column chromatography did not show specific protein 
components in the purified SKBR-3 or HT-1080 lysates after western blot 
analysis. Biacore analysis showed that only little amounts of soluble antigen 
14C5 are available in mAb 14C5 affinity-column purified SKBR-3 lysate. Both 
western blot and Biacore analysis indicate that the conformation of the soluble 
protein could be altered compared to the cell surface expressed antigen. 
Therefore, other strategies were explored to identify the antigen. 
Based on the immunohistochemical staining of Ag 14C5 on the cell membrane 
extensions of highly invasive tumour cells, De Potter et al. (1994) and Coene et 
al. (1997) suggested that Ag 14C5 could be related to the family of integrins. 
The integrins, a family of related membrane receptors involved in cell-cell and 
cell-matrix interactions, are heterodimeric complexes of α- and β-subunits. The 
cell substrate adhesion inhibition after coating with osteopontin and vitronectin 
suggests that the antigen could be a receptor for these extracellular matrix 
proteins. According to the literature, osteopontin is recognized by the αvβ3 
vitronectin receptor (Reinholt et al., 1990; Miyauchi et al., 1991). Integrins can 
also bind to other extracellular matrix proteins but with lower affinity. This 
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might explain the weaker inhibition after coating with fibronectin than 
osteopontin or vitronectin seen by De Potter et al. (1994) and Coene et al. 
(1997). 
The expression of the antigen 14C5 is compared with the expression of eight 
different integrin subunits (α1, α2, α3, αv, β1, β2, β3, and β4) and three 
different integrins (αvβ3, αvβ5, and α5β1). Basically, we selected integrins 
from literature data involved in cancer pathology and which could possibly 
block cell-substrate-adhesion (Mizejewski, 1999; Wehrle-Haller and Imhof, 
2003; Jin and Varner, 2004; Ruegg et al., 2004). At saturating conditions, anti-
αvβ5 specific antibody showed equivalent expression levels as mAb 14C5. By 
a blocking assay with mAb 14C5, the αvβ5 receptors could be significantly 
blocked by mAb 14C5, indicating that antigen 14C5 is the αvβ5 receptor. 
Flow cytometry analysis of Colo16 cells transfected with human αv and β5 
cDNA, indicated that both sub-units are involved in the mAb 14C5 binding. A 
possible conformation change of the soluble antigen 14C5, i.e. monomeric αv 
and monomeric β5, could explain why affinity-column chromatography, 
western blot analysis and Biacore with mAb 14C5 did not work to purify Ag 
14C5. However, Wayner et al. (1991) reported immunoprecipitation of the 
αvβ5 receptor by mAb P5H9 from UCLA-P3 lung carcinoma cells. In the 
future, we will work on a stable transfection of Colo16 cells with both αv and 
β5 sub-units and use the immunoprecipitation protocol from Wayner et al. 
(1991) to purify Ag 14C5. 
αvβ5 as tumour associated target is not novel. The cDNA sequence of the 
human integrin β5 sub-unit was elucidated by McLean et al. (1990). The cDNA 
sequence of the human integrin αv sub-unit was elucidated by Sims et al. 
(2000). Smith et al. (1990) reported the purification and functional 
characterization of integrin αvβ5 as an adhesion receptor for vitronectin.  
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The role of integrins αvβ3 and its closely related αvβ5 in cancer growth, 
angiogenesis and metastasis has been widely discussed with pros and contras 
(Leavesley et al., 1992; Mizejewski, 1999; Kerr et al., 2002; Ruegg et al., 2004; 
Taverna et al., 2005) and until today remains uncertain and complex. αvβ3 was 
the first vascular integrin targeted to suppress tumour induced angiogenesis. 
Evidence indicates that both αvβ3 and αvβ5 promote angiogenesis via distinct 
pathways, αvβ3 is involved in the response to basic fibroblast growth factor 
(bFGF) and tumour necrosis factor α (TNFα), and αvβ5 is involved in the 
response to vascular endothelial growth factor (VEGF) and transforming 
growth factor α (TGFα; Friedlander et al., 1995). Hynes (2002) hypothesized 
that these integrins could be in fact negative regulators of angiogenesis and that 
drugs targeting them may act as agonists rather than antagonists. This 
hypothesis is based on the fact that although pharmacological agents directed 
against integrins αvβ3 and αvβ5 have been reported to block angiogenesis, 
genetic ablations of the genes encoding these integrins fail to block 
angiogenesis. In a later study, both αvβ3 and αvβ5 did not show to be essential 
for tumour growth and progression, although they might play some role in 
mammary gland development (Taverna et al., 2005). Enns et al. (2005) 
suggested that αvβ5 integrins mediate early steps of metastasis formation, but 
supports the evidence of Mitjans et al. (2000) that anti-αvβ5 (P1F6) specific 
binding could not inhibit tumour growth. 
RGD peptide inhibitors binding to αvβ3 and αvβ5 have been tested in 
preclinical (Dechantsreiter et al., 1999; Li et al., 2004; Dayam et al., 2006; 
Dijkgraaf et al., 2006a) and clinical studies (Eskens et al., 2003). Monoclonal 
antibodies specific for αv (CNTO 95, fully human; Davis et al., 2004; Jayson et 
al., 2004; Trikha et al., 2004; Martin et al., 2005) and αvβ3 (LM609, murine; 
Brooks et al., 1994; Vitaxin, MEDI-522, humanized; Gutheil et al., 2000) have 
been investigated as therapeutic agents. Cilengitide, a cyclic RGD peptide in 
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clinical trials for metastatic cancer, has been tested in an aggressive breast 
cancer model in combination with 90Y-labeled chimeric anti-L6 
radioimmunotherapy, which remarkably increased efficacy and increased 
apoptosis, compared to single-modality therapy with either agent, without 
additional toxicity (Burke et al., 2002). Noninvasive PET and SPECT imaging 
of integrin expression have been done with monomeric, dimeric and tetrameric 
RGD peptides and peptidomimetics (Lewis, 2005; Dijkgraaf et al., 2006b; 
Haubner, 2006; Zhang et al., 2006). However, the potential role of a 
radiolabeled anti-mAb αvβ5 specific antibody in radioimmunodetection and 
radioimmunotherapy has not yet been investigated. 
3.5 Conclusion 
The studies presented indicate that antigen 14C5 is the αvβ5 receptor. The 
αvβ5 receptor belongs to the family of integrins. Many integrins have shown to 
be interesting targets for cancer therapy, and the most investigated target so far 
is the vascular integrin αvβ3. No research has been conducted to the target 
potential of αvβ5 for radioimmunodetection and radioimmunotherapy. The fact 
that the antibody 14C5 can block cell substrate adhesion combined with the 
ability of mAb 14C5 to deliver a radiotoxic dose to the tumour could provide 
new treatment possibilities: unlabeled mAb 14C5 could prevent the settlement 
of undetectable metastatic cells and radiolabeled mAb 14C5 could cause 
tumour regression of occult secondary tumours. Therefore, further studies to 
exploit the therapeutic potential of the labeled as well as the unlabeled mAb 
14C5 are warranted. Also, imaging αvβ5 integrin expression can be important 
to evaluate anti-integrin treatment efficacy and drug development of new drugs 
with favourable tumour targeting.  
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4.1 Introduction 
Radioimmunodetection and radioimmunotherapy involve the use of anticancer 
antibodies conjugated with diagnostic and therapeutic radionuclides, 
respectively. Intrinsic characteristics of antibody and antigen, as well as the 
choice of radionuclide, will determine the outcome of these targeted strategies 
(Goldenberg, 2002). One critical step in the development of a new antibody 
therapeutic is validation of the antigen (Carter et al, 2004). Because 
radiotoxicity to normal tissue should be kept as low as possible, high and 
tumour-associated expression of the target antigen is wanted. 
Coene et al. (1997) demonstrated abundant expression of antigen 14C5 (Ag 
14C5) on the tumour surface of in situ and invasive breast cancer tissue. The 
antigen was specifically overexpressed in 64 % of invasive ductal 
adenocarcinomas of the breast (n = 33), in all investigated cases of invasive 
squamous cell carcinoma (n = 7) and in 40 % of basocellular carcinomas of the 
skin (n = 5). The antigen 14C5 is located on the cell membrane of the 
carcinoma cells. When the tumour is characterized by a highly invasive 
phenotype, 65 % of the cases also show an extensive stromal expression on the 
fibroblasts between the tumour cells (n = 71). In normal tissues and stroma 
surrounding in situ carcinomas of the breast (n = 15), no expression of the Ag 
14C5 occurred (Coene et al., 1997). Normal epithelial, muscle, and connective 
tissues that did not show staining with mAb 14C5 were skin, thyroid, 
parathyroid, colon, stomach, lung, uterine tube, ovary, ureter, urethra, lymph 
node, nerve, chondroid tissue, skeletal muscle, oesophagus, and artery (De 
Potter et al., 1994; Coene et al., 1997). Sometimes, low-level staining of myo-
epithelial cells was observed in biopsies of breast tissue and in tubular cells of 
the kidney. 
Previous studies demonstrated that antigen 14C5 is most likely the αvβ5 
receptor. Table 4.1 shows ligands and cellular tissue distribution of the αv 
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integrins as described in literature. From this table it is clear that αvβ3 and 
αvβ5 are capable of recognizing multiple Arg-Gly-Asp(RGD)-containing 
ligands, whereas the other αv integrins are more restricted in their adhesion 
functions. 
Tabel 4.1 αv Integrins: ligands, cellular and tissue distribution (Kerr et al., 2002; Wehrle-Haller and 
Imhof, 2003) 
αv Integrins Ligands Cellular and tissue distribution Potential implications 
αvβ1 Ln, Fn, Opn Smooth muscle cells, fibroblasts, 
osteoclasts, tumour cells 
 
Vascular disorders 
αvβ3 Opn, Fg, Vn, Tn, 
Tsp, Fn, PCL, αCol 
MMP2, vWF 
 
Endothelial cells, smooth muscle cells, 
osteoclasts, platelets, fibroblasts, 
tumour cells, epithelial cells, leukocytes 
Angiogenesis, 
restenosis, vascular 
disorders, osteoporosis 
αvβ5 Opn, Fg, Vn, Fn, Tsp, 
Tat, bone sialoprotein 
Endothelial cells, smooth muscle cells, 
osteoclasts, platelets, fibroblasts, 
tumour cells, epithelial cells, 
leukocytes, pancreas 
 
Angiogenesis, vascular 
disorders 
αvβ6 Fn, Fg, Vn, Tn Epithelial cells, carcinoma cells - 
αvβ8 Vn Melanoma, kidney, brain, ovary, 
uterus, placenta 
- 
Col: Collagen; Fg: Fibrinogen; Fn: Fibronectin; Ln: Laminin; MMP2: Matrix Metalloproteinase 2; Opn: 
Osteopontin; PCL: perlecan; Tat: HIV tat protein; Tn: Tenascin, Tsp: Thrombospondin; Vn: Vitronectin: vWF: 
von Willebrand factor 
In pancreatic cancer cell lines, the integrin subunit β5 was associated with 
adenocarcinomas and ampullary tumours, whereas highly differentiated cell 
lines showed variable loss of one or more of the integrin chains (Mizejewski et 
al., 1999). In breast cancer, the αvβ5 and αvβ1 integrins were widely 
distributed among a variety of breast cancer cell lines (Meyer et al., 1998). 
Kemperman et al. (1997) reported high expression of αvβ5 on HT-29 colon 
carcinoma cells. Wayner et al. (1991) reported high expression of αvβ5 on 
different lung carcinoma cell lines and melanoma cells, and demonstrated that 
although αvβ3 and αvβ5 bind to the same ligand vitronectin, αvβ3 associates 
with focal contacts, whereas αvβ5 forms small patches distributed over most of 
the cell surface. This finding let to another study reported by the same research 
group, showing that the inability to form focal contacts inhibits spread and 
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migration of a human pancreatic cell line. This cell line fails to express αvβ3, 
but binds to vitronectin in an αvβ5 dependent way (Leavelsley et al., 1992). 
These results demonstrated that two homologous integrins, expressed on the 
same cells and recognizing the same ligand, can promote distinct signals 
potentiating diverse biological activities in response to a given extracellular 
matrix. Finally, increased levels of integrin αvβ5 were shown on the 
fibroblasts of scleroderma (Asano et al. 2004). 
In this study, we address the antigen 14C5 expression and look for possible 
discrepancies between Ag 14C5 binding of mAb 14C5 and the anti-αvβ5 
specific antibody (P1F6). To investigate expression, we performed 
immunocytochemistry on twenty-one human cancer cell lines from different 
origin. Levels of antigen expression were analysed with flow cytometry. In 
addition, with respect to possible imaging and therapy with radiolabeled mAb 
14C5, we investigated the expression of Ag 14C5 on 20 human colon 
carcinoma tissues and 16 human lung carcinoma tissues both with mAb 14C5 
and anti-αvβ5 antibody (P1F6). 
4.2 Materials and methods 
4.2.1 Antibodies 
The 14C5 antibody-producing hybridoma cells produced mAb 14C5 in Integra 
CL 350 flasks (Elscolab, Kruibeke, Belgium) containing protein-free 
hybridoma medium (Invitrogen, Merelbeke, Belgium). MAb 14C5 was protein 
G purified (Amersham Biosciences Europe, Roosendaal, the Netherlands) from 
concentrated supernatant and dialyzed against PBS (pH 7.4). The purity of the 
antibody was evaluated by SDS-PAGE using reducing and non-reducing 
conditions. The anti-αvβ5 (P1F6, mouse IgG1, Millipore, Belgium) was used 
for comparison in immunohistochemical studies. The 9E10 mAb (anti-c-myc, 
mouse IgG1, Becton Dickinson, BD, Erembodegem-Aalst, Belgium) was used 
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as a control for aspecific Fc-receptor binding during flow cytometric analysis. 
Alexa Fluor 488-conjugated goat anti-mouse IgG antibody (Invitrogen) was 
used during flow cytometry. 
4.2.2 Cell lines 
HT-29, LoVo, Capan-1, Capan-2, and C32 were a kind gift of J&J 
Pharmaceutical Research & Development (Beerse, Belgium). HT-1080, 
A2058, A549, AsPC-1, and MDA-MB-231 were obtained from the Laboratory 
of Tumor and Developmental Biology (University of Liège, Belgium). 
OVCAR-3, HeLa, K-562 and BT-20 were obtained from the Department of 
Molecular Biomedical Research (Flanders Institute for Biotechnology, Ghent, 
Belgium). SK-BR-3, MCF-7, T-47D, LN-229, Colo16, 791T and MOLT-4, 
were obtained from the N. Goormaghtigh Institute of Pathology, University of 
Ghent (Ghent, Belgium). All cell lines were cultured in standard medium with 
supplements according to the American Type Culture Collection (Manassas, 
VA) recommendations, except for Colo16, K-562 and MOLT-4 grown in 
RPMI1640 medium containing 10 mmol/l HEPES and 10% fetal bovine serum 
(Cambrex, Verviers, Belgium) and 791T grown in DMEM medium containing 
10% fetal bovine serum. All cells were cultured at 37 °C in a 5% CO2 
humidified incubator and passaged with 0.05% trypsin-0.02% EDTA.  
4.2.3 Immunocytochemical studies 
Confluent tumour cell lines were harvested by cell scraping and washing twice 
with PBS. Cells were cytocentrifuged for 5 minutes at 180 × g and fixed in 
acetone for 10 minutes. For immunocytochemical detection, an avidin-biotin 
system was applied (DakoCytomation, Heverlee, Belgium). MAb 14C5 (1 
µg/ml) was incubated for 1 hour in PBS 5% bovine serum albumin (BSA; 
Sigma-Aldrich, Bornem, Belgium) at room temperature. The cells were washed 
twice with PBS. Then, the sample was incubated with biotinylated anti-mouse 
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immunoglobulins for 15 minutes; the avidin-peroxidase complex was added for 
15 minutes followed by 3-amino-9-ethylcarbozole (DakoCytomation) for 10 
minutes as chromogen. Between each step, cells were washed twice with PBS. 
Cells were counterstained with Mayer’s hematoxylin and mounted in Aquatex 
mounting medium (VWR International, Leuven, Belgium). Negative control 
cells were obtained by omitting the primary antibody. 
4.2.4 Flow cytometry 
Confluent cells were harvested using cell dissociation buffer (Invitrogen). 
Aliquots of 2 × 105 cells were incubated with mAb 14C5 (10 nmol/l) in PBS-
0.5% BSA-0.02% (w/v) sodium azide (Sigma-Aldrich)(w/v) on ice. After 
washing the cells with PBS-0.5% BSA-0.02% sodium azide, cells were 
incubated with Alexa Fluor 488-conjugated goat anti-mouse on ice for 1 hour. 
Again, cells were washed with PBS-0.5% BSA-0.02% sodium azide and 
suspended in a final volume of 300 µL of PBS-0.5% BSA-0.02% sodium azide. 
In control samples, the primary antibody was omitted. For isotype control, 
mAb 9E10 (10 nmol/l) was used. 
Flow cytometric analysis was done using a FACScan flow cytometer (Becton 
Dickinson). Tumour cell populations were gated based on forward and side 
scatter variables. Data analysis was done using WinMDI (Joseph Trotter). 
4.2.5 Immunohistochemical study 
4.2.5.1 Patient tumour tissue 
As described by Coene et al. (1997), biopsy specimens from human colon and 
lung epithelial tumours, and normal colon and lung tissues were investigated 
for the expression of the antigen 14C5. Therefore, 5-μm sections from fresh 
frozen material were cut and fixed in acetone for 1 min at 4°C. For 
immunohistochemical detection, an avidin-biotin system was applied as 
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described previously for the immunocytochemical study (DakoCytomation, 
Heverlee, Belgium). 
4.2.5.2 Animal tumour tissue 
Male athymic mice (nu/nu; 5 weeks; Charles River, Brussels, Belgium) were 
injected s.c. into the right flank with A549 (lung), LoVo (colon), HT1080 
(fibrosarcoma), Capan-2 (pancreas) or SKOV3 (ovarium) cells (1 × 107) in 
200 µl fetal bovine serum-free culture medium. When tumours achieved a size 
of 0.2 to 0.5 g, 6-μm sections from fresh frozen material were cut and fixed in 
acetone for 1 min at 4°C. For immunohistochemical detection, an avidin-biotin 
system was applied as described previously for the immunocytochemical study 
(DakoCytomation, Heverlee, Belgium). 
4.3 Results 
4.3.1 Immunocytochemical analysis of human cancer cell lines 
Twenty-one human cell lines were examined by immunocytochemical analysis 
and/or flow cytometry analysis for expression of the antigen 14C5 (Table 4.2). 
Ag 14C5 is ubiquitously expressed in the investigated cell lines (18 of 21). Not 
all cells stained equally, but the positive cells had a membrane-associated 
staining (Fig. 4.1). No obvious correlation was observed between the level of 
immunostaining and the tissue origin of the neoplastic cells. 
4.3.2 Quantitative expression analysis with FACS 
Fifteen cell lines were investigated by flow cytometric analysis (Fig. 4.2). 
Significant binding of mAb 14C5 was observed with C32, OVCAR-3, A2058, 
LoVo and HeLa cells. The highest reactivity was found with SK-BR-3, HT-
1080, A549, BT-20, HT-29, Capan-1 and Capan-2 cells. 
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Table 4.2 Results of the immunoperoxidase staining for antigen 14C5 of 21 different human cancer 
cell lines 
As isotype control, an irrelevant mAb 9E10 was used. This antibody binds an 
intracellular epitope (c-myc) and therefore cannot bind to the cell membrane 
unless the antigen 14C5 is an Fc receptor or the mAb 9E10 is bound to the 
membrane by other Fc receptors. All plots of mAb 9E10 binding, matched the 
auto-fluorescence plots of unbound cells in the presence of secondary antibody. 
Cell line 14C5 reactivity 
Carcinoma Breast  
SK-BR-3 Positive  
MCF-7 Positive  
BT-20 Positive  
T-47D Positive  
MDA-MB-231 Positive  
Carcinoma Ovary  
OVCAR-3 Positive 
SKOV-3 Positive 
Carcinoma Cervix  
HeLa Positive 
Carcinoma Lung  
A549 Positive 
Carcinoma Colon  
HT-29 Positive 
LoVo Positive 
Carcinoma Squamous Cell  
Colo16 Negative 
Carcinoma Pancreas  
Capan-1 Positive 
Capan-2 Positive 
AsPC-1 Positive 
Fibrosarcoma  
HT-1080 Positive 
Osteosarcoma  
791T Positive 
Glioblastoma  
LN-229 Negative 
Leukemia  
MOLT-4 Negative 
Melanoma  
C32 Positive 
A2058 Positive 
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Fig. 4.1. Immunocytochemistry with mAb 14C5 on A549 lung carcinoma cells (200×). (A) 
Membrane-associated staining with mAb 14C5 (1:500; 1 mg/ml). (B) Negative control, mAb 14C5 
was omitted. 
 
Fig. 4.2. Histogram of fluorescence-activated cell sorting analysis showing the binding of mAb 
14C5 with various neoplastic cell lines. Cells were stained with mAb 14C5 (filled histograms) or 
anti-c-myc-IgG1 (open histograms) isotope control mAb. Bound mAbs were detected with 
Alexa488-conjugated anti-mouse IgG 
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4.3.3 Immunohistochemical analysis 
4.3.3.1 Patient study 
The results of the immunohistochemical staining with human colon cancer 
tissues (n = 20) are shown in Table 4.3 and Table 4.5. The carcinoma cells 
stained positive in 50% of carcinoma tumours. This staining was weak to focal 
strong positive (Fig. 4.3A). Sometimes, only apical staining of tumour cell 
membrane was observed (Fig. 4.3B). However, fibroblasts in the stroma 
surrounding the tumour cells showed extensive expression of the antigen 14C5. 
Table 4.3 Antigen 14C5 expression with human colon cancer tissue 
   Ag 14C5 expression 
Patient  Tumour  Normal 
Nr Diagnose Figure Stroma Cells   
1 rectum CA  +/- -  NA 
2 colon CA  + -  NA 
3 colon CA  +++ -  NA 
4 rectum CA  ++ -  NA 
5 rectum CA  ++ +/-  NA 
6 rectum CA  + -  NA 
7 colon CA  +++ -  NA 
8 rectum CA  + +  NA 
9 colon CA  + -  NA 
10 rectum CA  +++ +  NA 
11 colon CA  +++ +  - 
12 rectum CA  ++ +  NA 
13 rectum CA Fig. 4.3A +++ ++  NA 
14 colon CA  + -  - 
15 rectum CA  + -  NA 
16 colon CA  + +  NA 
17 colon CA  +++ +/++  NA 
18 colon CA Fig. 4.3B +++ +/++  NA 
19 recto sigmoid  + +  NA 
20 colon CA  + -  NA 
NA, not available; CA, carcinoma; +/-, weak positive; +, positive; ++, strong positive; +++, very strong 
positive; -, negative 
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Fig. 4.3. Immunohistochemistry with mAb 14C5 on frozen human tissue of colon carcinomas. A. 
Adenocarcinoma of the rectum. There is a distinct expression on the cytoplasmic membrane of the 
carcinoma cells. The surrounding fibrous tissue and the fibroblasts express the antigen 14C5 at 
high level (200×). B. Colon adenocarcinoma with apical expression on the cytoplasmic membrane 
of the carcinoma cells. There is also a distinct expression of the antigen 14C5 on the surrounding 
fibrous tissue and the fibroblasts (200×). Filled arrows, tumour cell membrane staining; Open 
arrows, stroma 
The results of the immunohistochemical staining with human non-small cell 
lung cancer (NSCLC) tissues (n = 16) are shown in Table 4.4 and Table 4.5. In 
bronchoalveolar carcinoma (BAC), which tends to be more inclined to stay 
within the lung and is less likely to spread to other organs, the carcinoma cells 
stained negative and stroma surrounding BAC stained only weakly positive in 
one case (n = 4). Typical carcinoid represents another uncommon group of 
pulmonary neoplasms. They are well differentiated and represent the least 
biologically aggressive type of pulmonary neuroendocrine tumour. These 
tumours characteristically grow slowly and tend to metastasize infrequently.  
The investigated carcinoid did not show staining with mAb 14C5. The more 
common types of NSCLC, i.e. squamous (n = 5) and adenocarcinoma (n = 3) 
stained focal positive in 2 of 5 squamous carcinomas (Fig. 4.4A and 4.4D) and 
in 1 of 3 investigated adenocarcinoma (Fig. 4.4C). Fibroblasts in the stroma 
surrounding the tumour cells showed positive to very strong positive staining in 
all squamous and adenocarcinoma samples (n = 8) (Fig. 4.4B-D). 
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Table 4.4 Antigen 14C5 expression with human lung cancer tissue 
   Ag 14C5 expression 
Patient  Tumour  Normal tissue 
Nr Diagnose Figure Stroma Cells  
1 md squamous  + - NA 
2 md adeno  ++ - NA 
3 pd squamous  +++ - NA 
4 BAC  - - NA 
5 md squamous Fig. 4.4A +++ + NA 
6 BAC  - - NA 
7 md-wd adeno  +++ - NA 
8 pd giant-cell adeno  + - NA 
9 BAC  - - NA 
10 md squamous Fig. 4.4D +++ + NA 
11 Carcinoid  - - NA 
12 BAC  +/- - NA 
13 md squamous Fig. 4.4B +++ - - 
15 adeno Fig. 4.4C +++ + NA 
16 LCUC  ++ - NA 
NA, not available; adeno: adenocarcinoma; BAC, bronchoalveolar adenocarcinoma; LCUC: Large 
Cell Undifferentiated Carcinoma; md: moderately differentiated; pd: poorly differentiated; RCC: 
renal cell carcinoma; wd: well differentiated  +/-, weak positive; +, positive; ++, strong positive; +++, 
very strong positive; -, negative 
Table 4.5 gives a summary of the immunohistochemical investigation of 
human lung and colon carcinoma tissues and their surrounding stroma.  
Tabel 4.5 Summary of the immunohistochemical investigation of human lung and colon 
carcinomas and their surrounding stroma 
  Stroma  Tumour cells 
Tumour type n + - + - 
Lung      
Squamous Cell carcinoma  5 5 (100 %) 0 (0 %) 2 (40 %) 3 (60 %) 
Adenocarcinoma 3 3 (100 %) 0 (0 %) 1 (33 %) 2 (67 %) 
BAC 4 1 (25 %) 3 (75 %) 0 (0 %)  4 (100 %) 
Large Cell Cancer 1 1 (100 %) 0 (0 %) 0 (0 %) 1 (100 %) 
Carcinoid 1 0 (0 %) 1 (100%) 0 (0 %) 1 (100%) 
Colon      
Adenocarcinoma 20 19 (95 %) 1 (5 %) 10 (50 %) 10 (50 %) 
BAC, bronchoalveolar adenocarcinoma 
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Fig. 4.4. Immunohistochemistry with mAb 14C5 on frozen tissue of human non-small cell lung 
carcinomas. (A) Moderately differentiated squamous carcinoma. Focal positive staining of cell 
membranes (400×). (B) Moderately differentiated squamous carcinoma. No staining of tumour cell 
membranes was observed. The surrounding fibrous tissue and the fibroblasts express the antigen 
14C5 at high level (200×). (C) Adenocarcinoma. A weak staining of the tumour cell membranes and 
strong to very strong expression of the antigen 14C5 on the surrounding fibrous tissue and the 
fibroblasts (400×). (D) Moderately differentiated squamous carcinoma. Focal positive staining of 
tumour cell membranes with high expression in surrounding stroma (400×). Filled arrows, tumour 
cell membrane staining; Open arrows, stroma 
Normal tissues of lung (n = 5) and colon (n = 5) were analyzed for expression 
of the antigen 14C5. No expression was detected on normal lung tissues. On 
colon tissues, sometimes small blood vessels and mucous secreting cells 
showed staining with mAb 14C5. 
This study was also performed with the αvβ5 specific antibody (P1F6). The 
location of the staining on the tissues was identical, but staining was more 
intense with P1F6 antibody. However, aspecific staining with normal tissue 
was higher with P1F6 than with mAb 14C5. 
Immunohistochemistry with Ag 14C5 
 
 111
4.3.3.2 Animal study 
Immunohistochemical studies were done with mAb 14C5 on human A549 
(lung), LoVo (colon), HT1080 (fibrosarcoma), Capan-2 (pancreas) and 
SKOV3 (ovarium) carcinoma tissues grown in athymic mice. Two tissue types, 
A549 and SKOV-3, showed specific binding of mAb 14C5 (Fig. 4.5 and Fig. 
4.6). On the other tumour tissues, staining with the anti-mouse IgG specific 
antibody showed too much background on the negative control samples, and 
therefore comparison between positive and negative samples was not possible. 
 
Fig. 4.5. Immunohistochemistry with mAb 14C5 on A549 lung carcinoma tissue (200×). (A) 
Negative control, mAb 14C5 was omitted. (B) Membrane-associated staining with mAb 14C5 
(1:500; 1 mg/ml). bar, 20 µm 
 
Fig. 4.6. Immunohistochemistry with mAb 14C5 on SKOV3 ovarium carcinoma cells (200×). (A) 
Negative control, mAb 14C5 was omitted. (B) Membrane-associated staining with mAb 14C5 
(1:500; 1 mg/ml). Stroma between the tumour cells showed high level expression of Ag 14C5. bar, 
20 µm 
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A549 tissue showed very strong staining of cell membranes. SKOV-3 tissue 
showed strong staining of the cell membranes and equivalent staining of the 
stroma between the tumour cells. 
4.4 Discussion 
Prior work has shown that mAb 14C5 recognizes a cell surface antigen on 
mammary tumours. No antigen 14C5 could be detected in normal tissues as 
well as in the stroma surrounding in situ carcinomas of the breast. Sometimes, 
low-level staining of myoepithelial cells was observed in biopsies of breast 
tissue and in tubular cells of the kidney (De Potter et al., 1994; Coene et al., 
1997). 
The present data show that the expression of antigen 14C5 is not restricted to 
the breast cancer cell lines but is also present in varying degrees on other 
neoplastic human cell lines from different origins: carcinomas of ovary, cervix, 
lung, colon, and pancreas, sarcomas, and melanomas. Flow cytometric results 
showed that 9 out of 15 of the investigated cell lines showed high expression of 
antigen 14C5. Moreover, the A549 lung cancer cells showed the highest 
antigen 14C5 expression, providing a possible new target for non-small cell 
lung cancer (NSCLC) therapy. Although breast cancer is currently second as 
the leading cancer causing death in women in Europe and the United States, 
lung cancer is the leading cause of cancer-related mortality in both men and 
women, followed by colorectal (Boyle and Ferlay, 2005). NSCLC accounts for 
~80% of all lung cancers (Ghambir et al. 2001; Gridelli, 2004; Maione et al., 
2004). Today, the therapy of NSCLC has reached a plateau in improving 
patient survival (Maione et al., 2004). Investigation on NSCLC-related antigen 
14C5 expression may result in antigen 14C5 as a novel target for NSCLC 
therapy. 
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Therefore, the expression of the antigen 14C5 was investigated in human lung 
carcinoma and human colon carcinoma. In these tumour types, Ag 14C5 
expression occurred mainly in the stroma surrounding the tumour cells and on 
the stromal fibroblasts (squamous cell carcinoma, 5/5; adenocarcinoma of lung, 
3/3; large cell carcinoma, 1/1; colon adenocarcinoma, 19/20) and was less 
localized at the tumour cells themselves (squamous cell carcinoma, 2/5; 
adenocarcinoma of lung, 1/3; large cell carcinoma, 0/1; colon adenocarcinoma 
10/20). The mechanisms that regulate fibroblast activation and their 
accumulation in cancer are not fully understood. Kalluri and Zeisberg (2006) 
showed in their review that it is conceivable that fibroblasts might serve as 
novel therapeutic targets. Such therapies can be given alone or in combination 
with chemotherapy, radiation or surgery. Fibroblast-directed therapy can be 
envisioned as either to ablate or to normalize the cancer-associated fibroblasts. 
One such a target that has already been associated with cancer fibroblasts is 
fibroblast-activating protein (FAP) (Garin-Chesa et al., 1990). A phase I dose-
escalation study with sibrotuzumab (anti-FAP IgG) in patients with advanced 
colorectal carcinoma or non-small-cell lung carcinoma showed that 
sibrotuzumab specifically binds to the tumour sites with no apparent side 
effects (Scott et al., 2003). Further investigation on the expression of antigen 
14C5 and its possible role as cancer-associated fibroblast target is necessary to 
fully understand the therapeutic and diagnostic potential of mAb 14C5. 
To further characterize the antigen 14C5, immunohistochemical staining with 
mAb 14C5 was compared with αvβ5 specific staining. No discrepancy was 
found in the expression patterns between the two antibodies. However, staining 
with anti-αvβ5 was more intense, as well as non-specific staining with this 
antibody. 
In the near future the expression of Ag 14C5 on normal tissues will be 
investigated in more detail. Normal epithelial, muscle, and connective tissues 
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that did not show staining with mAb 14C5 were skin, thyroid, parathyroid, 
colon, stomach, lung, uterine tube, ovary, ureter, urethra, lymph node, nerve, 
chondroid tissue, skeletal muscle, oesophagus, and artery (De Potter et al., 
1994; Coene et al., 1997). Sometimes, low-level staining of myo-epithelial 
cells was observed in biopsies of breast tissue and in tubular cells of the 
kidney. In this study, sometimes small blood vessels and mucous secreting 
cells of colon tissue showed staining with mAb 14C5. According to the FDA 
guidelines concerning the manufacturing and testing of monoclonal antibody 
products for human use, 32 tissues should be tested for cross reactivity. The 
following tissues remain to be tested with mAb 14C5: adrenal, bladder, blood 
cells, bone marrow, cerebellum, cerebral cortex, endothelium, eye, heart, liver, 
pancreas, pituitary, placenta, prostate, spinal cord, spleen, testis, and thymus. 
4.5 Conclusion 
The antigen 14C5 could be an interesting new target for radioimmunodetection 
and radioimmunotherapy. The localization in human breast, lung and colon 
carcinoma tissues is high on stromal fibroblasts surrounding invasive 
carcinomas. Therefore, staining for the antigen 14C5 receptor offers a possible 
diagnostic tool in predicting the metastatic potential of malignant tumours 
originating in the breast, lung and colon. Further investigation is necessary to 
understand its possible role as cancer-associated fibroblast target. A 
comparison between the expression of Ag 14C5 and αvβ5, confirms studies 
presented in chapter 3 that αvβ5 might be the receptor of mAb 14C5. Further 
studies to exploit the therapeutic potential of the labeled as well as the 
unlabeled mAb 14C5 are warranted. 
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5.1 Introduction 
An important future role of mAb 14C5 may lie in the ability of this antibody to 
prevent the spread of tumour cells in the patient’s body. MAb 14C5 recognizes 
an epitope at the extracellular domain of a membrane antigen, which plays a 
role in cell substrate adhesion. This could be deduced from the inhibition of 
adhesion of SK-BR-3 and MCF-7 breast cancer cells to culture plastic, 
pronectin-, osteopontin-, and vitronectin-coated wells (De Potter et al., 1994). 
The inhibition on fibronectin-coated wells was weaker. In addition, a 
confrontation experiment with precultured embryonic heart fragments showed 
that the cell substrate adhesion of breast cancer cells could be inhibited or at 
least delayed (De Potter et al., 1994; Coene et al., 1997). 
The localization of antigen (Ag) 14C5 in human breast, lung and colon 
carcinoma tissues is often high on stromal fibroblasts surrounding invasive 
carcinomas. Some studies have indicated that activated fibroblasts play a role 
at the initiation of cancer, as well as in the progression and in metastasis. 
Therefore these cancer associated fibroblasts might serve as targets for 
fibroblast-targeted therapy (Kalluri and Zeisberg, 2006). MAb 14C5 may offer 
a new tool for radioimmunodetection (RID) and radioimmunotherapy (RIT) of 
these fibroblasts. 123I-labeled mAb 14C5 could be used for tumour diagnosis or 
to evaluate chemotherapy response (RID), whereas 131I-labeled mAb 14C5 
could be used to ablate primary tumour cells, metastatic cells and possibly 
cancer-associated fibroblasts (RIT). 
Lahorte et al.(2004) reported on the radioiodination of mAb 14C5 with 123I. 
High radiochemical yields and purities were obtained, while maintaining good 
in vitro and in vivo stability, as well as in vitro binding properties. In this 
study, the targeting properties of radioiodinated mAb 14C5 with A549 lung 
and LoVo colon cells will be explored. In vitro, binding properties of 125I-
labeled mAb 14C5 will be examined with both A549 and LoVo cells. In vivo, 
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biodistribution and gamma camera imaging studies are shown with 
respectively 131I- and 123I-labeled mAb 14C5. 
5.2 Materials and methods 
5.2.1 Antibodies 
The 14C5 antibody-producing hybridoma cells produced mAb 14C5 in Integra 
CL 350 flasks (Elscolab, Kruibeke, Belgium) containing protein-free 
hybridoma medium (Invitrogen, Merelbeke, Belgium). MAb 14C5 was protein 
G purified (Amersham Biosciences Europe, Roosendaal, the Netherlands) from 
concentrated supernatant and dialyzed against PBS (pH 7.4). The purity of the 
antibody was evaluated by SDS-PAGE using reducing and non-reducing 
conditions. The anti-integrin β1 mAb, anti-α1, anti-α2, and anti-α3 IgG1 
(Millipore, Belgium) were used for comparison or as a control for nonspecific 
binding in biodistribution studies. 
5.2.2 Cell lines 
LoVo cells were a kind gift of J&J Pharmaceutical Research & Development 
(Beerse, Belgium). A549 cells were obtained from the Laboratory of Tumor 
and Developmental Biology (University of Liège, Belgium). All cell lines were 
cultured in standard medium with supplements according to the American Type 
Culture Collection (Manassas, VA) recommendations. All cells were cultured 
at 37 °C in a 5% CO2 humidified incubator and passaged with 0.05% trypsin-
0.02% EDTA.  
5.2.3 Radioiodination and quality control 
MAb 14C5, anti-integrin β1, anti-α1, anti-α2, and anti-α3 IgG1 were labeled 
with 123I, 125I, or 131I. Isotopes were obtained from Bristol-Myers Squibb 
(Brussels, Belgium). Radioiodination was done using the Iodo-Gen method 
(Fraker and Speck, 1978). Coating of the Iodo-Gen iodination reagent was 
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done according to the manufacturer’s instructions (Perbio, Erembodegem, 
Belgium). 
For radioiodination, iodide and mAb 14C5 dissolved in 0.1 mol/l potassium 
phosphate buffer (pH 8.5) were added to an Iodo-Gen-coated reaction vial for 
10 minutes at room temperature. Protein-bound iodine was separated from free 
iodide by passing over a PD-10 column (Amersham Biosciences Europe) 
equilibrated with PBS-1% BSA. Quality control of radiolabeled antibody was 
done by size exclusion high-performance liquid chromatography using an 
Ultrahydrogel 120 6-µm column (7.8 × 300 mm GPC; Waters, Brussels, 
Belgium) and 0.01 mol/l potassium phosphate buffer (pH 7.4) eluant at a flow 
rate of 0.8 ml/min. Stability of the radiolabeled antibodies in PBS at 4°C or in 
murine serum (50% in PBS) was analysed by iTLC and 50 mmol/l citric acid as 
eluant at 2 h, 15 h, 24 h and 48 h after radiosynthesis. 
5.2.4 Saturation binding study 
Saturation binding studies were done with 125I-labeled mAb 14C5 using LoVo 
and A549 cells. Twelve test solutions (in duplicate), containing increasing 
amounts of radiolabeled mAb 14C5 and 0.5 x 106 cells in a total volume of      
3 ml cell medium were incubated at 4°C for 2.5 hours. Then, supernatant was 
removed by centrifugation (8 minutes, 180 × g, 4°C) and cells were washed 
with 3 ml ice-cold PBS. For each sample, nonspecific binding was determined 
in the presence of 167 nmol/l of the unlabeled mAb 14C5. Radioactivity was 
counted by a gamma counter (Cobra II, Perkin-Elmer, Jügesheim, Germany). 
Kd values were determined with Graphpad Prism 3.1 software (San Diego, 
CA). 
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5.2.5 In vivo studies 
5.2.5.1 Animal model 
Male athymic mice (nu/nu; 5 weeks; Charles River, Brussels, Belgium) were 
injected s.c. into the right flank with A549 or LoVo cells (1 × 107) in 200 µl 
fetal bovine serum-free medium. When tumours achieved a size of 0.5 to 1 g 
(i.e., after 3 weeks for A549 tumours and 5 weeks for LoVo tumours), 
biodistribution studies were initiated. Male NMRI mice (5 weeks) were 
obtained from an in-house breeding program. All animal studies are in 
agreement with the Belgian laws and approved by the local ethical committee 
for animal experiments (ECP 02/54). 
5.2.5.2 Biodistribution studies 
Biodistribution studies were done with athymic mice bearing A549 (0.648 ± 
0.469 g) or LoVo (0.888 ± 0.468 g) tumours or with non-tumour-bearing 
NMRI mice. Mice were injected in the tail vein with 5 to 10 µCi 131I-labeled 
mAb 14C5 (2.5-5 µg). Typically, groups of three were sacrificed at 1, 3, 6, 24, 
48, and 168 h after injection of radiolabeled antibody. Tumours and organs 
(brain, heart, liver, spleen, kidney, lung, intestine, muscle, blood, and stomach) 
were immediately removed, blotted dry, and weighed. Samples were counted in 
a gamma counter (Cobra II). Standards prepared from the injected tracer 
material were counted each time with tissues and tumours, enabling 
calculations to be corrected for physical decay of the isotope. Radiolabeled 
antibody distribution over time was expressed as the percentage of injected 
dose per gram [%ID/g; (counts/min tissue sample per counts/min standard) × 
100 / weight (g)] and as tumour-to-blood ratios. 
5.2.5.3 Planar gamma camera imaging 
Scintigraphic imaging was done on LoVo and A549 tumour-bearing mice on a 
Toshiba GCA-9300A/hg single photon emission computed tomography camera 
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in the planar mode equipped with a low-energy high-resolution parallel-hole 
collimator. At 30 minutes, 6 hours, 24 hours and 48 hours after injection of 500 
µCi of 123I-labeled antibody (20 µg), 10-min images were acquired in a 1,024 × 
1,024-pixel matrix (field of view, 23.5 × 12.46 cm) with a photopeak window 
set at 15% around 159 keV. Animals were anesthetized by i.p. injection of 75 
µl (1.5 mg) of a pentobarbital solution (Nembutal, 20 mg/ml, Ceva Santé 
Animale, Brussels, Belgium). 
5.2.6 Statistical analysis 
A nonparametric Mann-Whitney test was used for comparison. 
5.3 Results 
5.3.1 Radioiodination and quality control 
The radioiodination yield for mAb 14C5 and anti-integrin control antibodies 
(β1, α1, α2, and α3) was typically 70% to 80%. The amounts of free iodide 
(125I, 123I, or 131I) in the purified iodinated mAb 14C5 was <2% and <5% for 
anti-integrin antibodies (β1, α1, α2, and α3) even after 24 hours at room 
temperature. 
 
Fig. 5.1. Saturation binding of 125I-labeled mAb 14C5 to A549 or LoVo cells. Increasing 
concentrations of 125I-labeled mAb 14C5 were incubated with 0.5 x 106 cells at 4°C for 2.5 hours. 
Bound activity was isolated by centrifuging the cells and washing them twice with ice-cold PBS 
buffer. 
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Fig. 5.2. Saturation binding of 125I-labeled mAb 14C5 to A549 (A) and LoVo cells (B). Increasing 
concentrations of 125I-labeled mAb 14C5 were incubated with 0.5 x 106 cells at 4°C for 2.5 h. Non-
specific binding was determined in the presence of 167 nmol/l unlabeled mAb 14C5. 
5.3.2 Affinity properties 
The dissociation constant (Kd) of the radiolabeled mAb 14C5 was determined 
for A549 and LoVo cell lines by a saturation binding assay. Figure 5.1 shows 
the saturation plot of 125I-labeled mAb 14C5 to A549 and LoVo cells. Under 
saturated conditions, A549 cells showed higher expression of antigen 14C5 
than LoVo (Bmax 319.4 ± 7.8 and 16.9 ± 1.1 fmoles/106 cells) , which agrees 
with the results previously obtained by flow cytometric analysis also showing 
higher expression of Ag 14C5 in A549 cells compared with LoVo cells. Figure 
5.2 shows the nonspecific binding of 125I-labeled mAb 14C5 to A549 and 
LoVo. Nonspecific binding was determined in the presence of 167 nmol/l 
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unlabeled mAb 14C5. MAb 14C5 bound to A549 and LoVo cells with similar 
affinity (Kd 0.19 ± 0.07 and 0.20 ± 0.05 nmol/l). The saturation binding curves 
generated were characteristics of high affinity binding of an antibody to its 
antigen and merits further evaluation of the radiolabeled mAb 14C5 in a 
tumour model. 
5.3.3 Biodistribution 
LoVo cells with a low antigen 14C5 expression were compared with A549 
cells with a high expression in a tumour model for the in vivo evaluation of 131I-
labeled mAb 14C5.  In a first series of experiments, pharmacokinetic properties 
of 131I-labeled mAb 14C5 were studied in mice bearing a LoVo tumour versus 
untreated NMRI mice. All tissues of LoVo-bearing mice, except for the 
stomach, showed significantly lower accumulation of 131I-labeled mAb 14C5 
than tissues of NMRI mice (Fig. 5.3). 
 
Fig. 5.3. Biodistribution of 5 to 10 µCi 131I-labeled mAb 14C5 (2.5-5 µg) at 24 hours after injection in 
NMRI mice without tumour (control; filled columns) and nude mice bearing a LoVo colon tumour 
(LoVo; open columns). Columns, mean %ID/g (n = 3); bars, SD. *, P < 0.05, significant differences 
between control and mice bearing a tumour. 
After 24 h, 9 %ID/g accumulated in the LoVo tumours. This tumour uptake is 
reflected in a decrease in radioactivity in the blood pool and other organs in the 
tumour-bearing mice (LoVo) compared with the non-tumour-bearing NMRI 
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mice (control; Fig. 5.3). The low accumulation of radioactivity in the stomach 
indicates a low dehalogenation of the tracer. 
 
Fig. 5.4. Biodistribution of 5 to 10 µCi 131I-labeled mAb 14C5 (2.5-5 µg) in nude mice bearing A549 
(A) or LoVo (B) tumours at 1, 6, 24 and 48 hours after injection. Columns, mean %ID/g normal 
tissues and tumours; bars, SD (n = 3). 
The biodistribution of 131I-labeled mAb 14C5 in the normal organs showed no 
significant differences between mice bearing either A549 or LoVo tumours 
(Fig. 5.4). The highest tumour uptake was observed within A549 tumours at 24 
hours after injection (10.4 ± 0.8%ID/g, n = 5), but was not significantly higher 
than LoVo tumours (9.3 ± 0.8%ID/g, n = 5) at 24 hours after injection (Fig. 
5.5). 
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Fig. 5.5. Tumour uptake (A) and tumour-to-blood ratios (B) of 131I-labeled mAb 14C5 in nude mice 
bearing an A549  lung tumour  or a LoVo colon tumour at 1, 3, 6, 24 and 48 h after injection. The 
data are expressed as the mean percentages of injected dose per gram of normal tissues and 
tumours; bars, SD (n = 3). *, data showing significant differences between A549 or LoVo tumour   
(P < 0.05). 
Radioactive counts varied greatly with tumour size, whereas tumour-to-blood 
ratios showed less variation with tumour size. To investigate the factors 
influencing the antibody pharmacokinetics of 131I-labeled mAb 14C5, the 
tumour uptake of mAb 14C5 versus an irrelevant anti-integrin β1 antibody in 
relation to the tumour mass was studied. To reduce the number of animals 
needed, we focused this experiment on mice bearing A549 lung tumours. 
The biodistribution results of 13 mice with tumour masses varying from 0.027 
to 1.9 g are shown in Fig. 5.6A. As a control, tumour uptake of the irrelevant 
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IgG1 anti-integrin β1 was measured in five mice bearing tumours varying from 
0.053 to 1.2 g. Figure 5.6A shows a high dependency of tumour uptake on 
tumour mass (the smaller the tumour, the higher the uptake), whereas no such 
relation was seen with the nonspecific control IgG1. 
 
Fig. 5.6. Factors influencing antibody pharmacokinetics of mAb 14C5 in A549 tumour-bearing 
mice. (A) Tumour uptake of tumour-specific antibody, mAb 14C5, vs. an irrelevant anti-β1 antibody 
in relation to tumour mass at 24 h p.i. (B) Antibody accumulation in the A549 tumour (%ID/g at 24h 
p.i.) in relation to protein dose. Tumour weights used varied between 0.5 and 1 g. All mice were 
injected with 1 µg of radiolabeled mAb 14C5, supplemented with unlabeled mAb 14C5 to yield the 
protein amounts indicated. 
In a second experiment, the antibody accretion in the tumour (%ID/g at 24 
hours after injection) in relation to the cold mAb 14C5 protein dose was 
investigated. Mice were injected with 1 µg radiolabeled mAb 14C5 
supplemented with an increasing amount of unlabeled mAb 14C5. Figure 5.6B 
shows that when 300 µg of unlabeled mAb 14C5 is added, the uptake of 131I-
labeled 14C5 at 24 hours after injection is decreased from 10% to 5%ID/g. This 
indicates the specific uptake of mAb 14C5. 
5.3.4 Imaging 
The planar gamma camera images of tumour-bearing mice at different time 
intervals post injection of 131I-labeled mAb 14C5 are shown in Fig. 5.7A-D (1, 
6, 24, and 48 hours, respectively). Tumours were visible within 6 hours after 
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tracer injection in both LoVo and A549 tumour models (Fig. 5.7B). The 
tumour-to-background contrast improved at later time points (Fig. 5.7C and D).  
 
Fig. 5.7. Whole-body planar gamma images of 500 µCi 123I-labeled mAb 14C5 (20 µg) in mice 
bearing a LoVo or an A549 tumour (arrows). Images were taken at 30 minutes (A), 6 hours (B), 24 
hours (C) and 48 hours (D) after injection of radiolabeled mAb 14C5. 
 
Fig. 5.8. Influence of tumour mass on the visibility of A549 tumours with planar gamma imaging. 
Whole-body planar gamma images were taken of three mice bearing an A549 tumour (arrows) with 
different size (A, 7 mg; B, 140 mg; C, 1 g) at 24 hours after injection of 500 µCi 123I-labeled mAb 
14C5 (20 µg). 
As background value, a region of interest was drawn round the contralateral 
flank. Highest tumour-to-flank ratios were obtained at 48 hours after injection. 
(A549 5.2 ± 1.8 and LoVo 2.0 ± 0.3: n = 3) for tumours weighing 1.3 ± 0.2 g. 
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The planar imaging results varied greatly with tumour size as seen in the 
biodistribution data. Figure 5.8 shows the influence of tumour size on the 
visibility of A549 tumours at 48 hours after injection. A549 tumours in the 
right flank of nude mice, as small as 0.140 g (6 × 7 mm), could be clearly 
visualized. 
5.4 Discussion 
The targeting properties of mAb 14C5 bound to 123I and 131I in nude mice 
bearing an A549 lung or a LoVo colon tumour were investigated. In RID and 
RIT, high-affinity binding with a long residence time on the specific target 
antigen is considered to be one of the most important properties of antibodies 
for achieving efficient tumour targeting. Although mAb 14C5 has not yet been 
evaluated in a clinical phase, the results in this chapter concerning the targeting 
properties of the 123I- and 131I-labeled antibody 14C5 are promising. The high 
affinity of mAb 14C5 for LoVo (Kd 0.20 ± 0.05 nmol/l) and A549 (Kd 0.19 ± 
0.07 nmol/l) and the ubiquitous expression of the antigen 14C5 in human 
cancer cell lines provide a potentially useful antibody for 
radioimmunodetection and radioimmunotherapy. 
The high antigen 14C5-expressing A549 lung tumours and even the low 
antigen 14C5-expressing LoVo colon tumours showed good tumour uptake 
with ~10 %ID/g tumour tissue at 24 hours after injection. This finding is in 
agreement with other high-affinity antibodies that bind effectively both high- 
and low-density antigen, whereas a low-affinity antibody only binds 
appreciably to high-density antigen because of its requirement for divalent 
attachment (Zuckier et al., 2000). This uptake is high enough to merit further 
evaluation in therapeutic trials (Behr et al., 2000; Clarke et al., 2000; Smith-
Jones et al., 2000; Zuckier et al., 2000; Popkov et al., 2001; Smith-Jones et al., 
2003). Via planar gamma camera imaging, A549 lung tumours as well as the 
LoVo colon tumours could be clearly visualized when tumours weighed ~1 g. 
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Even when A549 lung tumours were as small as 0.14 g, they were still clearly 
visible by planar gamma camera imaging. 
These results are encouraging, although modifications to mAb 14C5 are still 
possible to improve the targeting properties in patients. Many articles report on 
modifications that retain specificity but alter pharmacokinetics, involving the 
development of fragments of antibodies (e.g., F(ab’)2, Fab, and scFv; refs. 
Goldenberg, 2002; Winthrop et al., 2003; Adams et al., 2004) or recombinant 
multivalent antibodies (Goel et al., 2000; Schoonjans et al., 2000; Reff and 
Heard, 2001; Todorovska et al., 2001, Power et al., 2003; Olafsen et al., 2004). 
Also, the development of humanized antibodies should reduce the antigenicity 
of murine mAb 14C5 (Reff and Heard, 2001; Goldenberg, 2002). In addition, 
the choice of the radionuclide can be beneficial for radioimmunodetection and 
radioimmunotherapy. Development of radiolabeled mAb 14C5 with 99mTc or 
111In compared with 123I for radioimmunodetection and 90Y, 177Lu or 186Re 
compared with 131I for radioimmunotherapy could result in higher tumour 
uptake and therefore better tumour-targeting properties of radiolabeled mAb 
14C5 (Adams et al., 2004; Koppe et al., 2004). 
5.5 Conclusion 
The antigen 14C5 could be an interesting new target for radioimmunodetection 
and radioimmunotherapy. Therefore targeting properties of radioiodinated mAb 
14C5 were investigated in this study. Radioiodinated mAb binds its antigen 
with high affinity. Tumour uptake in mice bearing an A549 lung tumour or a 
LoVo colon tumour was high and specific. Antibody fragments and other 
radioisotopes than iodide can improve targeting properties of mAb 14C5 and 
therefore must be further explored. Furthermore, because antigen 14C5 is 
highly expressed on a variety of tumour cells, it offers great potential for a 
variety of cancer therapies, including non-small cell lung cancer and colon 
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carcinoma. Therefore, further studies to exploit the therapeutic potential of the 
labeled as well as the unlabeled mAb 14C5 are warranted.   
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6.1 Introduction 
Prior work has demonstrated that 125I-labeled monoclonal antibody (mAb) 
14C5 binds its antigen with high affinity (A549, Kd 0.19 ± 0.07 nmol/l; LoVo, 
Kd 0.20 ± 0.05 nmol/l) and tumours as small as 0.14 g could be clearly 
visualized by planar gamma imaging when using 123I-labeled mAb 14C5. 
However, the highest tumour-to-blood ratio (~ 3.0) was obtained only 168 
hours after injection (Burvenich et al., 2005). 
Compared to the use of 123I and 131I, 99mTc has some advantages: its ready 
availability, short physical half-life (t½, 6 h) and ideal γ energy (140 keV) 
(Zalutsky and Lewis, 2003). Intact monoclonal antibodies (~150 kDa) show 
rather slow antibody kinetics. As a result, short-lived radionuclides (e.g. 
SPECT, 99mTc (t½, 6 h); PET, 18F (t½, 1.8 h)) fall beyond imaging possibilities 
for radioimmunodetection when using intact antibodies. Also, the slow 
kinetics of intact mAbs limits their use in radioimmunotherapy (RIT). Their 
long persistence in circulation exhibits toxic radiation to normal tissues with 
limited quantities delivered to the tumours (Carter, 2006). Furthermore, intact 
mAbs show poor diffusion from the vasculature into and through the tumour 
(Jain, 1987; Goel et al., 2000). While micrometastases offer an interesting 
target for RIT, these lesions often show high interstitial pressure and low 
vascularization, in which only low sensitivities have been observed (Bock et 
al. 1992; Vijayakumar et al. 1993, Goldenberg et al. 2002). Another problem 
when using a murine mAb is that patients frequently develop an immune 
response to these murine proteins in the form of human anti-mouse antibodies 
(HAMA). In the worst case, this response leads to serious allergic 
hypersensitivity, but at best limits antibody efficacy by resulting in very rapid 
clearance. A gradual decrease in half-life with repeated dosage of injected 
murine antibodies has been demonstrated, limiting the use of multiple doses in 
RIT (Maynard and Georgiou, 2000). 
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To minimize these limitations of intact mAbs, many efforts of various groups 
have been undertaken in increasing the tumour-to-background ratio, tumour 
penetration and lowering HAMA response. A common approach is the 
development of smaller antibody fragments and genetically engineered single-
chain Fv (scFv) constructs of antibody molecules (Reff, 2001; Goldenberg, 
2002; Batra et al., 2002). The evaluation of the enzymaticly derived Fab and 
F(ab’)2 fragments may be useful to evaluate the potential of 14C5 mAb-
derived fragments. Indeed, enzymaticly derived bivalent F(ab')2 and 
monovalent Fab fragments have shown promising tumour penetration and 
good therapeutic results in animal (Wahl et al., 1983; Sharkey et al., 1990; 
Hansen et al., 1990; Blumenthal et al., 1992; Behr et al., 2000) and clinical 
studies (Murray et al., 1994; Willkomm et al., 2000; Libutti et al., 2001; 
Goldenberg, 2002). Disadvantages seen with these fragments are lower tumour 
uptake and high renal uptake particularly when a radiometal is used, which 
raises concern for renal toxicity. However, studies have shown that a high 
predose of cationic amino acids (e.g. L-lysine) could significantly reduce renal 
tubular reabsorption of radiometal-labeled Fab (Behr et al, 1995; Behr et al., 
1998).   
The objective of this study was to examine the biodistribution and elimination 
from the blood of 123I-labeled Fab and F(ab’)2 14C5 fragments and to compare 
with parental mAb 14C5 for the detection and possible therapy of non-small 
cell lung cancer. Additionally, we have explored the in vitro characteristics of 
125I-F(ab’)2 and 125I-Fab fragments of mAb 14C5, i.e., their stability, specificity 
and affinity. 
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6.2 Materials and methods 
6.2.1 Antibodies 
The mAb 14C5 was produced and purified as described previously (Burvenich 
et al., 2005). Fab and F(ab’)2 fragments were derived from murine mAb 14C5 
using the Immunopure IgG1 Fab and F(ab’)2 preparation kit (Perbio) according 
to the manufacturer’s instructions. IgG and Fc fragments were removed using a 
protein A sepharose column (Perbio). For concentration and exchange of buffer 
with PBS (pH 7.4), Centricon YM-30 (Millipore) was used. Fragments were 
evaluated by SDS-PAGE without reduction. When purity was <90%, fragments 
were further purified using a HiPrep 26/60 Sephacryl S-200 HR column (GE 
Healthcare Europe) on an Akta purifier, with PBS as eluant (pH 7.5, 0.5 
ml/min). 
PH2, an irrelevant anti-muc bivalent scFv-Fab dimer (75 kDa), was used as 
control antibody in biodistribution studies. 
6.2.2 Cell lines 
A549 cells, a human lung carcinoma cell line, were obtained from the 
Laboratory of Tumor and Developmental Biology (University of Liège, Liège, 
Belgium). A549 cells were cultured in DMEM (Cambrex), containing 2 mmol/l 
L-glutamine (Cambrex) and 10% fetal bovine serum (Cambrex). 
6.2.3 Radioiodination and quality control 
Fab, F(ab’)2 and mAb 14C5 were labeled with 123I, 125I, or 131I. Isotopes were 
obtained from Bristol-Myers Squibb. Radioiodination was performed using the 
Iodo-Gen method as previously described. In brief, sodium iodide and protein 
dissolved in 0.1 mol/l potassium phosphate buffer (pH 8.5) were added to an 
Iodo-Gen-coated reaction vial and reacted for 10 minutes at room temperature. 
Protein-bound iodine was separated from free iodide by passing over a PD-10 
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column (GE Healthcare Europe) equilibrated with 1% BSA in PBS. Quality 
control of radioiodinated protein was performed by size-exclusion high-
performance liquid chromatography using a Shodex KW 802.5 column (7.8 
mm × 300 mm; Thomson Instrument Company). Protein was eluted with 0.1 
mol/l potassium phosphate buffer (pH 7.4) at a flow rate of 0.8 ml/min. 125I-
labeled fragments were analyzed by SDS-PAGE followed by phosphor imager 
analysis for integrity. Samples of 2 µCi labeled protein were loaded on SDS-
PAGE, and SDS-PAGE gel was exposed to MultiSensitive Phosphor Screens 
(medium) for 5 minutes. In order to assess in vitro stability, radioiodinated 
fragments were incubated for 24 hours at 4°C in PBS with 1% BSA or at 37°C 
in PBS with 50% mouse serum in PBS. Samples were taken periodically for 
iTLC analysis (ITLC SG strips, Pall Corporations), using 20 mmol/l citric acid 
(pH 5.0) as eluant. Strips were divided in ten parts and radioactivity of each 
part was counted with a gamma counter (Cobra II; Perkin Elmer).  
6.2.4 Saturation binding study 
The affinities of 125I-F(ab’)2 and 125I-Fab were analyzed by a saturation binding 
assay using A549 cells. Specific activities of 1 µCi 125I/µg protein were 
typically used. Twelve duplicate test samples containing increasing amounts of 
125I-F(ab’)2 or 125I-Fab fragments and 0.5 x 106 A549 cells in a total volume of 
2 ml cell medium were incubated at 4°C for 2.5 hours. Supernatant was 
removed by centrifugation (8 minutes, 180 ×g, 4°C) and cells were washed 
with 2 ml ice-cold PBS. Nonspecific binding was estimated in the presence of 
300 nmol/l (i.e. approximately 1000-fold excess of Kd value of mAb 14C5) 
unlabeled mAb 14C5 for 125I-F(ab’)2. For 125I-Fab, no monovalent blocking 
agent was available. Therefore, nonspecific binding was not determined 
experimentally, but estimated by fitting total binding results using following 
equations: Specific = X × Bmax/(Kd + X); Nonspecific = NS × X, Y = Specific + 
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Nonspecific. Nonlinear regression and Kd values were determined using 
Graphpad Prism Software (San Diego, CA). 
6.2.5 In vivo studies 
6.2.5.1 Animal model 
Athymic mice (nu/nu; female, 5 weeks; Charles River) were used for the in 
vivo biodistribution and imaging studies. A549 cells (1 × 107) were injected 
subcutaneously. When tumours reached a size of 0.5 to 1.0 g, approximately 3 
weeks after injection, biodistribution studies were performed. All animal 
experiments were approved by the local ethics committee for animal 
experiments. 
6.2.5.2 Biodistribution studies 
For biodistribution studies, mice were injected in the tail vein with 5 to 10 µCi 
131I-labeled F(ab’)2 or Fab fragments (2.5-5.0 µg in 100 µl PBS). Typically, 
groups of three mice were sacrificed 0.02, 1, 3, 6, 24, and 48 hours after 
injection. Tumours and organs (brain, heart, liver, spleen, kidney, lung, 
intestine, muscle and stomach) were removed immediately, blotted dry and 
weighed. Also, a blood sample was taken. Tumour, organ and blood activities 
were counted in a gamma counter (Cobra II). Standards, prepared from the 
same tracer solution that was injected, were counted each time with tissues and 
tumours. Tissue radioactivity concentrations were expressed as the percentage 
of injected dose per gram of organ (% ID/g). 
The blood clearance studies were performed in non-tumour-bearing mice 
(NMRI; female, 4-6 weeks old). Blood samples (30 µL, n = 3) were drawn 
from the tail vein at various time points following the injection of 370 kBq of 
131I-labeled Fab, F(ab’)2 or mAb 14C5. The half-lives were calculated using 
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SPSS 12.0 for Windows. The data for Fab, F(ab’)2 and IgG were analyzed by a 
two-phase exponential curve fit. 
6.2.5.3 Planar gamma camera imaging 
Planar gamma camera imaging was done on a Toshiba GCA-9300A/hg single-
photon emission computed tomography camera equipped with a low-energy 
high-resolution parallel-hole collimator. Animals with an A549 tumour were 
anesthetized by intraperitoneal injection of 75 µl of a sodium pentobarbital 
solution (Nembutal, 20 mg/ml, Ceva Santé Animale). Images were acquired 1, 
6, 24 and 48 hours after injection of 500 µCi 123I-labeled F(ab’)2 or 123I-labeled 
mAb 14C5 (20 µg in 200 µl PBS). Ten-minute images were obtained in a 256 
× 256-pixel matrix (field of view, 23.5 × 12.46 cm) with a photopeak window 
set at 15% around 159 keV. For imaging of A549 tumours with 1 mCi 123I-
labeled Fab fragments (20 µg), 10-minute images were acquired 1, 6, 12 and 30 
hours after injection. 
6.2.6 Statistical analysis 
Comparison between mAb 14C5 and its fragments, F(ab’)2 and Fab was 
performed using nonparametric Mann-Witney test. 
6.3 Results 
6.3.1 Preparation of F(ab’)2 and Fab fragments 
The product of the ficin-treated mAb 14C5 (150 kDa) was evaluated by SDS-
PAGE (Fig. 6.1A). Pure F(ab’)2 fragments (> 90%, ~100 kDa) were generated 
in the presence of 1 mmol/l cysteine after 20 h of incubation at 37°C. Highest 
production of Fab fragments (~50 kDa) was obtained in the presence of 10 
mmol/l cysteine after 15 h of incubation at 37°C. MAb 14C5 was also run in 
parallel under nonreducing conditions and migrated at ~150 kDa. Fab and 
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F(ab’)2 migrated at ~50 and ~100 kDa, respectively. For Fab, purity of > 90% 
could only be obtained after separation of high-molecular-weight impurities 
(mAb and F(ab’)2) on a Sephacryl S-200 high-resolution column. 
 
Fig. 6.1. Quality control of F(ab’)2 and Fab 14C5 fragments. (A) Gel showing Coomassie Blue R-
250 staining of unlabeled mAb 14C5 (lane 1), F(ab’)2 (lane 2) and Fab (lane 3). (B) Quality control 
of 123I-labeled mAb 14C5, 123I-labeled F(ab’)2 and 123I-labeled Fab was done with size-exclusion 
high-performance liquid chromatography using an Ultrahydrogel 120 6-µm column (7.8 × 300 mm 
GPC) and 0.01 mol/l potassium phosphate buffer (pH 7.4) eluant at a flow rate of 0.8 ml/min. (C) 
Phosphorescence image of 125I-labeled mAb 14C5 (lane 1), 125I-labeled F(ab’)2 (lane 2) and 125I-
labeled Fab 14C5 (lane 3) fragments. 
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Fig. 6.2. Saturation binding of 125I-F(ab’)2 (A) or 125I-Fab (B) to A549 cells. Increasing 
concentrations of 125I-labeled fragments were incubated with 0.5 × 106 cells at 4°C for 2.5 hours. 
For 125I-F(ab’)2, nonspecific binding was determined in the presence of 300 nmol/L unlabeled mAb 
14C5. For 125I-Fab, nonspecific binding was estimated using nonlinear regression of total binding 
data with Graphpad. 
6.3.2 Radio-iodination and Binding Capacity of 125I-F(ab’)2 and 125I-Fab 
14C5 
The radioiodination yield for F(ab’)2 and Fab fragments was typically 70-80%. 
125I-Radiolabeling of Fab, F(ab’)2 and mAb 14C5 was analyzed by ITLC, SDS-
PAGE and HPLC to check the integrity of the radioiodinated molecules. The 
amount of free iodide (125I, 123I, or 131I) in the purified iodinated products was   
< 5% as determined by HPLC (Fig. 6.1B). 123I-Labeled Fab, F(ab’)2, and mAb 
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eluted at  9.1, 8.0, and, 7.5 minutes, respectively, as single peaks. Even after 48 
hours at 37°C in the presence of murine serum, the amount of free iodide 
remained < 5% as determined with ITLC. Electrophoresis of the labeled 
products under nonreducing conditions and autoradiography showed the     
~150-kDa protein band of mAb (Fig. 6.1C, lane 1), the ~100-kDa protein band 
of F(ab’)2 (Fig. 6.1C, lane 2) and, the ~50-kDa band of Fab (Fig. 6.1C, lane 3). 
To investigate the binding capacity of iodinated fragments, the dissociation 
constants (Kd) of 125I-labeled F(ab’)2 and 125I-labeled Fab were estimated for 
A549 cells by a saturation binding assay. Figure 6.2 shows the saturation 
binding plots of 125I-labeled F(ab’)2 (Fig. 6.2A) and 125I-labeled Fab (Fig. 6.2B) 
to A549 cells. F(ab’)2 bound to A549 cells with higher affinity than Fab (Kd 
0.37 ± 0.10 nmol/l and 2.25 ± 0.44 nmol/l, respectively; P < 0.05). The 
obtained saturation binding curves were characteristic of high-affinity specific 
binding of a ligand to its receptor. 
6.3.3 Pharmacokinetic properties of 131I-labeled mAb 14C5 and its 
F(ab’)2 and Fab fragments in NMRI mice 
Figure 6.3 shows the results of the pharmacokinetic studies performed to 
determine the blood clearance of 131I-labeled Fab, F(ab’)2 and intact mAb 
14C5. The data were analyzed using a bi-exponential model for Fab, F(ab’)2 
and mAb 14C5, showing an α-phase t½ (clearance of immunoconjugates from 
the central compartment (blood) to the peripheral compartments) and β-phase 
t½ (clearance of immunoconjugates from the blood out of the body) (Wen et al., 
1999). The alpha half-life (t½α) value for Fab, F(ab’)2 and mAb 14C5 was 14.9, 
21 and 118 min, respectively. The beta half-life t½β value for Fab, F(ab’)2 and 
mAb 14C5 was 439, 627 and 4067 min, respectively. Thus, 123I-labeled Fab 
and F(ab’)2 showed markedly lower t½α (respectively 7.9 and 5.5 times lower) 
and t½β (respectively 9.3 and 6.5 times lower) values than intact mAb 14C5. 
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Fig. 6.3. Blood clearance of 131I-labeled Fab, F(ab’)2 and mAb 14C5 in NMRI mice. An average of 
three mice per group is presented. Values are corrected for the decay of the radionuclide. 
6.3.4 Biodistribution of 131I-labeled mAb 14C5 and its F(ab’)2 and Fab 
fragments in Swiss nu/nu mice bearing an A549 lung tumour 
Biodistribution studies were performed in athymic mice bearing A549 lung 
tumours. Although 131I-labeled mAb 14C5 showed 10.7 ± 2.2 %ID/g in 
tumours at 24 h post injection, the nonspecific retention of radiolabeled mAb 
14C5 in the liver, kidneys, spleen, heart, lungs and blood was higher than that 
of Fab and F(ab’)2 (Table 6.1). 
The highest tumour uptake was observed for Fab as early as 3 hours after 
injection, after 6 hours for F(ab’)2, and was specific (P < 0.05) (Fig. 6.4). 
Tumour uptake (% ID/g) was highest for mAb 14C5 (10.7 ± 2.23% ID/g, n = 5) 
and lowest for Fab (2.4 ± 0.8% ID/g, n = 3), with an intermediate value for 
F(ab’)2 (4.7 ± 0.7% ID/g, n = 3). After 6 hours, uptake of fragments in all other 
organs (except kidneys, stomach and lung) remained significantly lower than in 
tumour and blood. The kidneys showed an initially high uptake of both 
fragments (34.3 ± 3.8 % ID/g 1 h after injection for 131I-Fab, 23.9 ± 3.5% ID/g 
for 131I-F(ab’)2 versus 5.6 ± 1.5 % ID/g for 131I-mAb). 
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 Tabel 6.1 Biodistribution of 131I-labeled mAb 14C5, F(ab’)2 and Fab 14C5 (%ID/g) in athymic mice 
bearing an A549 tumour 
Tumour-to-blood ratios increased up to 2.6 ± 0.7 for Fab and 3.5 ± 2.5 for 
F(ab’)2, compared to 1.3 ± 0.2 for 131I-labeled mAb 14C5 48 h after injection 
(Table 6.2). Tumour-to-contralateral muscle ratios increased up to 46.8 ± 7.7 
for Fab and 13.0 ± 2.1 for F(ab’)2 24 h after injection, compared to 7.6 ± 2.3 for 
131I-labeled mAb 14C5 (P < 0.05). Tumour-to-liver ratios were significantly 
lower for 131I-labeled mAb (0.3 ± 0.1) at early time points than for Fab (2.0 ± 
0.9; P < 0.05) and F(ab’)2 (1.2 ± 0.7; P < 0.1). 
 Time (h) 
Tissue 0.02 1 3 6 24 48 
mAb       
Tumour 0.61 ± 0.17 1.67 ± 0.24 2.74 ± 0.65 5.35 ± 1.75 10.66 ± 2.23 9.49 ± 1.68 
Blood 37.44 ± 8.97 26.32 ± 3.93 19.74 ± 2.35 16.91 ± 2.35 10.48 ± 0.95 7.25 ± 0.43 
Liver 13.21 ± 2.31 9.36 ± 1.69 7.31 ± 0.97 5.23 ± 0.57 3.43 ± 0.73 2.16 ± 0.68 
Kidneys 7.68 ± 2.00 5.59 ± 1.49 4.92 ± 0.72 3.57 ± 0.22 2.59 ± 0.30 1.56 ± 0.13 
Intestine 0.86 ± 0.37 2.28 ± 0.40 2.46 ± 0.42 2.06 ± 0.18 1.42 ± 0.19 0.89 ± 0.05 
Stomach 0.62 ± 0.19 2.21 ± 0.27 1.99 ± 1.64 1.29 ± 0.33 1.53 ± 0.19 1.00 ± 0.56 
Spleen 3.07 ± 1.87 5.25 ± 0.59 4.35 ± 0.46 3.75 ± 0.54 2.60 ± 0.71 1.44 ± 0.29 
Lungs 13.02 ± 9.71 8.30 ± 3.06 6.68 ± 0.93 5.89 ± 1.47 4.91 ± 1.05 2.99 ± 0.09 
F(ab’)2       
Tumour 1.16 ± 0.35 2.30 ± 1.07 4.25 ± 1.21 4.74 ± 0.66 3.54 ± 2.10* 1.97 ± 0.66* 
Blood 40.45 ± 5.05 17.92 ± 2.51 13.55 ± 3.84 8.91 ± 2.17 1.63 ± 0.78 0.56 ± 0.53 
Liver 10.03 ± 0.54 5.39 ± 0.62 4.29 ± 2.02 3.07 ± 1.31 0.64 ± 0.22 0.37 ± 0.23 
Kidneys 9.29 ± 3.06 23.89 ± 3.52 8.95 ± 1.78 5.51 ± 0.90 0.81 ± 0.30 0.29 ± 0.27 
Intestine 1.19 ± 0.17 2.36 ± 0.18 2.89 ± 0.90 2.19 ± 0.80 0.57 ± 0.38 0.12 ± 0.07 
Stomach 1.19 ± 1.07 6.26 ± 3.33 5.25 ± 3.33 5.70 ± 3.17 1.15 ± 0.14 0.20 ± 0.19 
Spleen 3.09 ± 0.30 3.31 ± 0.24 3.22 ± 1.10 3.06 ± 1.70 0.46 ± 0.11 0.13 ± 0.02 
Lungs 14.43 ± 3.12 6.92 ± 1.66 4.84 ± 1.31 4.00 ± 1.47 0.87 ± 0.44 0.27 ± 0.21 
Fab       
Tumour 0.69 ± 0.54 1.86 ± 1.19 2.40 ± 0.79 1.62 ± 0.86* 0.74 ± 0.25* 0.24 ± 0.06* 
Blood 33.71 ± 6.38 5.58 ± 0.64 2.77 ± 1.65 1.50 ± 0.83 0.30 ± 0.06 0.10 ± 0.02 
Liver 5.93 ± 1.12 1.74 ± 0.21 0.96 ± 0.60 0.52 ± 0.28 0.11 ± 0.06 0.04 ± 0.01 
Kidneys 8.66 ± 3.33 34.30 ± 3.84 12.69 ± 1.04 4.20 ± 1.52 0.34 ± 0.24 0.14 ± 0.10 
Intestine 0.72 ± 0.65 1.35 ± 1.26 1.68 ± 1.56 1.07 ± 1.03 0.15 ± 0.17 0.03 ± 0.03 
Stomach 0.71 ± 0.15 9.41 ± 4.99 12.20 ± 5.01 3.32 ± 2.81 0.40 ± 0.13 0.09 ± 0.06 
Spleen 3.38 ± 1.03 1.34 ± 0.21 0.80 ± 0.52 0.41 ± 0.43 0.10 ± 0.06 0.06 ± 0.04 
Lungs 11.87 ± 1.03 2.69 ± 0.27 1.62 ± 0.96 0.95 ± 0.51 0.17 ± 0.09 0.06 ± 0.01 
*, significant differences between tumour uptake of fragments and tumour uptake of mAb 14C5, P < 0.05 
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6.3.5 Planar Gamma Camera Imaging 
Figure 6.5 shows the planar gamma camera images of tumour-bearing mice at 
different time intervals after injection of 123I-labeled mAb 14C5 (Fig. 6.5A), 
123I-labeled F(ab’)2 (Fig. 6.5B) and 123I-labeled Fab 14C5 fragments (Fig. 
6.5C). Fab and F(ab’)2 show improved tumour-to-background contrast compa-
red to tumour imaging with 123I-labeled mAb 14C5.  
Tabel 6.2 Biodistribution of 131I-labeled mAb 14C5, F(ab’)2 and Fab 14C5 (tumour-to-tissue ratios) 
in athymic mice bearing an A549 tumour 
 Time (h) 
Tissue 0.02 1 3 6 24 48 
mAb       
Blood 0.02 ± 0.01 0.06 ± 0.01 0.12 ± 0.06 0.31 ± 0.07 0.90 ± 0.21 1.31 ± 0.19 
Liver 0.08 ± 0.06 0.18 ± 0.04 0.31 ± 0.10 1.04 ± 0.41 2.92 ± 1.02 4.65 ± 1.36 
Kidneys 0.12 ± 0.08 0.31 ± 0.10 0.46 ± 0.12 1.49 ± 0.42 3.84 ± 0.89 6.16 ± 1.59 
Intestine 0.83 ± 0.55 0.73 ± 0.05 0.92 ± 0.21 2.59 ± 0.81 6.54 ± 1.40 10.69 ± 2.28 
Stomach 1.09 ± 0.61 0.75 ± 0.04 1.45 ± 0.58 4.40 ± 2.19 6.10 ± 0.50 12.09 ± 6.82 
Spleen 0.27 ± 0.22 0.32 ± 0.03 0.53 ± 0.19 1.40 ± 0.30 3.83 ± 1.60 6.69 ± 1.18 
Lungs 0.07 ± 0.07 0.23 ± 0.10 0.36 ± 0.17 0.91 ± 0.24 1.98 ± 0.76 3.18 ± 0.54 
Muscle 1.64 ± 0.50 2.90 ± 1.58 3.16 ± 1.70 9.59 ± 4.07 7.57 ± 2.30 n.d. 
F(ab’)2       
Blood 0.03 ± 0.01 0.13 ± 0.08 0.33 ± 0.15* 0.55 ± 0.09* 1.04 ± 0.15 3.52 ± 2.48* 
Liver 0.12 ± 0.03 0.43 ± 0.21 1.15 ± 0.66 1.41 ± 1.07 2.89 ± 1.14 5.80 ± 3.71 
Kidneys 0.13 ± 0.05 0.17 ± 0.15 0.50 ± 0.22 0.63 ± 0.47 2,15 ± 0.55 5.43 ± 4.11 
Intestine 0.96 ± 0.22 0.99 ± 0.49 1.58 ± 0.72 1.64 ± 1.27 3.57 ± 2.01 12.33 ± 4,43 
Stomach 1.50 ± 1.05 0.40 ± 0.13 1.21 ± 0.84 0.88 ± 0.94 1.61 ± 0.84 9,68 ± 2.05 
Spleen 0.37 ± 0.09 0.70 ± 0.35 1.48 ± 0.78 1.65 ± 1.18 4.08 ± 2.19 8.66 ± 1.84 
Lungs 0.08 ± 0.03 0.36 ± 0.21 0.72 ± 0.56 1.06 ± 0.80 2.22 ± 0.44 5.16 ± 3.41 
Muscle 1.83 ± 0.60 3.42 ± 1.07 6.40 ± 2.40 6.78 ± 1.55 13.03 ± 2.07 n.d. 
Fab       
Blood 0.02 ± 0.01 0.35 ± 0.27* 0.68 ± 0.29* 1.11 ± 0.46* 1.95 ± 0.97* 2.55 ± 0.73* 
Liver 0.11 ± 0.07 1.04 ± 0.57 1.98 ± 0.87 3.07 ± 0.83 5.27 ± 1.72 6.31 ± 3.23 
Kidneys 0.07 ± 0.03 0.05 ± 0.04 0.13 ± 0.06 0.38 ± 0.15 1.91 ± 0.95 1.97 ± 1.44 
Intestine 0.63 ± 0.35 0.88 ± 0.35 1.04 ± 0.44 1.54 ± 0.48 3.41 ± 1.41 5.28 ± 1.39 
Stomach 0.96 ± 0.69 0.19 ± 0.03 0.24 ± 0.23 0.59 ± 0.30 1.61 ± 1.24 3.03 ± 2.23 
Spleen 0.19 ± 0.11 1.33 ± 0.64 2.51 ± 1.36 3.69 ± 1.18 6.20 ± 2.13 4.52 ± 3.07 
Lungs 0.06 ± 0.04 0.69 ± 0.43 1.13 ± 0.40 1.73 ± 0.65 3.60 ± 1.58 3.77 ± 1.74 
Muscle 1.14 ± 0.96 2.98 ± 1.42 4.57 ± 0.40 11.16 ± 1.88 46.80 ± 7.71 n.d. 
n.d., data not determined; *, tumour-to-blood ratios of fragments that are significantly higher than tumour-to-blood ratios of mAb 
14C5, P < 0.05 
Imaging with 123I-labeled mAb 14C5 and 123I-labeled F(ab’)2 showed retention 
in the liver region, whereas imaging with 123I-labeled Fab fragments showed 
high uptake in the kidney region, stomach and bladder. Despite the higher 
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background contrast with 123I-F(ab’)2, imaging with 123I-labeled mAb 
14C5 could provide superior quality images due to higher sensitivity. 
Imaging with 123I-F(ab’)2 and 123I-mAb in patients is necessary to 
conclude which radiopharmaceutical is superior for imaging. 
 
Fig. 6.4. Antigen specificity of in vivo tumour binding. Tumour uptake of tumour-specific mAb 14C5 
fragments, Fab and F(ab’)2, versus an irrelevant PH2 anti-MUC1 dimer (75 kDa, scFv-Fab dimer). 
Bars, SD (n  = 3). *, P < 0.05, significant differences between Fab or F(ab’)2 and irrelevant PH2. 
6.4 Discussion 
When optimizing RID and RIT, it is a challenge to improve the tumour uptake 
while reducing the uptake in normal tissues (Wahl et al., 1983; Reff, 2001; 
Goldenberg, 2002; Batra et al., 2002; Koppe et al., 2005; Sharkey and 
Goldenberg, 2005). Although 123I-labeled mAb 14C5 clearly showed A549 
lung tumours of 0.14 g by planar gamma imaging, the use of enzymatically 
digested antibody fragments (Fab and F(ab’)2) or engineered antibodies (e.g., 
scFv, sc(Fv)2, diabodies, etc) may offer advantages such as improved tumour 
penetration (Wu et al., 2005) and rapid blood clearance (Goldenberg, 2002; 
Koppe et al., 2005). As a consequence, tumour uptake of Fab fragments is 
often low, although some authors support the efficacy of Fab in RIT (Behr et 
al., 2000; Goldenberg, 2002). 
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Fig. 6.5. Planar images of athymic mice bearing A549 tumours, using 500 µCi 123I-labeled mAb 
14C5 (A), 500 µCi F(ab’)2 (B), and 1 mCi Fab (C) (20 µg protein in 200 µL PBS). Animals were 
anesthetized by intraperitoneal injection of 75 µl of a sodium pentobarbital solution (Nembutal, 20 
mg/ml, Ceva Santé Animale). Ten-minute images were obtained in a 256 × 256-pixel matrix (field 
of view, 23.5 × 12.46 cm) with mAb and F(ab’)2. Thirty-minute images were obtained with Fab. 
Tumours are indicated by arrows. B = Bladder, K = Kidney, L = Liver, T = Thyroid, S = Stomach. 
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Larger fragments (e.g. [sc(Fv)2]2 and F(ab’)2) show intermediate clearance 
rates, and higher tumour uptake is observed (Goldenberg, 2002; Wu et al., 
2005). Therefore, the aims of this study were to develop radioiodinated F(ab’)2 
and Fab 14C5 fragments and to perform a first preclinical evaluation of 14C5 
antibody-derived fragments to improve pharmacokinetics in a mouse model 
with an A549 lung tumour. These classic mono- and bivalent antibody 
fragments are easy to produce with fast enzymatic proteolysis, although 
genetically engineered antibodies can be produced more economically and 
possess other unique and superior properties for a range of diagnostic and 
therapeutic applications (Schoonjans et al., 2000; Goel et al., 2000; Todorovska 
et al., 2001; Power et al., 2003; Olafsen et al., 2004; Holliger et al., 2005). 
The receptor-binding capacity of both fragments was tested. 125I-F(ab’)2 
showed excellent receptor binding (Kd 0.37 ± 0.10 nmol/l). These properties are 
comparable with the data previously obtained with mAb 14C5 (e.g., Kd 0.19 ± 
0.07 nmol/l) (Burvenich et al., 2005). Faster blood clearance in vivo combined 
with preservation of good binding properties resulted in improved tumour-to-
background contrast images at 24 and 48 h postinjection when using 
radioiodinated F(ab’)2 14C5 fragments instead of intact mAb 14C5. The 
thyroid activity demonstrates dehalogenation, but blocking the thyroid with 
0.1% NaI before injection of radioactive agents can reduce this uptake. 
Nevertheless, deiodination in vivo will diminish the tumour signal and increase 
normal tissue uptake (i.e. in stomach, salivary glands, intestines and bladder). 
Using other labeling strategies may improve the targeting potential of F(ab’)2 
and Fab 14C5 fragments. Radiometals such as 99mTc or 111In have shown better 
tumour retention compared to 123I, especially when internalizing agents were 
used (Steffens et al., 1999; Smith-Jones et al., 2000). 
Compared with mAb 14C5 and F(ab’)2 14C5 fragments, in vitro binding 
properties of Fab 14C5 fragments were less favourable (Kd 2.25 ± 0.44 nmol/l). 
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In vivo, 131I-labeled Fab 14C5 showed the fastest blood clearance. Six hours 
after injection, 123I-Fab 14C5 activity was higher in the tumour than in the 
blood, which agrees with the improved tumour-to-background imaging using 
this fragment compared to imaging with 123I-mAb 14C5. However, tumour 
uptake of 123I-labeled Fab 14C5 is much lower compared to 123I-mAb 14C5 and 
123I-F(ab’)2 14C5. High uptake in bladder, kidneys, and stomach is visible, 
which could interfere with tumour imaging in patients. However, tumour 
retention is still visible at 30 h postinjection, making it possible to visualize 
breast, lung, liver and, possibly, colon tumours at that time.  
Preclinical therapeutic studies with 131I-F(ab’)2 and 131I-Fab are necessary to 
demonstrate the therapeutic potential. These results warrant the further 
development of mAb 14C5-derived multivalent engineered antibodies. 
6.5 Conclusion 
This study showed that 123I-F(ab’)2 and 123I-Fab fragments of mAb 14C5 have 
improved characteristics as tumour imaging agents compared to the intact mAb 
14C5: the fragments accumulate more rapidly in the tumour, and clear faster 
from the blood and nontumour tissues. However, tumour uptake remains 
highest for mAb 14C5. Preclinical RIT studies with 131I-mAb 14C5 and its 
fragments, 131I-F(ab’)2 and 131I-Fab, will demonstrate which immunoconjugate 
has the highest therapeutic potential. Further improvements may be obtained 
with bioengineering techniques for the development of a 14C5-scFv-based 
radiopharmaceutical for imaging and therapy. 
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7.1 Introduction 
In the development of an antibody-based diagnostic or therapeutic 
radiopharmaceutical, intrinsic properties of the antigenic target, the molecular 
form of the antibody and the characteristics of the radionuclide of choice will 
influence the potential of the radiopharmaceutical (Goldenberg, 2002; 
Goldenberg, 2003; Milenic et al., 2004). 
The most important factor influencing the choice of the radionuclide apart from 
its purpose (i.e. diagnostic or therapeutic) is probably the fate of the target 
antigen after the labeled mAb-antigen complex is formed. Depending upon 
whether the antigen-antibody complex remains on the cell membrane, is shed 
into the circulation, or is internalized into the tumour cell, the labeled mAb will 
be exposed to different catabolic processes, necessitating different labeling 
strategies (Zalutsky and Lewis, 2003). 
Previously, we have shown that Ag 14C5 most likely is the integrin αvβ5 
receptor. Integrin-mediated internalization is exploited by bacterial and viral 
intracellular pathogens and, the integrin αvβ5 receptor mediates the 
internalization of vitronectin (Memmo and McKeown-Longo, 1998; Hart, 
1999). Therefore, it is possible that the mAb 14C5-Ag complex will internalize. 
Internalization can lead to a rapid loss of the radiolabel from the tumour cell, 
because this process exposes the labeled mAb to intracellular catabolic 
processes in the lysosomes. Labeling internalizing mAbs with radiometals (e.g. 
111In) results in higher retention. Also, several approaches have been developed 
for residualizing radioiodine activity in the tumour: oligosaccharide conjugates, 
positively charged templates, and D-amino-acid peptides (Zalutsky and Lewis, 
2003). 
In this study we will investigate the fate of the 125I-labeled mAb-Ag 14C5 
complex. Internalization of mAb 14C5 and its fragments F(ab’)2 and Fab was 
evaluated by confocal laser scanning microscopy. Internalization and cellular 
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catabolism of the molecules was also monitored using 125I-labeled antibody and 
its fragments. 
7.2 Materials and methods 
7.2.1 Antibodies 
The mAb 14C5 was produced and purified as described before (Burvenich et 
al., 2005). Fab and F(ab’)2 fragments were derived from murine mAb 14C5 
using the Immunopure IgG1 Fab and F(ab’)2 preparation kit (Perbio) according 
to the manufacturer’s instructions. IgG and Fc fragments were removed using a 
protein A sepharose column (Perbio). For concentration and exchange of buffer 
with PBS (pH 7.4), Centricon YM-30 (Millipore) was used. Fragments were 
evaluated without reduction by SDS-PAGE. When purity was <90%, fragments 
were further purified using a HiPrep 26/60 Sephacryl S-200 HR column (GE 
Healthcare Europe) on an Akta purifier, with PBS as eluant (pH 7.5, 0.5 
ml/min). Alexa Fluor 488-conjugated goat anti-mouse IgG antibody 
(Invitrogen) was used during flow cytometry. 
7.2.2 Cell lines 
A549 cells were obtained from the Laboratory of Tumour and Developmental 
Biology (University of Liège, Belgium). Cells were cultured in standard 
medium with supplements according to the American Type Culture Collection 
(Manassas, VA) recommendations. All cells were cultured at 37 °C in a 5% 
CO2 humidified incubator and passaged with 0.05% trypsin-0.02% EDTA.  
7.2.3 Confocal laser scanning microscopy 
A549 cells were confluently grown in 8-well confocal chamber slides (Lab-Tek 
Chamber CVG, Nalge Nunc International, Neerijse, Belgium) and incubated 
with 10 µg of mAb 14C5, F(ab’)2 or Fab in 200 µl of medium at 0 °C or at     
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37 °C for various time periods. Subsequently, the cells were washed with PBS 
and the surface-bound antibody was removed by treatment with low-pH 
medium (pH 2.25) to improve visibility of the intracellular fraction. Cells were 
fixed with 3.7% formaldehyde for 20 min at room temperature, incubated with 
0.4% Triton in PBS for 5 min and finally with 50 mM NH4Cl in PBS for 5 min. 
Cells were incubated overnight in PBS 1% BSA 0.02% NaN3 until incubation 
with Alexa Fluor 488-labeled secondary antibody was performed for 1 h at    
37 °C. After washing cells once with PBS and once with 50 mM Tris (pH 8), 
80 % glycerol in 50 mM Tris (pH 8) was added. Nuclei were stained by using 
propidium iodide. The cells were analyzed with a Zeiss LSM-410 confocal 
laser scanning microscope (CLSM, Carl Zeiss, Zaventem, Belgium). Control 
samples were obtained by omitting the acidic wash step. 
7.2.4 Radioiodination and quality control 
Fab, F(ab’)2 and mAb 14C5 were labeled with 125I. Isotopes were obtained 
from Bristol-Myers Squibb. Radioiodination was performed using the Iodo-
Gen method as previously described. In brief, iodide and protein dissolved in 
0.1 mol/l potassium phosphate buffer (pH 8.5) were added to an Iodo-Gen-
coated reaction vial and reacted for 10 minutes at room temperature. Protein-
bound iodine was separated from free iodide by passing over a PD-10 column 
(GE Healthcare Europe) equilibrated with 1% BSA in PBS. Quality control of 
radioiodinated protein was performed by size-exclusion high-performance 
liquid chromatography using a Shodex KW 802.5 column (7.8 mm × 300 mm; 
Thomson Instrument Company). Protein was eluted with 0.1 mol/l potassium 
phosphate buffer (pH 7.4) at a flow rate of 0.8 ml/min. 125I-labeled fragments 
were analyzed by SDS-PAGE followed by phosphor imager analysis for 
integrity. Samples of 2 µCi labeled protein were loaded on SDS-PAGE and 
SDS-PAGE gel was exposed to MultiSensitive Phosphor Screens (Medium) for 
5 minutes. In order to assess in vitro stability, radioiodinated fragments were 
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incubated for 24 hours at 4°C in PBS with 1% BSA or at 37°C in PBS with 
50% mouse serum in PBS. Samples were taken periodically for ITLC analysis 
(ITLC SG strips, Pall Corporations), using 50 mmol/l citric acid (pH 5.0) as 
eluant. Strips were divided in ten parts and radioactivity of each part was 
counted with a gamma counter (Cobra II; Perkin Elmer). 
Specific activities of 10 µCi/µg protein were used in radioimmunoassays. 
7.2.5 Internalization of 125I-labeled mAb 14C5 and its fragments 
Confluently grown A549 in 10 cm²-dishes were incubated with 1 µCi 125I-
labeled mAb 14C5, corresponding to 0.1-0.2 µg mAb 14C5, in 1 ml of medium 
at 4 °C for 2 hours. Cells were washed twice with ice-cold medium to remove 
unbound mAbs. Two ml of ice-cold medium was added, and the cells were 
incubated at 4°C (no internalization) or at 37°C (allowing internalization). 
Triplicate samples were removed at different time points, and the medium was 
isolated. The 125I-labeled antibodies still present on the cell surface were 
stripped by washing the cells twice with ice-cold low-pH culture medium (pH 
2.25) for 1 min. Cell surface bound and intracellular activity were determined 
by measuring the activity of the acid washes and cell-associated radioactivity 
after treatment with low-pH medium. The different fractions were counted with 
a gamma counter (Cobra II). The fraction of internalized antibody was 
calculated from the intracellular activity divided by the initially bound 
radioactivity. 
Analogously, studies were conducted with 125I-labeled F(ab’)2 and Fab 
fragments and with acetone-fixed cells and non-fixed cells. 
7.2.6 Cellular retention and catabolism 
The cellular retention of radioactivity was studied after 2 hours of incubation at 
4°C with 125I-mAb or its fragments. At the end of incubation the cells were 
washed thoroughly to eliminate unbound conjugate, and the incubation was 
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continued in fresh medium at 37°C (allowing internalization) or at 4°C 
(inhibiting internalization). After 0.25-2.0 h, the cells were washed with fresh 
medium and counted for radioactivity. Supernatants of samples incubated at 
37°C for 2 hours were passed over a PD-10 column. Fractions of 500 µl were 
obtained. Fractions 3-9, containing labeled antibody or antibody fragments, 
were pooled, concentrated with centricon YM-30 for 125I-mAb 14C5 and 125I-
F(ab’)2, and with YM-10 for 125I-Fab, and analyzed with SDS-PAGE and 
Cyclone Phosphor Imager (PerkinElmer). 
7.2.7 Statistical analysis 
Comparison between mAb 14C5 and its fragments, F(ab’)2 or Fab was 
performed using a nonparametric Mann-Witney test. 
7.3 Results 
7.3.1 Confocal laser scanning microscopy 
In a first experiment, internalization of mAb 14C5, F(ab’)2 and Fab was 
monitored by CLSM. A549 cells incubated on ice showed no internalized 
antibody (Fig. 7.1A). A549 cells incubated with mAb 14C5 at 37°C, showed 
both membrane and intracellular fluorescence (Fig. 7.1C), whereas cells treated 
with an acid wash after incubation at 37°C with mAb 14C5 showed only 
intracellular fluorescence (Fig. 7.1E). The intracellular fluorescence detected in 
Fig. 7.1C and E, indicates the presence of internalized mAb 14C5. To improve 
visibility, the nuclei of the cells are included in Fig. 7.1 B, D and F. Similar 
results were obtained with F(ab’)2 (data not shown). No internalization was 
seen with Fab. 
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Fig. 7.1. Confocal laser scanning immunofluorescence images of A549 cells incubated with mAb 
14C5 and Alexa-fluor 488-conjugated anti-mouse IgG. The cells shown in (A, B) were incubated 
with mAb 14C5 on ice for 1 h. After incubation with Alexa Fluor 488-conjugated anti-mouse IgG, no 
intracellular fluorescence was detected, indicating there is no internalization of mAb 14C5 at 0°C. 
The cells shown in (C, D) and (E, F) were incubated with mAb 14C5 at 37°C for 1 h. After 
incubation with Alexa Fluor 488-conjugated anti-mouse IgG, intracellular fluorescence was 
detected, indicating internalization of mAb 14C5 at 37°C. To improve the visibility of the intracellular 
fluorescence, an acid wash was used to remove the membrane-bound mAb 14C5 of cells shown in 
(E, F). Also to improve the visibility, the nucleus is shown by propidium iodide in images (B), (E) 
and (F). cell diameter, 5-10µm 
7.3.2 Internalization of 125I-mAb 14C5, 125I-F(ab’)2 and 125I-Fab 14C5 
fragments 
In a second experiment, the degree of internalization was investigated in a 
radioimmunoassay with A549 cells. Cells were incubated with 125I-labeled 
mAb 14C5, F(ab’)2 or Fab at 4°C for 2 h. After removing unbound mAb, 
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F(ab’)2 or Fab 14C5 the cells were incubated at 37°C for various time periods 
to allow internalization. 
The fraction of 125I-labeled mAb 14C5 that remained associated with the cells 
after treatment with a low-pH buffer, increased with longer incubation periods 
from 12.1 ± 1.4 % (t = 0 min) to 32.5 ± 0.1 % for A549 cells (t = 120 min) 
(Fig. 7.2A). The fraction of 125I-labeled F(ab’)2 that remained associated with 
the cells after treatment with a low-pH buffer increased with longer incubation 
periods at 37°C from 3.9 ± 0.3 % (t = 0 minute) to 24.5 ± 0.3 %  (t = 120 
minutes) (Fig. 7.2C). In contrast, the fraction of 125I-labeled Fab associated 
with A549 cells varied with time only from 3.0 ± 0.6 % (t = 0 minute) to 5.6 ± 
0.3 % (t = 120 minutes) (Fig. 7.2E). 
Because internalization is an energy-dependent process it takes place at 37°C, 
but will be inhibited at 4°C. Figure 7.2 shows no increase of radioactivity 
associated with A549 cells after placing the cells at 4°C. The 10% intracellular 
125I-labeled mAb 14C5 at the start of the internalization assay or 3% 
intracellular for F(ab’)2 and Fab (t = 0 h, T = 37°C), can be considered as the 
acid-resistant fraction. 
As a negative control, studies were repeated with acetone-fixed cells (Fig. 
7.2B, mAb; Fig. 7.2D, F(ab’)2; Fig. 7.2F, Fab). These cells only present target 
epitopes for binding, but no internalization can occur. Figure 7.2 shows no 
increase in intracellular activity with acetone-fixed cells, both at 4°C and 37°C 
with neither mAb, F(ab’)2 nor Fab. Because the acid-resistant fraction was 
higher with the acetone-fixed target cells, a control test with mAb 14C5 was 
performed to test the efficiency of the acid wash in function of time both for 
non-fixed and acetone-fixed A549 cells (Fig. 7.3). 
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Fig. 7.2. Internalization of 125I-mAb, 125I-F(ab’)2 and 125I-Fab with A549 cells. Petri dishes (10 cm2) 
with confluent cells were incubated with 1 µCi of 125I-labeled mAb or its fragments at 4°C for 2 h. 
Supernatant containing unbound antibody was removed. Fresh medium was added and samples 
were incubated at 37°C (full lines) to allow internalization or at 4°C (dashed lines) to inhibit 
internalization. At various time points, the 125I-labeled antibodies still present on the cell surface 
were stripped by washing the cells with ice-cold low-pH buffer (pH 2.25) for 1 min. The remaining 
radioactivity (fraction internalized) was counted as a fraction of the initially bound radioactivity (%). 
Studies were done with non-fixed A549 cells (A, mAb; C, F(ab’)2; E, Fab) and acetone-fixed A549 
cells (B, mAb; D, F(ab’)2; F, Fab). Bars, SD. 
 
Internalization of mAb 14C5 and its fragments 
 
 167
 
Fig. 7.3. Efficiency of acid wash for both acetone-fixed (grey) and non-fixed (blue) A549 cells. Petri 
dishes (10 cm2) with confluent cells were incubated with 1 µCi of 125I-labeled mAb at 4°C for 2 h. 
Supernatant containing unbound 125I-mAb 14C5 was removed. Cells were washed twice with PBS 
(blanco, 1 min) or with culture medium (pH 2.25) for the indicated time. *, P < 0.05, significant 
differences between acetone and non-acetone conditions; Bars, SD. 
Figure 7.3 shows a significant influence of the fixation on washing efficiency. 
The efficiency increased in function of time both for acetone and non-acetone 
conditions, but at each amount of time remained significantly lower for acetone 
conditions (P < 0.05). As fixatives can have an impact on the conformation of 
the antigen, it could be possible that 125I-labeled mAb 14C5 or its fragments, 
can bind its epitope stronger after acetone-fixation. 
7.3.3 Intracellular catabolism and cellular retention 
In order to get additional information for the processing of mAb 14C5 and its 
fragments, the catabolism of this antibody and its fragments by target A549 
cells were studied. The processing of the antibody and fragments was followed 
over a period of 2 h. Radioactivity associated with the cells (which includes the 
activity both on the cell surface and within the cell, which were not separated 
in this study), or released into the supernatant was determined. In addition, the 
radioactivity released into the supernatant was analysed further on a PD-10 
column to determine the percentage of free 125I or 125I-monoiodotyrosine. 
Fractions 3 to 9 (500 µL) were considered to contain the 125I-labeled antibodies 
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and were further analyzed for the presence of metabolites using SDS-PAGE 
and autoradiography. 
As shown in figure 7.4, the radioactivity was released gradually into the 
supernatant. 125I-labeled mAb 14C5 and 125I-labeled F(ab’)2 demonstrated 
similar cellular retention of radioactivity with A549 cells (Fig. 7.4A en 7.4C). 
Placed at 37°C for 2 h, A549 released 43.7 ± 1.4 % of 125I-mAb and 49.5 ± 1.0 
% of 125I-F(ab’)2. At 4°C this could be reduced to 8.3 ± 0.2 % for 125I-mAb and 
7.2 ± 0.5 % for 125I-F(ab’)2. 125I-labeled Fab showed poor cellular retention. 
Placed at 37°C for 2 hours, the cells released 92.7 ± 0.3 % of initially bound 
125I-labeled Fab (Fig. 7.4E). At 4°C, with no internalization occurring, this was 
reduced to 40.6 ± 0.5 % for 125I-labeled Fab. As a control, studies were 
repeated with 125I-labeled mAb (Fig. 7.4B), 125I-F(ab’)2 (Fig. 7.4D) and 125I-Fab 
(Fig. 7.4F) with acetone-fixed cells. Since no internalization will take place 
with these fixed cells, release of radioactivity into the supernatant will only be 
a result of dissociation or dehalogenation processes. As shown in figure 7.4, a 
high portion of released radioactivity of 125I-mAb, 125I-F(ab’)2 and 125I-Fab with 
non-fixed cells could be attributed to dissociation of the antibodies. 
Figure 7.5 shows the amount of free 125I (possibly 125I-monoiodotyrosine and 
other small metabolites) in the supernatant by eluting the supernatants over a 
PD-10 column. For the three immunoconjugates, the percentage free 125I was 
higher for non-fixed cells than acetone-fixed cells (Fig. 7.5A, mAb 14C5; Fig. 
7.5C, F(ab’)2; Fig. 7.5E, Fab). However, the percentages are very low, 
indicating that mAb 14C5 and its fragments are slowly degraded after 
internalization. Also, after PD-10 purification, pure radioiodinated mAb 14C5, 
F(ab’)2 and Fab (i.e. fractions 3 to 9) showed no metabolites attributable to 
internalization by SDS-PAGE and autoradiography (Fig. 7.5B, mAb 14C5; Fig. 
7.5D, F(ab’)2; Fig. 7.5F, Fab). 
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Fig. 7.4. Cellular retention of 125I-mAb, 125I-F(ab’)2 and 125I-Fab with A549 cells. Petri dishes (10 
cm2) with confluent cells were incubated with 1 µCi of 125I-labeled mAb or its fragments at 4°C for 2 
h. Supernatant containing unbound 125I-mAb 14C5 or its fragments was removed. Fresh medium 
was added and samples were incubated at 37°C to allow internalization (full lines) or at 4°C to 
inhibit internalization (dashed lines). At various time points, supernatants were removed and cells 
were washed twice with 1 ml fresh medium. The remaining radioactivity (cell-associated activity) 
was counted as a fraction of the initially bound radioactivity (% total added). Studies were done 
with non-fixed A549 cells (A, mAb; C, F(ab’)2; E, Fab) and acetone-fixed A549 cells (B, mAb; D, 
F(ab’)2; F, Fab). Bars, SD. 
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Fig. 7.5. Analysis of metabolites released to the supernatant during internalization. Studies were 
done with acetone-fixed A549 cells (full lines, lanes 1) and non-fixed A549 cells (dashed lines, 
lanes 2) and with 125I-mAb 14C5 (A, B), 125I-F(ab’)2 (C, D) and 125I-Fab (E, F). Petri dishes (10 cm2) 
with confluent A549 cells were incubated with 1 µCi of 125I-labeled antibody or fragments at 4°C for 
2 h. Supernatant containing unbound antibody or fragments was removed. Fresh medium was 
added and samples were incubated at 37°C to allow internalization. At various time points, the 
supernatant was removed and free 125I or 125I-monoiodotyrosine (fraction 10 to 20) were separated 
from 125I-labeled antibody and fragments (fraction 3 to 9) with a PD-10 column (A, mAb 14C5; C, 
F(ab’)2; E, Fab). Subsequently, fraction 3 to 9 of each protein was concentrated and evaluated for 
metabolites with autoradiography after separating possible metabolites with SDS-PAGE (B, mAb; 
D, F(ab’)2; F, Fab; lane 1, acetone-fixed cells; lane 2, non-fixed cells). Bars, SD. 
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7.4 Discussion 
Antibody internalization into the cell is required for many targeted 
therapeutics, such as antibody-toxin conjugates (Altenschmidt et al., 1997), 
immunoliposomes (Mamot et al., 2003), antibody-drug conjugates and for 
targeted delivery of genes or viral DNA into cells (Fominaya and Wels, 1996). 
In radioimmunodetection and radioimmunotherapy, radioisotope (e.g., γ and β-) 
conjugates can exert their toxic effect without having to be inside or even 
bound to the cells. Therefore antibody internalization is less important in this 
situation. However, internalization might be advantageous in α- and Auger-
therapy because of the short range of α-particles (40-100 µm) and Auger 
electrons (a few Å) (Hofer, 2000; Mattes, 2002; Milenic et al., 2004). On the 
other hand, with respect to pretargeting strategies, internalization might be 
unwanted (Sharkey and Goldenberg, 2006).  
Moreover, after internalization, the majority of the antibody will be delivered 
to the lysosomal compartment for degradation (Geissler et al., 1991; Geissler et 
al., 1992). Therefore, after internalization, cell-associated radio-iodine can 
rapidly decrease due to the escape of iodotyrosine from the cells. Many 
research groups have investigated the importance of different labeling 
strategies with respect to internalization (Mattes et al., 1994; Press et al., 1996; 
Yao et al., 2001). Labeling of internalizing mAbs with radiometals results in 
higher retention of the radionuclide in tumour cells due to the intracellular 
retention of metal containing catabolic products. However, three approaches 
have been developed for residualizing radioiodine activity in tumour cells after 
mAb internalization: oligosaccharide conjugates, positively-charged templates, 
and D-amino acid peptides (Zalutsky and Lewis, 2003). Using radiometals or 
residualizing radioiodine strategies, internalization may offer a therapeutic 
advantage in RIT because it traps these isotopes into the cell. 
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Our studies have demonstrated the internalization of mAb 14C5 and its F(ab’)2 
fragment by A549 cells. No protein metabolites attributable to the 
internalization process are shown within the first 2 hours of internalization, but 
some authors have reported antibody degradation starting at 2 h (Shih et al., 
1994). The amount of free 125I or 125I-monoiodotyrosine released into the 
supernatant was < 5% of initially bound radioactivity. These data suggest that 
mAb 14C5 and F(ab’)2 are slowly catabolized. 125I-Fab 14C5 fragments were 
almost not internalized, suggesting that there might be a need of bivalency for 
internalization. For many antibodies, bivalency seems to be mandatory for 
internalization (Nielsen and Marks, 2000), although this is not seen with every 
antibody (Shih et al., 1994; Poul et al., 2000). Further studies using 
recombinant Fab and bispecific multivalent fragments will be conducted to 
investigate the role of bivalent epitope binding. Also, subcellular fractionation 
studies of A549 cells can show where catabolism of the investigated fragments 
takes place. In addition, it is suggested by some authors that antibodies binding 
the same antigen might demonstrate a different way of intracellular trafficking 
after internalization (Shih et al., 1994). Since F(ab’)2 and mAb show similar 
intracellular uptake and cellular retention different from Fab, it could be 
possible that the monovalent epitope binding of Fab is responsible for these 
differences (Press et al., 1988).  
In comparison, mAb and F(ab’)2 show better retention of radioactivity than Fab 
both at 4°C and 37°C. Using acetone-fixed cells or non-acetone fixed cells at 
4°C, no internalization takes place. Under these conditions, the amount of 
activity released in the supernatant is due to the dissociation of membrane-
bound antibody or fragments. This agrees with the lower affinity measured 
with Fab (Kd 2.25 ± 0.44 nmol/l) compared to F(ab’)2 (Kd 0.37 ± 0.10 nmol/l) 
and mAb 14C5 (Kd 0.19 ± 0.08 nmol/l). Also, the loss of cell-associated 
radioactivity for mAb 14C5 and both fragments is higher at 37°C than at 4°C. 
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This could be explained by an effect of temperature on the dissociation rate 
(Ong and Mattes, 1993; Xavier et al., 1999). Xavier et al. (1999) showed an 
increase in kdiss of monoclonal antibody HyHEL-5 from 0.10 s-1 at 10°C to 2.7 
s-1 at 32°C. 
7.5 Conclusion 
Internalization was seen with mAb 14C5 and its F(ab’)2 fragment, but to a 
much lesser extent with Fab. This offers the possibility of using Auger 
electrons and α-particles with mAb 14C5 and F(ab’)2, and possibly other 
targeted strategies than radioimmunotherapy such as the use of immunotoxins. 
The rapid dissociation seen with the Fab 14C5 fragment may limit its use in 
clinical practice.  
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8.1 Introduction 
Maximal tumour targeting with minimal background or minimal exposure to 
normal organs is the goal for the clinical application of monoclonal antibodies 
(mAbs) in cancer diagnosis and therapy. In that regard, Fab and F(ab’)2 
fragments of intact mAb 14C5 were developed  and targeting properties were 
evaluated. Although improved background clearance was obtained at early time 
points compared with intact mAb 14C5, tumor uptake of fragments was 
significantly lower than that of intact mAb 14C5. These classic mono- and 
bivalent antibody fragments are easy to produce with fast enzymatic 
proteolysis, and can be evaluated within a short time frame. However, 
enzymatical proteolysis has a low efficiency and therefore is not economically 
interesting for clinical applications. 
Genetic engineering provides powerful tools for manipulating the structure and 
pharmacokinetic properties of antibodies. One useful strategy has been the 
production of single chain fragments (scFv) containing the variable regions of 
the immunoglobulin heavy chain and light chain, covalently connected by a 
flexible peptide linker (Colcher et al., 1990). Several scFvs have been 
evaluated for their specific in vivo tumour targeting to antigens such as TAG-
72, carcinoembryonic antigen (CEA) and the HER2/neu receptor. They 
demonstrated more rapid clearance and higher tumour-to-normal tissue ratios 
than the corresponding IgG or Fab fragments (Milenic et al., 1991; Adams GP 
et al., 1993; Wu AM et al., 1996). Furthermore, penetration of scFv into a 
tumor from the vasculature, as demonstrated with autoradiography, was 
superior to that of corresponding intact IgG, F(ab’)2 or Fab (Yokota et al., 
1993). 
Because of the rapid clearance of 25 kDa proteins from the blood pool, the 
maximum tumor uptake of a monomeric scFv is limited. Multivalent antibody 
constructs have demonstrated improved tumour uptake and intermediate blood 
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clearance ratios compared with scFv and intact antibodies. Different strategies 
have been described in literature for the formation of multivalent antibodies 
with altered pharmacokinetics and improved tumour uptake. Adams et al. 
(1993) described an improvement in in vivo tumour targeting using divalent 
forms of anti-neu-scFv with a C-terminal Gly4Cys joined by a disulfide bond 
(Huston et al., 1994). Another antibody fragment, a minibody, was produced by 
fusion of T84.66 anti-CEA scFv to the human IgG1 CH3 domain (Hu et al. 
1996). Others have fused scFvs to protein domains capable of multimerization, 
e.g., leucine zipper proteins (Kostelny et al., 1992), streptavidin (Dubel et al., 
1995), or the κ-constant region (McGregor et al. 1994). The easiest approach 
for the production of dimeric scFvs is based on spontaneous formation of 
noncovalent dimers such as 50 kDa diabodies (Holliger, 1993). A recent 
overview of alternative antibody formats based on the scFv as building block is 
given by Carter (2006). 
Except for altering pharmacokinetics, genetic engineering has another 
advantage. Mouse monoclonal antibodies have shown limited use as 
therapeutic agents in humans as a result of the production of human anti-
mouse-antibodies (HAMA response). In an attempt to reduce the 
immunogenicity of mouse antibodies, genetic engineering was also used to 
generate chimeric antibodies, that is, antibodies with human constant regions 
and mouse variable regions. However, anti-chimeric antibody responses 
(HACAs) have been observed. Further minimization of the mouse component 
of antibodies can be achieved through complement determining region (CDR) 
grafting. In these humanized antibodies, only the CDR loops are inserted into 
the human variable framework. 
Manipulating the structure and pharmacokinetic properties of mAb 14C5, 
increases the clinical usefulness of mAb 14C5 as novel agent for radioimmuno-
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detection and radioimmunotherapy. The aim of this study was to clone and 
characterize Fv 14C5. 
8.2 Materials and methods 
8.2.1 Cell lines 
HEK293T, a human embryonic kidney cell line transfected with SV40 large T-
Ag (SV40TtsA1609), was used for transient eukaryotic expression of recombinant 
Fab 14C5. 
A549 cells, a human lung carcinoma cell line, were obtained from the 
Laboratory of Tumor and Developmental Biology (University of Liège, Liège, 
Belgium). A549 cells were cultured in DMEM (Cambrex), containing 2 mmol/l 
L-glutamine (Cambrex) and 10% fetal bovine serum (Cambrex). 
8.2.2 scFv 14C5  cDNA synthesis and cloning with Recombinant Phage 
Antibody System 
Purified mRNA was isolated from total RNA of 1 × 108 14C5 hybridoma cells 
(De Potter et al., 1994) by oligo(dT)-cellulose affinity chromatography. cDNA 
was synthesized using oligodT primers and avian myeloblastosis virus reverse 
transcriptase (AMV RT) (Promega) or Moloney murine leukaemia virus 
(MMLV) RT (Promega). The resulting cDNA was subjected to PCR using the 
primers (Heavy Primer 1, Heavy Primer 2, Light Primer Mix) of the 
Recombinant Phage Antibody System (Amersham Biosciences) for the 
isolation of the VH (340 bp) and VL (325 bp) domain. Both Taq and Vent 
polymerase conditions were used. Hot start PCR was carried out (5 min at 
95°C, followed with 35 cycles under conditions of denaturing at 94°C for 1 
min, annealing at 52°C for 1.5 min, and extension at 72°C for 1 min). 5 µl of 
PCR reaction was evaluated on a 1% agarose gel. VH and VL were sliced and 
purified with Qiaex II gel extraction kit (Qiagen). The antibody heavy chain 
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and light chain DNA are joined into a single chain using the Linker-Primer mix 
with Taq polymerase and Vent polymerase conditions (7 cycles as follows: 
94°C for 1 minute, 63°C for 4 minutes). Reaction is analysed on a 1.5% 
agarose gel, sliced and purified with Qiaex II gel extraction kit. Following 
assembly, the amplified product (~750 bp) is digested with Sfi I and Not I for 
subsequent cloning into the pCANTAB 5 E phagemid. cDNA sequences were 
screened with PCR using 5’ and 3’ pCANTAB5 sequencing primer set (GE 
Healthcare). Nucleotide sequencing was performed by dideoxynucleotide 
chain-termination method using a DNA sequencing kit (BigDye terminator 
version 3.1 cycle sequencing) and nucleotide sequence homology analyses 
were performed using Clone Manager (Professional Suite 8, Scientific & 
Educational Software, NC, USA). 
8.2.3 Fab 14C5 cDNA synthesis and cloning 
Light and heavy chain of mAb 14C5 were separated with SDS-PAGE and 
transferred to a PVDF membrane. Protein bands were stained with Ponceau S 
before direct N-terminal sequence analysis (Edman degradation). 
Purified mRNA was isolated from total RNA of 1 × 108 14C5 hybridoma cells 
by oligo(dT)-cellulose affinity chromatography. cDNA was synthesized using 
oligodT primers and avian myeloblastosis virus reverse transcriptase (AMV 
RT) (Promega) or Moloney murine leukaemia virus (MMLV) RT (Promega). 
The resulting cDNA was subjected to PCR using degenerate primers designed 
for VH (VH1-4 F) and VL (VL F) ends deduced from the N-terminal amino 
acid sequences obtained by the Edman degradation (Table 8.1). 
Based on the alignment of different mouse IgG1 constant domain sequences, 
primers were designed for CH1 (CH1 B) and CL (CL B) Fab 14C5 ends. The 
CH1 B and CL B primers were designed to contain a BamHI, a BspEI and an 
ApaI restriction site. 
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Hot start touchdown PCR was carried out using Vent polymerase: 5 min at 
95°C, followed with 9 cycles under conditions of denaturing at 95°C for 1 min, 
annealing starting at 57°C for 1 min (for every subsequent cycle, the 
temperature is decreased with 0.5°C), extension at 72°C for 2 min, and 25 
cycles under conditions of denaturing at 95°C, annealing starting at 52°C for 1 
min, extension at 72°C for 2 min. A final elongation step of 10 min at 72°C 
was used at the end. 
Tabel 8.1 Primers and primer sequences for PCR with cDNA Fab 14C5 
Name Primers (5´ to 3´) 
VH1 F GARGTRAGYCTNGTKGARTCTGGDGGMG 
VH2 F GARGTRAGYTTRGTKGARTCTGGDGGMG 
VH3 F GARGTRTCNCTNGTKGARTCTGGDGGMG 
VH4 F GARGTRTCNTTRGTKGARTCTGGDGGMG 
VL F AGYATYGTGATGACHCAGACTCCMAAATTC 
CH1 B ATGGATCCTTATCCGGAGGGCCCAATTTTCTTGTCCACCTTGGTGCTGCTG 
CL B ATGGATCCTTATCCGGAGGGCCCACACTCATTCCTGTTGAAGCTCTTG 
NM101 CAACGTGCTGGTTATTGTGCTGTC 
NM105 TCGAGCCACCATGGGTTGGAGCTG 
NM87 CAACAGATGGCTGGCAACTAGAAG 
A, deoxyadenine; C, Deoxycytosine; G, deoxyguanidine; T; deoxythymidine; D, A+T+G; H, A+T+C; 
K, T+G; M, A+C; Y, C+T ; R, A+G ; N, A+G+C+T 
restriction sites :          , BamHI,          ,  BspEI;          ,ApaI 
The resulting PCR products were gel-purified in agarose and extracted using 
Qiaex II (Qiagen). The light chain VL-CL (L) was then cloned into a 
combination of pES33 (Eco47III/PvuI digest) 2030 bp fragment and 
pES31PH1LEZeo (BspEI/PvuI and Xho I digest) 3900 bp expression vector 
fragment containing a zeomycin selection site and E-tag. Similarly, the heavy 
chain fragment VH-CH1 (Fd) was cloned into a combination of pES33 
(Eco47III/PvuI digest) 2030 bp fragment and pES31PH1HHisNeo (BspEI/PvuI 
and Xho I digest) 3535 bp expression vector fragment containing a neomycin 
selection site and (His)6-tag. The L and Fd fragments were kinated with T4 
kinase and introduced into the expression vectors by BspEI digest. cDNA 
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sequences were screened with PCR using 5’ and 3’ primers VH1 F, VH2 F, 
VH4 F, CH1 B, CL B, NM101, NM105, and NM87 (Table 8.1). 
Nucleotide sequencing was performed by the dideoxynucleotide chain-
termination method using a DNA sequencing kit (BigDye terminator version 
3.1 cycle sequencing) and nucleotide sequence homology analyses were 
performed using Clone Manager. 
8.2.4 Production of recombinant Fab 14C5 fragment 
For transient expression, HEK293T cells were transfected according to the 
Ca3(PO4)2 precipitation method (O’Mahoney et al., 1994). Twenty hours before 
transfection, HEK293T cells were seeded at 4 × 106 cells/175 cm2. 1 µg DNA 
of each expression plasmid was added to the cells for 24 h, after which the cells 
were covered with supplemented DMEM containing 5 mg/l bovine insulin, 5 
mg/l transferrin, and 5 µg/l selenium (ITS) replacing FCS. Medium was 
harvested every 48 hours after transfection. 200 µl Fab 14C5 of concentrated 
(40×) supernatant was applied to 2 × 105 A549 breast cancer cells and Fab 
14C5 binding was analysed by flow cytometry. Secondary goat anti-mouse 
(H+L) Alexa-488 antibody was used (Invitrogen). 
8.3 Results 
8.3.1 cDNA cloning of the scFv 14C5 by Recombinant Phage Antibody 
System 
The Recombinant Phage Antibody System (Amersham Biosciences) was used 
in a first attempt to isolate VH and VL cDNA of mAb 14C5. The amplified 
VH, VL and scFv DNAs were about 340 bp, 320 bp and 750 bp respectively. 
Following assembly, the amplified scFv product (~750 bp) was digested with 
Sfi I and Not I for subsequent cloning into the pCANTAB 5 E phagemid vector 
(Fig. 8.1). 
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After transformation, formed colonies were PCR screened and cDNA 
sequences were analyzed. After homology analyses, none of the analyzed 
sequences matched with sequences of heavy and light chain variable domains 
of a murine IgG1 antibody. 
 
 
 
 
 
Fig. 8.1. Digest of scFv amplified product from hybridoma 14C5 cells. lane 
1, 1 kb Plus DNA Ladder; lane 2, SfiI/NotI/BsaI digest of pCANTAB5 E 
phagemid vector (3070 bp, 1401 bp, 748 bp); lane 3, SfiI/NotI digest of 
amplified scFv 14C5 product; *, restriction fragments used in ligation 
8.3.2 Fab 14C5 cDNA synthesis and cloning based on N-terminal amino 
acid sequences of mAb 14C5 
Edman degradation of pure mAb 14C5 generated nine amino acid sequences 
(Glu-Val-Ser-Leu-Val-Glu-Ser-Gly-Gly) for the heavy chain and fifteen amino 
acid sequences (Ser-Ile-Val-Met-Thr-Gln-Thr-Pro-Lys-Phe-Leu-Leu-Val-Ser-
Ala) for the light chain of mAb 14C5.  
 
Fig. 8.2. Primer design for constant domains of light and heavy chain of mAb 14C5 
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Degenerate primers were designed (Table 8.1) based on these amino acids. In 
order to reduce degeneracy, N-terminal sequences of homologous IgG1 
antibodies were compared to select the most common used codons. Based on 
the alignment of different mouse IgG1 constant domain sequences, primers 
were designed for CH1 (CH1 B) and CL (CL B) Fab 14C5 ends (Fig. 8.2). 
These primers were designed to contain a BamHI, a BspEI and an ApaI 
restriction site (Table 8.1). Touchdown PCR resulted in Fd chains when VH1, 
VH2, VH4 F and CH1 B primers were used, but not when the combination of 
VH3 F and CH1 B primers was used (Fig. 8.3). Light chain PCR fragment was 
formed when VL F and CL B primers were used. 
 
Fig. 8.3. PCR of 14C5 hybridoma cDNA with designed Fab primers. Lane 1, positive control, β-
actine PCR product; lane 2, PCR fragment with VH1 F and CH1 B primer; lane 3, PCR fragment 
with VH2 F and CH1 B primer; lane 4, PCR fragment with VH3 F and CH1 B primer; lane 5, PCR 
fragment with VH4 F and CH1 B primer; lane 6, 1 kb Plus DNA Ladder (Invitrogen); lane 7, PCR 
fragment with VL F and CL B primer 
The resultant PCR products (VH1, VH2, VH4, L) were introduced into a 
pES31 vector. After transformation, formed colonies were PCR screened and 
cDNA sequences were analyzed. 
8.3.3 cDNA sequence analysis of variable domains of  Fab 14C5 
The DNA sequence and amino acid sequence of the heavy and light chain 
variable regions were deduced from the heavy chain and light chain sequences 
of the positive clones. As shown in Fig. 8.4, amino acid numbering and 
complementary determining regions (CDRs) of the VH (H1, H2 and H3) and 
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VL (L1, L2, and L3) domains were determined according to Kabat et al. 
(1991). The VH gene of mAb 14C5 belongs to the VH3d family. The Vκ gene 
fragments belong to the Vκ5 family (Kabat et al., 1991). 
 
Fig. 8.4. The amino acid sequences are aligned and organized into different complement 
determining regions (CDR) and framework regions, as defined by Kabat et al. (1991). (A) Vκ gene 
of mAb 14C5 with L1, L2, and L3 showing CDR regions of kappa light chain. (B) VH gene of mAb 
14C5 with H1, H2, and H3 showing CDR regions of heavy chain.  
8.3.4 Quantitative analysis of the recombinant Fab 14C5 
Co-expression of L and Fd chains is expected to yield Fab 14C5 fragments in 
the supernatant. Supernatant was concentrated and analysed for binding with 
A549 lung cancer cells. The antigen-binding of the concentrated recombinant 
Fab proteins by flow cytometry is shown (Fig. 8.5). 
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Fig. 8.5. Histogram of flow cytometric analysis of recombinant Fab 14C5 binding to A549 lung 
cancer cells. Open histograms, negative control; filled histograms, recombinant Fab 14C5 
8.4 Discussion 
In this study, we described the cloning and sequencing of the variable (V) 
genes of mAb 14C5. Following Kabat et al. (1991) the CDR regions were 
deduced. The VH gene of mAb 14C5 belongs to the VH3a/d family. The Vκ 
gene belongs to the Vκ5 family (Kabat et al., 1991). Flow cytometry study with 
recombinant Fab 14C5 demonstrated binding with the antigen 14C5. This 
indicates that the cloned variable genes encode the variable domains of a 
functional anti-Ag 14C5 antibody fragment. 
These results offer opportunities for further optimization of mAb 14C5 with 
antibody engineering for applications in radioimmunodetection and -therapy. 
The V-genes can be used to construct a functional scFv fragment. Based on the 
V-gene sequences, primers can be designed hybridizing to the flanking regions 
of the Vκ and VH gene. After amplification of V genes, the two variable 
regions can be artificially joined using a single 15-amino acid linker (Gly4Ser)3. 
This flexible peptide linker is specifically designed to bridge the 3.5 nm gap 
between the carboxy-terminus of the VH chain and the amino-terminus of the 
VL chain (Huston et al., 1988). The affinity and stability of scFv antibodies 
containing the (Gly4Ser)3 linker are generally comparable to those of the native 
antibody (Huston et al., 1988; Glockshuber et al., 1991; Takkinen et al., 1991). 
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Altering pharmacokinetics of mAb 14C5, the recombinant Fab chain can be 
used as heterodimerization scaffold for the construction of multivalent anti-
mAb 14C5 antibodies (Schoonjans et al., 2000) or the resulting scFv molecules 
can be linked with polypeptide linkers resulting in multivalent scFv constructs 
(Carter, 2006). Tags can be added such as (His)6 which facilitates radiolabeling 
with other isotopes than radioiodine, i.e. 99mTc can be used by the tricarbonyl 
system (Willuda et al., 2001). 
Moreover, to reduce the immunogenicity of murine mAb 14C5, the 14C5 V 
genes can be used to construct chimeric antibodies (Imai et al., 2006). 
Secondly, although labour-intensive, grafting the CDR regions into the most 
closely related human antibody framework is an established technique. Ewert 
et al. (2004) reviewed two methods for knowledge-based improvement of 
antibody stability and folding efficiency. Hereby, CDR grafting is done in more 
distantly related, but stable acceptant frameworks and secondly, improving a 
suboptimal framework is done by the introduction of point mutations designed 
to optimize key residue interactions. 
Also, a broader range of applications of mAb 14C5 is now possible. Toxins and 
drugs instead of isotopes can be coupled to mAb 14C5 and guided to the 
tumour. Bispecific antibodies can be designed and used to activate the immune 
system or to be employed in pretargeting strategies (Sharkey and Goldenberg, 
2006). 
8.5 Conclusion 
In this study, mAb 14C5 was characterized by cloning and sequencing its 
variable genes. This opens the way to a broad range of applications including 
altering pharmacokinetics, reducing immunogenicity, the use of a variety of 
isotopes, conjugation of drugs or toxins, the design of bispecific antibodies and 
pretargeting strategies. 
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GENERAL DISCUSSION AND 
FUTURE PERSPECTIVES 
 
In the first part of this thesis (Chapter 3 and Chapter 4), we tried to 
identify and characterize antigen 14C5 as a new tumour associated antigen for 
antibody targeting. We found that antigen 14C5 is likely to be the integrin αvβ5 
receptor and that the antigen is highly expressed on a variety of human cancer 
cell lines. Analysing the expression levels on human lung and colon cancer 
tissues by immunohistochemistry showed that the location of antigen 14C5 in 
patients is often associated with fibroblasts in the stroma surrounding the 
tumour cells and to a lesser extent associated at the tumour cell surface. This 
was also reported by Coene et al. (1997) for the expression of Ag 14C5 on 
human breast cancer tissues. Interestingly, Kalluri et al. (2006) discuss the 
potential role of fibroblast as cancer targets. A promising candidate for 
specifically targeting cancer associated fibroblasts is sibrotuzumab, an antibody 
to human fibroblast-activation protein (FAP). A phase I dose-escalation study 
with sibrotuzumab in patients with advanced colorectal or non-small cell lung 
cancer showed that sibrotuzumab specifically binds to the tumour sites without 
apparent site effects (Scott et al., 2003). Preclinical therapeutic studies with 
mAb 14C5 have to show whether our antibody is capable of showing similar or 
better therapeutic effects. Further studies on the expression of Ag 14C5 and 
αvβ5 have to show whether αvβ5 is an indicator of the fibroblast phenotype 
(Scaffidi et al., 2001). 
Because antigen 14C5 is expressed on epithelial cancer cells as well as in 
the surrounding tumour stroma, Ag 14C5 is potentially suitable for antibody 
targeting. For many years, all of the efforts to treat cancer have been 
concentrated on the inhibition or destruction of tumour cells. Recently, many 
research groups start to believe that strategies to treat the tumour cell and to 
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modulate the host microenvironment could provide a better approach for the 
treatment of cancer. Therefore, many recent reviews discuss the role of the 
tumour microenvironment as potential target for targeted therapies (Fidler et 
al., 2002; Fidler et al., 2003; Hofmeister et al., 2006; Kalluri et al., 2006). The 
different strategies involve anti-angiogenesis and anti-vascularization 
(Folkman, 2006; Kerbel, 2006), anti-fibroblast (Micke et al., 2005; Kalluri et 
al., 2006), and anti-integrin therapeutics (Pasqualini et al., 1997; Paulhe et al., 
2005). This supports the potential of antigen 14C5 as target and warrants its 
further investigation. 
Comparing the binding of mAb 14C5 with another αvβ5 antibody 
(P1F6), we showed similar expression patterns, although specific as well as 
non-specific staining of the latter was more intense. Also, blocking studies with 
mAb 14C5 could block the specific binding of 125I-labeled anti-αvβ5 to A549 
lung cancer cells, confirming that the identity of antigen 14C5 most likely is 
the integrin αvβ5 receptor. Integrin αvβ5 belongs to a widely expressed family 
of cell adhesion receptors that recognise extracellular matrix proteins and cell 
surface antigens. Different integrin members have been associated with tumour 
progression (Mizejewski et al., 1999; Hynes et al., 2002; Kerr et al., 2002; 
Wehrle-Haller et al., 2003; Jin et al., 2004; Haubner, 2006; Serini et al., 2006). 
Moreover, antibodies targeting similar integrins are currently under clinical 
investigation, including CNTO95 (a fully human anti-αv antibody, binds αvβ3 
and αvβ5) (Davis et al., 2004; Jayson et al., 2004; Trikha et al., 2004; Martin et 
al., 2005) and Vitaxin (a humanized anti-αvβ3 antibody). The high-affinity 
humanized anti-αvß3 antibody (Vitaxin) is in clinical development as an anti-
angiogenic therapeutic (Gutheil et al., 2000); unfortunately, so far its tumour-
targeting performance for cancer imaging and therapy has been unsatisfactory 
(Posey et al., 2001; Cai and Chen, 2006). Cilengitide, a cyclic RGD peptide in 
clinical trials for metastatic cancer has been tested in an aggressive breast 
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cancer model in combination with 90Y-labeled chimeric anti-L6 
radioimmunotherapy, which remarkably increased efficacy and apoptosis, 
compared to single-modality therapy with either agent, without additional 
toxicity (Burke et al., 2002). Noninvasive PET and SPECT imaging of integrin 
expression have been done with monomeric, dimeric and tetrameric RGD 
peptides and peptidomimetics (Lewis, 2005; Dijkgraaf et al., 2006a-b; 
Haubner, 2006; Zhang et al., 2006). 
In the near future, the most important challenge will be the novelty or 
lack of novelty regarding antigen 14C5 as a new cancer associated target from 
an intellectual property perspective, limiting its potential application in the 
clinic. Therefore, distinguishing antigen 14C5 and/or mAb 14C5 from the 
already existing targets and antibodies must be the highest priority in further 
mAb 14C5 development. Secondly, priority must be given to the non-specific 
targets in normal tissues. De Potter et al. (1994) and Coene et al. (1997) 
reported no expression of Ag 14C5 on normal epithelial, muscle, and 
connective tissues including skin, thyroid, parathyroid, colon, stomach, lung, 
uterine tube, ovary, ureter, urethra, lymph node, nerve, chondroid tissue, 
skeletal muscle, oesophagus, and artery. Sometimes, low-level staining of myo-
epithelial cells was observed in biopsies of breast tissue and in tubular cells of 
the kidney. In this thesis, sometimes small blood vessels and mucous secreting 
cells on normal colon tissue were stained with mAb 14C5. The FDA guidelines 
(1997) concerning the development of antibody drugs suggest sampling of 32 
different normal tissue types to look for expression on normal tissue for risk 
assessment. However, it is not necessary to fully satisfy all of these criteria as 
evidenced by clinical approval of antibodies targeting HER2 (Herceptin), 
CD20 (Rituxan, Zevalin and Bexxar), CD33 (Mylotarg), CD52 (Campath) and 
epidermal growth factor receptor (EGFR) (Erbitux) (Carter et al., 2004). To 
conclude antigen 14C5 expression, the involvement of Ag 14C5 in the cancer 
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associated fibroblasts should be further explored, as it might lead to an 
interesting antibody-based therapeutic concept for mAb 14C5. 
 
Potentially suitable for antibody targeting, the second part of the thesis 
investigated the in vitro and in vivo targeting properties of radioiodinated mAb 
14C5 (Chapter 5) and optimization strategies including mAb 14C5 fragments 
Fab and F(ab’)2 (Chapter 6), the possibility of internalization (Chapter 7) and 
finally the cloning and sequencing of scFv 14C5 (Chapter 8). 
Few validated surface antigens have demonstrated robust anti-tumour activity 
using so-called ‘naked’ antibodies. Fortunately, the potency of anti-cancer 
antibodies can be improved in numerous ways including arming with potent 
drugs (Payne, 2003) or radionuclides (Goldenberg, 2003). These arming 
technologies have lead to the regulatory approval of the antibody drugs, 
Mylotarg, Zevalin, and Bexxar, conjugated with the drug calicheamicin, and 
the radionuclides 90Y and 131I, respectively (Carter, 2006). For this reason and 
working at a radiopharmaceutical lab, our first antibody-based therapeutic 
concept of choice was investigating the potency of radioimmunotherapy with 
mAb 14C5. However, given the anti-substrate adhesion function of mAb 14C5, 
we can not exclude that the naked antibody itself could have a significant 
therapeutic activity. Initial steps are made to investigate the blocking function 
of mAb 14C5 in vivo by a model which uses HT-1080 fibrosarcoma cells 
transfected with the lacZ gene (Schweinitz et al., 2004). 
The studies presented in this thesis showed that radioiodinated mAb 
14C5 binds its antigen with high affinity (Kd, 0.2 nmol/l), showed good and 
specific tumour uptake in vivo and good planar gamma camera imaging quality. 
However, the blood clearance is slow which is typical for a 150 kDa sized 
intact antibody. Many efforts of various groups have been undertaken in 
increasing the tumour-to-background ratio and to increase tumour penetration. 
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A common approach is the development of smaller antibody fragments by 
enzymatic digestion (papain, pepsin or ficin) and genetically engineered single-
chain Fv (scFv) constructs of antibody molecules (Reff, 2001; Goldenberg, 
2002; Batra et al., 2002). Being able to provide Fab and F(ab’)2 fragments of 
mAb 14C5 in an easy and short way, we investigated targeting properties of 
these both fragments. Biodistribution results showed increased tumour-to-blood 
and tumour-to-muscle ratios, but the overall tumour uptake of both fragments 
was significantly reduced, necessitating the further optimization of mAb 14C5. 
Genetic engineering provides powerful tools for manipulating structure 
and pharmacokinetic properties of antibodies. One useful strategy has been the 
production of single chain fragments (scFv) containing the variable regions of 
the immunoglobulin heavy chain and light chain, covalently connected by a 
flexible peptide linker (Colcher et al., 1990). Although a scFv is too small (25 
kDa) and therefore often not suitable for targeting due to rapid clearance, it can 
be used as a building block for multivalent molecules which have intermediate 
sizes above the exclusion limit for kidney filtration. Moreover, genetic 
engineering can be used to reduce the immunogenicity of mouse antibodies, 
generating chimeric antibodies or through complement determining region 
(CDR) grafting. In chapter 8, the VH and VL chain genes of mAb 14C5 were 
identified, which makes it now possible to develop a multivalent intermediate 
of mAb 14C5 with less immunogenicity and more suitable targeting properties. 
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SUMMARY 
 
In search of new antibody therapeutics for inhibition of metastatic breast 
cancer, De Potter et al. (1994) developed several mouse monoclonal antibodies 
(mAbs) against epitopes on the extracellular membrane of SK-BR-3 human 
breast cancer cells. One of these mAbs is the IgG1 mAb 14C5, which recognizes 
an extracellular plasma membrane antigen expressed on SK-BR-3 and MCF-7 
human breast cancer cells. The antibody is capable of reversibly inhibiting the 
adhesion of SK-BR-3 cells on both culture-treated plastic and on pronectin-, 
fibronectin-, osteopontin-, and vibronectin-precoated culture plates. 
Furthermore, mAb 14C5 has been shown to prevent invasion and, subsequently, 
metastasis of SK-BR-3 and MCF-7 cells on host tissue in vitro. In addition, mAb 
14C5 and its anti-idiotypic counterpart (mAb ACA 14C5) was able to signi-
ficantly inhibit tumor growth in a dose-dependent way in Sprague–Dawley rats 
bearing HH-16 clone 1/2 adenocarcinomas or fibrosarcomas overexpressing 
the 14C5 antigen. In the past, different strategies have failed to identify the 
antigen 14C5. Therefore, the foci of this research were to identify and further 
characterize antigen 14C5 as potential target for mAb 14C5-based 
immunotherapies and to explore the targeting properties of radioiodinated mAb 
14C5 for radioimmunodetection and –therapy. 
 
First, we tried to purify antigen 14C5 by mAb 14C5 affinity-column 
chromatography. No specific protein components in the purified SKBR-3 or 
HT-1080 lysates were found after western blot analysis. Biacore analysis 
showed that only little amounts of soluble antigen 14C5 are available in mAb 
14C5 affinity-column purified SKBR-3 lysate. A possible explanation for both 
western blot and Biacore analysis failure could be a conformation change of the 
soluble protein as compared to the cell surface expressed antigen. Therefore, 
other strategies were explored to identify the antigen. 
It was already suggested by De Potter et al. (1994) and Coene et al. (1997) that 
antigen 14C5 could be related to the family of integrins. We further explored 
this idea by comparing the expression of the antigen 14C5 with the expression 
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of eight different integrin subunits (α1, α2, α3, αv, β1, β2, β3, and β4) and three 
different integrins heterodimers (αvβ3, αvβ5, and α5β1). Basically, we selected 
integrins involved in cancer pathology which could possibly block cell-
substrate-adhesion, since these are both characteristics of mAb 14C5. By flow 
cytometry at saturating conditions, anti-αvβ5 specific antibody (P1F6) showed 
equivalent expression levels to mAb 14C5. In a blocking assay with mAb 
14C5, the αvβ5 receptors could be significantly blocked by mAb 14C5, 
indicating that antigen 14C5 is the αvβ5 receptor. Flow cytometry analysis of 
Colo16 cells transfected with human αv and β5 cDNA, demonstrated that 
subpopulations expressing both sub-units bind mAb 14C5. 
Immunocytochemical analysis and flow cytometry analysis show that the 
expression of antigen 14C5 is not restricted to the breast cancer cell lines but is 
also present in varying degrees on other neoplastic human cell lines from 
different origins: carcinomas of ovary, cervix, lung, colon, and pancreas, 
sarcomas, and melanomas. Flow cytometric results showed that 9 out of 15 of 
the investigated cell lines showed high expression of antigen 14C5. Among 
these, the A549 lung cancer cells showed the highest antigen 14C5 expression, 
providing a possible new target for non-small cell lung cancer (NSCLC) 
therapy. Further expression analysis of the antigen 14C5 was done by 
immunohistochemistry of human lung carcinoma and human colon carcinoma. 
In both these tumour types, Ag 14C5 expression mainly occurred in the stroma 
and on stromal fibroblasts surrounding the tumour cells and to a lesser extent at 
the tumour cells. Further studies on the expression of antigen 14C5 have to 
show whether antigen 14C5 is an indicator of the fibroblast cancer-associated 
phenotype. 
To further characterize the antigen 14C5, immunohistochemical staining with 
mAb 14C5 was compared with αvβ5 specific (P1F6) staining. No discrepancy 
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was found in the expression patterns between the two antibodies. However, 
staining with anti- αvβ5 was more intense, specific as well as non-specific. 
 
The second part of the thesis explored the potential of radioiodinated 
mAb 14C5 as agent for radioimmunodetection and –therapy. Saturation 
binding analysis showed that radioiodinated mAb 14C5 binds its antigen with 
high affinity (Kd, 0.2 ± 0.1 nmol/l, A549 lung carcinoma cells), showed good 
and specific tumour uptake in vivo and good planar gamma camera imaging 
quality. However, the blood clearance was slow, which is typical for a 150 kDa 
sized intact antibody. 
Fab and F(ab’)2 fragments of intact mAb 14C5 were generated with a ficin 
column. Saturation binding analysis showed that radioiodinated F(ab’)2 still  
binds antigen 14C5 with high affinity (Kd, 0.4 ± 0.1 nmol/l), while 
radioiodinated Fab looses affinity due to its monomeric binding (Kd, 2.3 ± 0.4 
nmol/l). Clearance from the blood was faster with Fab and F(ab’)2 fragments. 
The alpha half-life (t½α) values for Fab, F(ab’)2 and mAb 14C5 were 14.9 min, 
21 min and 118 min, respectively. The beta half-life (t½β) values for Fab, 
F(ab’)2 and mAb 14C5 were 439 min, 627 min and 4067 min, respectively. 
Biodistribution results showed increased tumour-to-blood and tumour-to-
muscle ratios, but the overall tumour uptake of both fragments was 
significantly reduced, necessitating further optimization of mAb 14C5. 
Internalization can lead to a rapid loss of the radiolabel from the tumor cell, 
because this process exposes the labelled mAb to intracellular catabolic 
processes in the lysosomes. We investigated the fate of the 125I-labelled mAb 
14C5-antigen complex. Studies were also conducted with 125I-labeled F(ab’)2 
and Fab fragments. Internalization of mAb 14C5 and its F(ab’)2 fragment was 
seen in A549 cells, both with confocal laser scanning microscopy and using 
radioiodinated antibodies. No protein metabolites attributable to the 
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internalization process are shown within the first 2 hours of internalization, 
although some authors have reported antibody degradation starting at 2 hours. 
Also, the amount of free 125I or 125I-monoiodotyrosine released into the 
supernatant was <5% of initially bound radioactivity. These data suggest that 
mAb 14C5 and F(ab’)2 are slowly catabolized. 125I-Fab 14C5 fragments were 
almost not internalized, suggesting that there might be a need of bivalency for 
internalization of the antibody-antigen 14C5 complex. However, 125I-Fab 
showed a rapid dissociation, which can limit its use in patients. 
Genetic engineering provides powerful tools for manipulating the structure and 
pharmacokinetic properties of antibodies. It offers the opportunity to change 
the antibody characteristics (structure, size, valence, immunogenicity, etc.) in 
order to obtain optimal targeting properties. In this context, the variable heavy 
and variable light chain genes were sequenced and the complement 
determining regions characterizing mAb 14C5 were identified. This opens the 
way to a broad range of applications including altering pharmacokinetics, 
reducing immunogenicity, the use of a variety of isotopes, conjugation of drugs 
or toxins, the design of bispecific antibodies and pretargeting strategies. 
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SAMENVATTING 
 
In een poging om nieuwe therapeutische antilichamen te maken voor de 
inhibitie van borstkankermetastasen, ontwikkelden De Potter et al. (1994) 
verschillende monoklonale muisantilichamen (MALs) gericht tegen epitopen 
gelegen op het extracellulaire membraan van SK-BR-3 humane 
borstkankercellen. Eén van deze antilichamen, het IgG1 MAL 14C5, herkent 
een extracellulair membraanantigeen dat voorkomt op SK-BR-3 en MCF-7 
borstkankercellen. Dit antilichaam heeft als eigenschap dat het de adhesie kan 
inhiberen van SK-BR-3 cellen op een celcultuurplaat en op cultuurplaten 
waarop pronectine, fibronectine, osteopontine of vibronectine werd gebonden. 
Bovendien toonden in vitro testen aan dat het MAL 14C5 invasie en 
metastasering in gastweefsel kon verhinderen. Significante tumorgroei-inhibitie 
werd waargenomen in Sprague-Dawley ratten met een anti-idiotypische 
tegenhanger van MAL 14C5 (MAL ACA 14C5). Deze groei-inhibitie was dosis 
afhankelijk en werd aangetoond met HH-16 kloon ½ adenocarcinomas of 
fibrosarcomas die beide het antigeen 14C5 tot overexpressie brachten. Ondanks 
vele pogingen, kon men het antigeen 14C5 nog niet identificeren. De 
doelstellingen van deze studie waren de identificatie en verdere karakterisatie 
van het antigeen als mogelijk doelwit voor immunotherapie met MAL 14C5 en 
onderzoek naar de targeting eigenschappen van radiogejodeerd MAL 14C5 
voor radioimmunodetectie en -therapie. 
 
In eerste instantie probeerden we het antigeen 14C5 op te zuiveren via 
affiniteitschromatografie waarbij 14C5 MAL werd geïmmobiliseerd op een 
kolom. Met western blot analyse konden geen specifieke eiwitten worden 
aangetoond, noch in het opgezuiverde SK-BR-3 borstkanker cellysaat, noch in 
HT-1080 fibrosarcoma cellysaten. Biacore-analyse toonde bovendien aan dat 
er slechts weinig oplosbaar antigeen 14C5 beschikbaar was in de opgezuiverde 
SK-BR-3 lysaten (~140 RU). Een mogelijke verklaring voor het falen van deze 
proeven, is een conformatiewijziging van het antigeen in oplossing ten 
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opzichte van het membraangebonden antigeen. Daarom werd een andere 
identificatiestrategie toegepast. 
De idee dat het antigeen kon behoren tot de integrine eiwitfamilie werd al 
aangebracht door De Potter et al. (1994) en Coene et al. (1997). Dit idee 
werkten we verder uit in een vergelijkende expressiestudie, waarbij met 
flowcytometrie onder verzadigde condities de expressie van acht verschillende 
integrine subeenheden (α1, α2, α3, αv, β1, β2, β3, and β4) en drie verschillende 
integrine heterodimeren (αvβ3, αvβ5, and α5β1) werd vergeleken met die van 
antigeen 14C5. Deze integrines werden geselecteerd omdat ze betrokken zijn 
bij kankerpathologie en beschikken over een celadhesie blokkering functie. 
Enkel anti-αvβ5 specifiek antilichaam (P1F6) toonde een gelijkaardig 
bindingspatroon als MAL 14C5. MAL 14C5 kon de αvβ5 receptoren 
significant blokkeren in een blokkeringsstudie. Flowcytometrie met humaan αv 
and β5 getransfecteerde Colo16 cellen toonde aan dat enkel een subpopulatie 
waarin beide subeenheden tot expressie werden gebracht, 100% in staat was 
om MAL 14C5 te binden. 
Immunocytochemie en/of flowcytometrie toonde hoge expressie van het 
antigeen 14C5 in een grote variëteit van kankercellen: ovarium-, baarmoeder-, 
long-, darm- en pancreascarcinoma, sarcomas en melanomas. De A549 
longkanker cellijn toonde de hoogste expressie. Dit biedt de mogelijkheid dat 
antigeen 14C5 een nieuw doelwit kan zijn voor niet-kleincellige 
longkankertherapiën. Immunohistochemie van longkanker en darmkanker 
weefsels toonde aan dat het antigeen 14C5 voornamelijk tot expressie komt in 
het stroma en op de stromale fibroblasten die de tumorcellen omringen. 
Momenteel verkennen vele onderzoeksgroepen de mogelijkheid om de ruimte 
rondom de tumor als doelwit te kiezen voor diverse therapieën, in plaats van de 
tumorcellen zelf en dit kan eveneens een mogelijke strategie worden met MAL 
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14C5. Verder onderzoek moet uitwijzen of het antigeen 14C5 een indicator kan 
zijn voor het kankergeassocieerde fibroblast fenotype. 
Voor verder karakterisatie van het antigeen werd de immunohistochemische 
studie van longkanker en darmkankerweefsels eveneens uitgevoerd met het  
αvβ5 specifieke antilichaam (P1F6). Er werd geen verschil gevonden in het 
expressiepatroon, wel was de aankleuring met P1F6 sterker zowel voor de 
specifieke binding, als voor de niet-specifieke binding. 
 
In het tweede deel van de thesis werd het gebruik van radiogejodeerd 
MAL 14C5 als een radiotherapeutisch en/of een radiodiagnostisch farmacon 
onderzocht. Verzadigingsexperimenten toonden een hoge affiniteit tussen MAL 
14C5 en zijn antigeen (Kd, 0.2 ± 0.1 nmol/l, A549 longkanker cellen). Een hoge 
specifieke tumoropname en een kwalitatieve planaire beeldvorming werden 
aangetoond in tumordragende naakte muizen. Echter, de bloedklaring van het 
farmacon was traag en typisch voor een 150 kDa monoklonaal antilichaam. 
Fab en F(ab’)2 fragmenten werden gemaakt met behulp van een ficine 
geïmmobiliseerde kolom. Verzadigingsexperimenten met radiogejodeerd 
F(ab’)2 toonden een hoge affiniteit (Kd, 0.4 ± 0.1 nmol/l), terwijl 
radiogejodeerd Fab meer affiniteit verloor door zijn enkelvoudige binding (Kd, 
2.3 ± 0.4 nmol/l). De bloedklaring was sneller met de Fab and F(ab’)2 
fragmenten. Alfa halflevens (t½α) van Fab, F(ab’)2 en MAL 14C5 waren 
respectievelijk 14.9 min, 21 min and 118 min. De beta halflevens (t½β) van Fab, 
F(ab’)2 en mAb 14C5 waren respectievelijk 439 min, 627 min and 4067 min. 
Biodistributies toonden verhoogde tumor-bloed en tumor-spier verhoudingen, 
maar de absolute tumoropname van beide fragmenten lag beduidend lager dan 
dat van MAL 14C5. Hierdoor is een verdere optimalisatie van het antilichaam 
noodzakelijk, vooraleer klinische toepassingen met dit antilichaam mogelijk 
worden. 
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Internalisatie kan leiden tot snelle afbraak van een radiogejodeerd antilichaam 
door blootstelling aan lysosomale afbraak in de cel. Daarom onderzochten we 
wat er gebeurt met het radiogejodeerde mAb 14C5-antigeen complex na 
binding van MAL 14C5. Deze studies werden eveneens uitgevoerd met de 
radiogejodeerde F(ab’)2 en Fab fragmenten. Internalisatie van MAL 14C5 en 
zijn F(ab’)2 fragmenten werd aangetoond in A549 cellen, zowel indirect met 
confocale microscopie als direct met radiogejodeerde eiwitten. Twee uur na 
internalisatie konden geen afbraakprodukten als gevolg van het internalisatie-
proces worden waargenomen. Bovendien bleef de hoeveelheid ongebonden 
jood en jood-monotyrosine vrijgesteld in het supernatans lager dan 5%. Deze 
data suggereren dat zowel MAL als F(ab’)2 fragmenten internalizeren, maar dat 
hun afbraak traag verloopt. Internalisatie met radiogejodeerd Fab fragmenten 
werd nauwelijks waargenomen. Dit doet denken dat een bivalente binding van 
het antilichaam met zijn antigeen noodzakelijk blijkt vooraleer internalisatie 
kan doorgaan. Hoewel evenmin afbraakprodukten met radiogejodeerd Fab 
werden waargenomen, vertoonde dit fragment een snelle dissociatie. Dit kan 
verdere toepassingen van Fab 14C5 bij patiënten limiteren. 
Genetische manipulatie maakt het mogelijk om de structuur en de 
karakteristieken van een volledig antilichaam te wijzigen, zodat gunstige 
farmacokinetische eigenschappen worden behaald die optimaal zijn voor 
gebruik bij patiënten. Om deze mogelijkheid te onderzoeken werden de 
variabele lichte keten en variabele zware keten genen van MAL 14C5 
gesequentieerd. De complementaire determinerende regio’s die karakteristiek 
zijn voor MAL 14C5 werden geïdentificeerd. Dit opent de weg naar de 
constructie van alternatieve antilichaamfragmenten met gunstigere 
farmacokinetische eigenschappen en verminderde immunogeniciteit. Dit laat 
eveneens toe een bredere waaier radioisotopen te gebruiken en andere 
componenten, zoals toxines en therapeutische stoffen, aan MAL 14C5 te 
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koppelen. Bispecifieke antilichamen kunnen worden aangemaakt, waardoor 
ook pretargeting strategieën en andere immunotherapeutische strategieën tot de 
nabije toekomst van het 14C5 antilichaam kunnen behoren. 
